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ABSTRACT 
Presentation of tumor peptides by HLA molecules is required for immune system 
recognition and eradication of tumors. This study characterized 11 breast cancer cell lines 
(BCCLs) as potential antigen presenting cells, assessed expression of CUT A, a regulator of 
HLA class II and co-chaperone transcription, and examined expression of HLA-DR allelic 
products in these cells. 
Gene tninscription was determined by RT-PCR. Protein expression was demonstrated 
using monoclonal antibodies and flow cytometry and immunocytochemistry. 
Unexpectedly, constitutive HLA class II and/or co-chaperone protein expression was 
detected in 5 of 11 BCCLs. Follm¥ing IFN-y treatment, most cell lines up-regulated HLA 
class II and co-chaperones and the co-stimulatory molecule CD40 suggesting a capacity for 
HLA class II mediated antigen presentation. 
Several BCCLs constitutively expressed HLA class II and co-chaperones in the 
absence of CIIT A suggesting CIIT A independent regulation of these genes in BCCLs. 
Some cell lines selectively up-regulated certain HLA-DR allelic products. Since all 
HLA-DR alleles were transcribed following IFN-y treatment, post-transcriptional events may 
be implicated in this selective expression. 
Failure to express HLA class II antigens and co-stimulatory molecules may allow 
tumors to escape immune recognition. 
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CHAPTER 1. INTRODUCTION 
According to the immunosurveillance theory, the immune system is instrumental in 
eradicating spontaneously arising epithelial neoplasms (Shankaran et al., 2001). HLA class 
1 (HLA-A, -B, -C) and class ll (HLA-DR, -DP, -DQ) molecules, by virtue of their ability to 
present tumor antigens to T lymphocytes, are critical in activating the cellular tumor antigen-
specific immune response (Accolla et al., 1995, Germain, 1994). Since the immune system 
does not prevent the development or progression of all cancers, it seems apparent that 
immune surveillance can be evaded. One mechanism by which tumors escape immune 
recognition is to alter their HLA phenotype (reviewed by Marincola el al., 2000). Much has 
been reported on HLA class I down-regulation by human cancers but little is known about 
HLA class ll alterations .. 
This thesis, continuing and expanding research initiated by a Bachelor of Science 
Honour' s student, Jamie Tibbo, investigates the selective up~regulation of HLA-DR genes 
by breast cancer cell lines. Potentially, tumors not expressing a particular HLA-DR type 
proficient at tumor antigen presentation may not be recognized nor eliminated by CD4+ T 
cells. The possibility that breast tumor cells themselves may act as HLA class II restricted 
antigen presenting cells was addressed by examining HLA class ll, class ll co-chaperone and 
co-stimulatory molecule expression. Further, since CllT A is believed to be a critical 
activator of class ll and co-chaperone transcription in non-neoplastic cells, the expression of 
this factor and its correlation with class II and class II co-chaperone expression in breast 
cancer cells was studied. Therefore, this chapter reviews pertinent literature on HLA class 
II and its involvement in the anti-cancer immune response. 
1.1. The Major Histocompatibility Complex (MHC) 
The major histocompatibility complex (MHC), termed human leukocyte antigen 
(HLA) complex in humans, is a group of highly polymorphic genes whose products are 
essential to the immune response (Kaufman et al., 1984). The two predominant classes of 
HLA molecules, class I (HLA-A, -B and -C) and class Il (HLA-DR, -DP and -DQ), are 
expressed on the cell smface of multiple cell types (Klein & Sato, 2000). T cell recognition 
of foreign antigen mainly occurs when antigen is presented by HLA molecules (Zaleski, 
1991 and Germain, 1994). 
1.1.1. Genomic Organization of the MHC 
The MHC in humans is located on the short arm of chromosome six, 6p21.3, and 
spans 4Mb (Beck & Trowsdale, 1999, van den Elsen et al., 1998). There are over 200 genes 
in this complex, of which only 10-20% have recognized roles in class I and class II antigen 
presentation (Klein & Sato, 2000). Three genetic regions have been identified within the 
MHC: the class !.region, the class II region and the class III region (Figure 1.1). 
The class ill region is located between the class I and class IT regions and spans 
approximately 1 Mb (Campbell & Trowsdale, 1993). It contains approximately 75 genes 
encoding a variety of different proteins including the complement components (C2, C4A, 
C4B and Factor B) (Marsh et al. , 2000). The class Ill region does not encode proteins 
involved in antigen presentation . 
. . The class 1 region is located nearest the telomere and spans approximately 1.5 Mb 
. 2 
Chromosome 6 
q p 
Regions 
(Class ll Class ill Class I J 
Class II 
II II 
('1('1~..-<- ..--< N * 0\ 
<t: <t:~ C'l_,.....,N rJ:i r:o..:t:r:or:o..:t: r:or:o~ ~< 0 :S:E o.,~~p... 0 CICICICICJ ~~~ ~~ 0 00 ~E--~~ 0 ooooo 000 oo 
I II II II I IIIII Ill II l 
Class III rJ:i I 
s 
..... 
DRB* 
(.) ('1 DRB3 ~ ~ u II I I ] DRB4 DRB5 
Class I 
rJ:i u 
<!: ..1: . 
....:I ....l 
::x:: · ::r: 
I I I I I I I I 
Figure 1.1. Organization of the HLA complex on chromosome six. The HLA 
complex is divided into three regions: class I, class ll and class ill. The class I and 
class II regions encode genes involved in antigen processing and presentation but 
the class III region does not. Among other functions, class III genes encode 
complement proteins. Adapted from Klein & Sato, 2000, Abbas et al., 1997 and 
Marsh et al., 2000. 
3 
(Roitt et al., 1998). The principal class I genes encode heavy chains of six class I molecules: 
HLA-A, -B, -C, -E, -F and -G. HLA-A, -B, -C are termed classical class 1 molecules while 
HLA-E, -F and -G are known as class I-like molecules. Additionally, there are four 
nonfunctional pseudogenes termed HLA-H, -J, -K and "'"L. The gene encoding the common 
class llight chain, ~2-microglobulin, is located on chromosome 15 (Marsh et al., 2000). 
The class II region is positioned nearest the centromere and extends over 1 Mb (Beck 
& Trowsdale, .1999). These genes code for five main class II proteins: HLA·DR, -DQ, -DP, 
-DM and -DO. Class II molecules are heterodimers consisting of an a-chain and a ~-chain, 
both ofwhich are encoded by genes in the class II region. All of the class II genes, with the 
exception of HLA-DO, are arranged in related pairs of a and~ genes i.e. HLA-DQA1 next · 
to HLA-DQB 1 (Beck & Trowsdale, 1999). The genes encoding HLA-DQ a and ~chains are 
HLA-DQAl and HLA-DQBl. There are three nonfunctional HLA-DQ pseudogenes: HLA-
DQA2, HLA-DQB2 and HLA-DQB3. HLA-DP a and~ chains are encoded by HLA-DPAl 
. and HLA-DPBl. HLA~DPA2 and HLA-DPB2 are pseudogenes (Marsh et al., 2000). HLA-
DM a and~ chains are encoded by HLA-DMA and HLA-DMB genes while HLA-DO a and 
~chains are encoded by HLA-DOA and HLA-DOB genes (Marsh et al. , 2000). 
The HLA-DR locus is more complex than the other class II loci. HLA-DR a and ~ 
chains are encoded by HLA-DRAl and HLA-DRB genes. The number of expressed HLA-
. . 
DRB genes depends on the HLA-DRB haplotype inherited (Figure 1.2). TheseHLA-DRB 
haplotypes are HLA-DRl, HLA-DR51 , .HLA-DR52, HLA-DR53 and HLA-DR8. All HLA-
. . 
·. DRB haplotypes have a functional HLA-DRB 1 gene and may have one other functional 
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Figure 1.2. Arrangement of HLA-DRB genes in different HLA-DRB haplotypes. 
There are five HLA-DRB haplotypes: DRl, DR51, DR52, DR53 and DRS. 
Pseudogenes are indicated by shaded boxes and expressed genes are indicated by 
open boxes. The serological specificity of the DRBl encoded gene is indicated in 
italics. The DRB5, DRB3 and DRB4 genes e11code theDR51 , DR52 and DR53 
antigens. Adapted from Marsh et al., 2000. 
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HLA-DRB gene (HLA-DRB3, -DRB4 or -DRB5). All HLA-DRB haplotypes also have 
nonfunctional DRB pseudogenes. The number of pseudogenes depends on the HLA-DRB 
haplotype (Marsh et al., 2000) . 
. The class II region also contains genes critical for class I antigen processing including 
proteasome genes and transporter in antigen processing (TAP) 1 and 2 genes (Beck & 
Trowsdale, 1999). The proteasome is involved with generating antigenic peptides while 
TAPs transport peptides into the endoplasmic reticulum where they bind class I molecules 
(Klein & Sato, 2000). 
Recombination between HLA-DR and HLA-DQ is rare (Beck & Trowsdale, 1999). 
Thus, HLA-DR and HLA-DQ genes are in linkage disequilibrium i.e. certain HLA-DQ 
alleles are inherited together with certain HLA-DR alleles (Abbas et al., 1997). In contrast, 
linkage disequilibrium between HLA-DRIHLA-DQ and HLA-DP is weaker allowing higher 
rates of recombination between these loci (Bcgovich et al., 1992, Howell et al., 1993, Baisch 
& Capra, 1993). · 
1.1.2. HLA Class II Nomenclature 
Class II molecules were identified m the 1970's when it was observed that 
lymphocytes from two genetically different individuals combined in vitro proliferated in 
response to . their distinct cell surface antigens (Marsh et al. , 2000). There was limited 
success in characterizing class II molecules using the lymphocyte activation model so 
identification based on serology was attempted i. e. the recognition of different class II 
molecules by antibodies. This method defined several I-ILA-DR and HLA-DQ antigens but 
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was not useful for the identification of HLA-DP antigens (Marsh et al., 2000). HLA class 
II serological specificities are listed in Table 1.1 . 
Molecular biological methods such as restriction fragment length polymorphism 
(RFLP), nucleotide sequencing and polymerase chain reaction (PCR) enabled the 
identification of numerous HLA class ll alleles (Marsh et al. , 2000). Genes encoding a-
chains are designated A (i.e. HLA-DRA) while genes encoding B-chain genes are labeled B 
(i.e. HLA-DRB). In the example HLA-DRB1*0401, HLA~DRBI refers to the Bl gene 
encoding the B-chain ofthe HLA-DR molecule. 04 refers to the serological specificity i.e. 
HLA-DR4 and 01 identifies the allelic variant of the HLA-DRBl *04 gene (Klein & Sato, 
2000, Marsh et al. , 2000). 
1.1.3. HLAClass II Genetic Polymorphism 
Within the population, there is extensive HLA class ll genetic variation i.e. multiple 
class ll allelic variants (Beck & Trowsdale, 1999). This is not surprising given that the 
physiological role of class II molecules is to bind foreign antigenic peptides. Accordingly, 
much of the genetic variation within HLA class II genes occurs at positions encoding the 
peptide binding pockets. HLA class ll genes not directly involved in peptide binding, HLA-
DM and HLA-DO, have minimal genetic variation (Beck & Trowsdale, 1999). The ability 
to display numerous pathogen derived peptides is both advantageous to an individual and to 
a population as it increases the odds of warding off deadly pathogens. 
Depending on the HLA class II isotype, both the a-chain and the B-chain may 
contlibute to class Upolymorphism. The HLA-DR a-chain has limited polymorphism as . 
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Table 1.1. HLA-DR and HLA-DQ serological specificities. Numbers in parenthesis indicate 
the original serological classification of a particular class ll antigen. Adapted from Marsh et 
al., 2000. 
HLA-DR 
DRI 
DR2 
DR3 
DR4 
DRS 
DR6 
DR7 
DRS 
DR9 
DRlO 
.DRll (5) 
DR12 (5) 
DR13 (6) 
DR14 (6) 
DR15 (2) 
DR16 (2) 
DR17 (3) 
DR18 (3) 
DR51 
DR52 
DR53 
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HLA-DQ 
DQl 
DQ2 
DQ3 
DQ4 
DQ5 (1) 
DQ6 (1) 
DQ7 (3) 
DQ8 (3) 
DQ9 (3) 
there are only 2 D.RA alleles. Thus, HLA-DR polymorphism is derived from DRB genes. 
There are 221 HLA-DRBl alleles, 19 HLA-DRB3 alleles; 9 HLA-DRB4 alleles and 14 
HLA-DRBS alleles currently defined at the population level. Both HLA.:.DQA and HLA-
DQB genes are polymorphic. In fact, there arc 19 HLA-DQAl alleles and 39 HLA-DQB 1 
alleles. Genes encoding the HLA-DP a-chain and the HLA-DP ~-chain are also 
polymorphic. There are 15 HLA-DPl alleles and 84 HLA-DPBl alleles. As indicated, 
HLA-DM and HLA-DO exhibit little polymorphism. Presently, there are 4 HLA-DMA 
alleles, 5 HLA-DMB alleles, 8 HLA-DOA alleles and 3 HLA-DOB alleles (Marsh et al., 
2000). 
1.2. HLA Class II Structure 
HLA class IT molecules are cell smface glycoproteins which are formed by the non-
covalent association of two transmembrane polypeptide chains: an a-chain (33-35kDa) and 
a p,..chain (27-29kDa) (Kaufman et aL, 1984, Germain, 1994). Each class II a and~ chain 
has four domains: a peptide binding domain ( -90 amino acids), an immunoglobulin-like 
domain (95 amino acids), a transmembrane domain (-25 amino acids) and a cytoplasmic 
domain (variable length) (Figurel.3A) (Kaufman et al., 1984, Abbas et al. , 1997). The two 
a chain extracellular domains are tem1ed a 1 and a2 while the two ·~· chain extracellular 
domains are called ~ ~ and ~2. The peptide binding site is formed by the association of the a 1 
domain and the ~I domain (Klein & Sato, 2000). 
The organization of exons and introns within class IT a- and P-chain genes is depicted 
in Figure 1.3B. 
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Figure 1.3. Structure and exon-intron organization of HLA class II. A) Structure of 
the l-ILA class II molecule. Class II molecules are cell surface heterodimers 
composed of an a-chain and a P-chain. Each a and ~ chain has four domains: a 
peptide binding domain, an immunoglobulin-like domain, a transmembrane domain 
and a cytoplasmic domain. The peptide binding site is formed by the association of 
the al domain and the .~ 1 domain. Adapted from Tizzard, 1995 and Abbas et al., 
1997. B) Exon-intron organization of the HLA class II a-chain and ~-chain, The a 
chain is organized as follows: cxon 1 encodes the leader peptide (L), exon · 2 
encodes the al domain, exon 3 encodes the a2 domain, exon 4 encodes the 
transmembrane region (TM) andthe cytoplasmic tail (C) and exon 5 encodes the 3' 
untrarislated region (UT). The ~ chain is organized similarly. Exon 1 encodes the 
leader peptide (L), exon 2 encodes the ~1 domain, exon 3 encodes the ~2 domain, 
exon 4 encodes the transmembrane region (TM), exon 5 encodes the cytoplasmic 
tail (C) and exon 6 encodes the 3' untranslated region (UT). Notably, exon 2 
exhibits extensive sequence variability among class II alleles since it encodes 
peptide binding domains. Adapted from Marsh et al., 2000. 
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1.3. HLA Class II Expression 
1.3.1. Cellular Distribution of HLA Class II Molecules 
Unlike HLA class I molecules which are expressed on most nucleated cells, 
constitutive HLA class II expression is restricted to conventional antigen presenting cells 
(APCs) such as dendritic cells, macrophages, B cells, thymic epithelial cells and activated 
T cells (Klein & Sato, 2000). However, class ll expression is easily induced on a variety of 
cell types using immunomodulators such as IFN-y (Boehm et al., 1997). Other 
immunomodulators may also alter class ll expression in a cell type dependent manner. For 
example, class 11 expression may be suppressed by JL-1 0, TNF-a, TGF-~, IL-l~ or IFN-~ (Lu 
et al., 1995, Koopleman et al., 1997, Lee et al., 1997, Han et al., 1999, Ito et al., 1999, Rohn 
et al., 1999). ln: contrast, class ll expression may be induced by IL-4, GM-CSF, TNP.:-0:, IL-
l a, retinoic acid or prolactin (Bernard et al., 1986, Gerrard et al., 1990, Sedlak et al., 1992, 
de Waal Malefyt et al., 1993, Gardner & Walker, 1993, Speiser ct al., 1993). 
1.3.2. Co-dominant Expression of HLA Class II Molecules 
HLA molecules are co-dominantly expressed i.e. all maternally and all paternally 
inherited functional class ll genes are expressed as cell surface proteins (Figure 1.4). The 
complete set of HLA alleles present on each chromosome is called the HLA haplotype 
(Abbas et al., 1997). Therefore, assuming heterozygousity, each individual inherits two 
haplotypes and thus will express at least six and as many as eight distinct HLA class IT 
molecules i.e HLA-DR7, -DR53, -DRl, -DQ2, -DQ5, -DP1, -DP3. The reason for the 
variable number of functionally expressed HLA class II molecules is that some HLA-DRB 1 
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Offspring antigen presenting cell 
Figure 1.4. HLA class II molecules are co-dominantly expressed. All 
functional HLA class II alleles inherited from both parents are expressed as 
cell surface proteins. 
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genes are expressed with an additional HLA-DRB gene (Marsh et al., 2000) (Figure 1.2). 
1.4. HLA Class II Regulation 
Since constitutive class II expression has restricted cellular distribution and many cell 
types may be induced to express class II, strict regulation of these genes is implied. The class 
II regulatory region is located approximately 1 SO base pairs upstream of the transcription 
initiation site (Boss, 1997). Within this promoter, there is a conserved set of cis-acting 
regulatory elements (van den Elsen et al., 1998) (Figure 1.5), These include (5' to 3'): the 
seven nucleotide S box that is part of a larger, approximately 20 nucleotide, \V box; the 15 
nucleotide XI box which overlaps by two nucleotides with the eight nucleotide X2 box; and 
the 10 nucleotide Y box (Abbas et al., 1997). Proximal to the transcription initiation site is 
a TAT A motif (Singal et al., 1993). The HLA-DRA promoter contains an additional 
regulatory element termed the octamer binding site (OBS) located between the Y and TAT A 
boxes (Sherman et al. , 1989, Voliva et al., 1995). 
W, X andY boxes are characteristic of class II (HLA-DR, -'-DQ and -DP) and class 
IT co-chaperone.(Ii, HLA-DM and HLA-DO) promoters (Boss, 1999, Taxman et al. , 2000). 
This infers coordinate regulation of these genes. However, Ii and HLA-DM promoters 
contain additional regulatory elements which may trigger their expression in the absence of 
class II expression (Westerheide et al., 1997, Moore et al., 1998, Tai et al., 1999). HLA-DO 
expression, ·in particular, infrequ.ently correlates with expression of other class II genes 
(Taxman et al., 2000). 
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Figure 1.5. Regulatory elements in the HLA c:lass II promoter and their respective 
transcription factors. The regulatory region of all class II promoters and class II 
co-chaperones (the invariant chain, HLA-DM and HLA-DO) contains · the W/S, 
X1, X2, Y and TATA box elements. The HLA-DRA promoter, depicted above, 
also contains the Octa.iner binding site (OBS). Adapted from Boss, 1997 and 
Harton & Ting, 2000. 
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1.4.1. Transcription Factors Binding HLA Class II Regulatory Elements 
The class U regulatory elements and the ubiquitously expressed DNA binding 
proteins which bind these elements have been extensively investigated (van den Elsen et al., 
1998, Boss, 1999). These are illustrated in Figure 1.5. 
TheW box contains the Sand Z subregions (Boss, 1997). Factors which bind theW 
box are not well defined since this region has poor affinity for DNA binding proteins (Boss, 
1999). However, Jabrane-Ferret et al. (1996) demonstrated that RFX binds this regulatory 
element. 
The X box is composed of two elements, Xl and X2, that bind distinct transcription 
factors (TFs). XI is bound by RFX which consists of three subunits: RFX5 (regulatory 
factor thatbinds the X box), RFXAP (RFX-associated protein) and RFXANK (RFX-
associated protein with <:mkyrin repeats) (Fontes et aL, 1999b). Activation of class IT 
transcription requires the association of all three subunits (Boss, 1999). 
The X2 box shares homology with TPA (12-o-tetradecanoylphorbol-13-acetate) and 
cAMP responsive elements (Boss, 1997). This regulatory element is bound by a homodimer 
of X2BP (X2-specific binding protein) (Boss, 1999). Recently, .Moreno et al. (1999) 
demonstrated that X2BP is CREB (cAMP responsive element binding protein). 
TheY box is an inverted CCAAT box (van den Elsen et aL, 1998) which is bound 
by NF-Y (nuclear factor binding to the Y box). NF-Y is a heterotrimer consisting of 1\TF-Y A, 
NF-YB and NF-YC (Boss, 1999). NF-Y A and NF-YC share homology with histone fold 
domains. Thus, 1\o'F-Y subunits may bt~ involved in DNA bending which would allow direct 
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contact between NF-Y and RFX (Sinha et al. , 1996, Boss, 1999). 
The OBS is found exclusively in HLA-DRA promoters (She1man et al., 1989). In B 
lymphocytes, this regulatory region is bound by octam~r-binding TFs, Oct-! and Oct-2. This 
binding is enhanced in the presence of the B cell octamcr-binding protein l (Bob-1) (Stmbin 
et al., 1985,Gstaiger et aL, 1995). 
The presence of all regulatory elements is necessary for optimal class IT expression. 
In fact, deletion or replacement of the X or Y boxes dramatically decreases class II 
expression whileS box deletion is not as catastrophic (Tsang et al., 1988, Koch et al., 1989, 
Tsang et al., 1990, Janitz et al., 1997). 
1.4.2. The Class II Transactivator (CIITA) 
Even when all app!opriate TFs have bound theW, X 1, X2 and Y regulatory elements, 
class ll transcription is normally not initiated. Another protein, termed the class II 
transactivator (CIIT A), is required for efficient constitutive and IFN-y inducible class II 
expression (Steimle et al., 1993, Steimle et al., 1994). CIITA also activates Ii, HLA:.DM and 
HLA-DOA transcription (Chang et al., 1999, Taxman et al., 2000). HLA-DOB expression 
is not controlled by CITTA (Taxman et al., 2000)~ 
1.4.2.1. CIITA Regulation 
Four independent promoters control CIITA expression in a cell-type specific manner. 
Promoter I controls constitutive class II expression in dendritic cells, promoter ill controls 
constitutive class ll expression in B cells and promoter IV controls IFN->y inducible 
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expression in a variety of class IT negative cells. Promoter IT function is not yet determined 
(Muhlethaler-Mottet et al. , 1997). Promoter ill may also triggerlFN-)' inducible expression 
(Piskurich et al.,l999). 
Mechanisms of post-translational control of this transactivator have been suggested 
although none have been identified (Mach, 1999). 
1.4.2.2. CIITA Interacts with Class II Promoter Bound Transcription Factors 
CliT A does n.ot directly bind DNA (Steimle et al., 1993). However, it interacts with 
TFs bound to regulatory elements of the HLA class IT promoter and components of the basal 
transcription machinery (Figure 1.6) (Fontes et al., 1999a, Harton & Ting, 2000, Zhu et al., 
2000). Zhu et al. (2000) demonstrated that CliTA directly interacts with the RFXcomplex, 
specifically RFX5 and RFXANK and with the NF-Y complex, specifically NF-YB and NF-
YC. Interactions between CIITA and CREB have been described. However, further studies 
are required to elucidate whether CREE directly binds CUT A or binds indirectly through 
interaction with another TF (Zhu et al., 2000). 
CITT A recruits CREB-binding protein (CBP). This histone acetytransferase promotes 
chromatin remodeling and thus is recognized as a co-activator of class IT transcription 
(Fontes et al., 1999a). Another co-activator of class IT transcription, Bob-1, is also recruited 
by CllTA (Fontes et al., 1996). This factor contains activation domains different from those 
of CIITA and thus may interact with additional general TFs (Fontes et al., 1996). 
Interactions between CITT A and components of the basal transcription complex have 
· been identified (Fontes et al. , 1999b). Specifically, TAT A-binding protein-associated factors 
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X2 Xl W/S 
y OBS TATA 
Figure 1.6. · HLA class II and class II co-chaperone promoters have . common 
regulatory clements: the W/S box, the X box, the Y box and the TATA box. 
CIIT A interacts with transcription factors bound to these regulatory elements and 
components of the basal transcriptional machinery to activate class II 
transcription. The above diagram depicts the DRA promoter in B cells. Adapted 
from Fontes et al., 1999b, Zhu et al., 2000 and Harton & Ting, 2000. 
18 
(TAFs) or TFIIB, a basal transcription factor, may bridge TATA box-binding protein (TBP) 
to CIIT A (Mahanta et al., 1997). · As well, T AFu32 which is a subunit of the basal 
transcription complex TFIID interacts with CIIT A (Fontes et al., 1997). 
Therefore, CIIT A has been characterized as a transcriptional scaffold that mediates 
recruitment and organization of transcription factors and basal transcriptional machinery to 
ultimately activate HLA class IT expression (Harton & Ting, 2000, Zhu et al., 2000). 
1.4.3. Transcriptional Control of HLA Class II Expression 
HLAclass II expression is predominantly regulated at the transcriptional level (Chang 
et al., 1999). 
1.4.3.1. CIITA as a Rate Limiting Factor 
CIITA has been described as the primary rate limiting factor for class ll expression 
. .. 
(Otten et al., 1998). In fact, Otten et aL (1998) demonstrated a quantitative correlation 
between the level ofCllTA mRNA and HLA-DRA mRNA. Eventually, increasing CllTA 
did not further increase HLA-DRA mRNA but this occurred at levels of HLA-DRA 
expression far exceeding that observed in control cells. 
1.4.3.2. HLA Class II Promoter Polymorphism 
Polymorphism within the class ll promoter may alter the ability of TFs to bind 
regulatory elements and thus alter class ll transcription. For example, sequence variation in 
the regulatory element X 1 allows RFX to hind class ll promoters in B cells with differing 
affinities as follows: DRA>DPA>>DQA=DQB>>>DRB and DPB (reviewed by Beaty et al., 
1999). 
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Additionally, polymorphism within regulatory clements influences class II allele 
expression (reviewed in Beaty et al., 1999). For example, sequencing of numerous HLA-
DRB allele promoters has revealed sequence variation within X andY boxes and spacing 
differences between these elements (Perfetto et al., 1993, Emery et al., 1993, Singal et al., 
1993, Louis et al., 1994, Singal & Qiu, 1995). 
Several studies have characterized B cell line HLA-DRB promoter transcriptional 
activity using chloramphenicol acetyltransferase (CAT) reporter assays (Leen et al., 1994, 
Louis et al., 1994, Singal & Qiu, 1994, Singal & Qiu, 1995). Singal & Qiu (1994,1995) 
found that the transcriptional activity ofDRB 1 promoters in the DR1/DR5 1 haplotype groups 
was higher than that of DRB1 promoters in the DR52/DR8 and DR53 haplotype groups. 
DRBI promoters in the DR53haplotype were slightly more active than DRB4 promoters 
while DRB 1 promoters in the DR52 haplotype were slightly more active than DRB3 
promoters. It was found that differences in HLA-DRB transcriptional activities were the 
result of sequence and spacing variations within HLA-DRB promoters (Singal &Qiu, 1995). 
In contrast, Leen et al. (1994) showed that the transcriptional activities of HLA-
DRBl*1501, HLA-DRB1*0701 and HLA-DRB5*010lpromotcrs were similar. However, 
the DRB 1 * 1501 promoter was slightly more transcriptionally active than theDRB 1 *0701 
promoter and the DRB5*0 101 promoter. Conflicting data may be explained by several 
differences in experimental protocol. For instance, Lecn et al. (1994) cloned a larger 
fragment of the HLA-DRB promoter into the CAT reporter plasmid than Singal & Qiu 
(1994,1995). Additionally, different methodologies were utilized to assess CAT activity. 
20 
Louis et al. ( 1994) observed that DRB 1 promoters in the DR52 haplotype displayed 
the highest transcriptional activity. DRB 1 promoters of the DR1/DR51 and DRS haplotypes 
also showed high activity. All DRB 1 promoters of the DR53 haplotype showed low 
transcriptional activity. DRB3 promoters showed the same level of transcriptional activity 
as DRB 1 promoters of the DR52 group while DRB4 promoters displayed lower 
transcriptional activity than DRB 1 promoters of the DR53 haplotype. These data differ from 
those reported by Singal & Qiu (1994,1995) and Leen et al.(l994). There are several 
explanations for these discrepant findings. The CAT plasmid used by Louis et al. (1994) i.e. 
pCAT3 was different than that used in the other studies i.e. pCAT. Louis et al. (1994) 
transfected CAT constructs into the B cell line BM92 while the other studies used the B cell 
line Raji (Singal & Qiu, 1994, Singal & Qiu,l995 and Leen etal., 1994}. As well, different 
methodologies were used to measure CAT activity. 
Vincent et al. ( 1996) attempted to correlate HLA-DRB promoter transcriptional 
activities with levels of HLA-DRB transcripts. This group extracted RNA from peripheral 
blood B cells. Using competitive polymerase chain reaction (PCR), they found that DRBl 
transcripts fromthe DR52 haplotype were2.5 to 3.5 times more prevalent than DRBl*Ol 
transcripts, 1.5 to 2 times more abundant than DRB 1 *04 transcripts and 7 times more 
abundant than DRBl *08 transcripts. DRB 1 transc1ipts from the DR52 haplotype were 
quantitatively identical to DRB3 transcripts. The levels of HLA-DRB transcripts assessed 
by Vincent et al. (1996) best correlated with HLA-DRB p romoter transcriptional activity 
measured by Louis et al. (1994) with one exception. Even thoughDRB 1 *04 transcriptional 
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activity was lower than that ofDRBl *01 and DRBl *08 (Louis et al., 1994), HLA-DRBl *04 
transcripts were detected in greater abundance (Vincent et al., 1996). It was suggested that 
post-transcriptional modifications enhanced stability of DRB 1 *04 mRNA (Vincent et al., 
1996). 
1.4.4. Post-Transcriptional Control of HLA Class II Expression 
Post-transcriptional regulation of class II expression has been described (reviewed 
in Del Pozzo et al., 1999). For example, Lcen & Gorski (1996) demonstrated that I-ILA-
DRB 1 *07 pre-mRNA levels were 3 to 4 fold higher than DRB4 pre-mRNA levels in B cell 
lines. In contrast, DRB 1 *07 mRNA was 7 fold higher than that of DRB4 suggesting post-
transcriptional regulation (Leen & Gorski; 1996). 
Maffei et al. ( 1989) reported the existence of labile proteins involved in stabilizing 
class II mRNA. When B cells were treated with cycloheximide, an inhibitor of protein 
synthesis, a dramatic decrease in class II mRNA was observed. It was postulated that 
cycoheximide inhibited the expression ofclass Il mRNA stabilizing proteins (Maffei et al., 
] 989). Del Pozzo & Guardiola (1996) argued that cycloheximide did not inhibit synthesis 
of class ll mRNA stabilizing proteins. Instead, it was suggested that in the absence of class 
ll translation, classll mRNA was rapidly degraded. Thus, class II translation stabilized class 
IT mRNA (Del Pozzo & Guardiola, 1996). 
Gonalons et el. (1998) reported that IFN-y increased class IT surface expression on 
mouse B cells without a concomitant increase in class IT mRNA. They showedthat IFN'T 
increased binding of class II mRNAto ribosomes thus enhancing translation. More recently, 
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Cullell-Young et al. (200 1) demonstrated that regulation of IFN-y induced class II expression 
in mouse macrophages occurs at different levels. Specifically, IFN-y increased class II 
transcription, ribosome loading, protein synthesis, protein half life and level of class II 
expression on the cell surface. 
Caplen et al. (1992) suggested that post-transcriptional mechanisms regulated class 
ll cell surface expression in peripheral blood T cells. Class IT mRNA was detected in resting 
T cells but class IT surface protein was not. Following T cell activation, class II expression 
was rapidly detected on the cell surface. ·This indicated that class II was already transcribed, 
processed and transported to the cytoplasm. It was speculated that a post -transcriptional 
negative regulator inhibited class II smface expression in resting T cells (Caplen et al., 1992). 
1.5. IFN-y Induction of HLA Class II Expression 
IFN-y is the most potent inducer ofHLA class II expression (Jabrane-Ferret et al., 
1990). Initially, the exact mechanism of how IFN-y induced class II expression remained 
elusive as research failed to identify an frN-y response element within the class II promoter 
(Piskurich et al., 1999). However, the identification of CIIT A as an activator of class II 
expression and its ability to be induced by IFN-y quickly resolved this quandary (Chang et 
al., 1999). IFN-y induction of class II expression is depicted in Figure 1.7. 
CUT A promoter TV has three cis-acting regulatory elements which are crucial for 
IFN-y induction: the GAS (IFN-y-activating sequence) element, theE box and the IRF-1 
(interferon regulating factor.:.!) binding site (Muhlethaler-Mottet et al. , 1998, Reith et al., 
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Figure 1.7. IFN-y activates transcnptwn of HLA class II and class IT co-
chaperone genes. IFN-y interacts with its receptor which activates JAK-1 and 
JAK-2. Subsequently, JAK-1 and JAK~2 activate STAT-1. STAT-1 dimerizes 
and transclocates to the nucleus where its binds to the GAS element in CIIT A 
promoter IV (PIV). Binding of IRF-1· to the IRF-1 response element and USF-1 to 
the E box activates CIIT A transcription. CUT A has three additional promoters: 
promoter I (PI) involved in CIIT A regulation in dendritic cells, promoter III 
involved in CIITA regulation in B cells and promoter II whose function is not 
known. CIITA it1teracts with transcription factors bound to regulatory elements 
on the class II promoter thereby activating class II transcription. Adapted from 
Mohlethaler-Mottet et al., 1998 and Piskurich et al. , 1999. 
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1999). IFN-y interacts with its cell surface receptor. Thisphosphorylates the protein tyrosine 
kinases Jakl and Jak2. The Jak kinases phosphorylate the latent cytoplasmic protein, STAT-
1 (signal transducer and activator of transcription). Activated STAT -1 dirnerizes and 
translocates into the nucleus (Darnell et al., 1994, Darnell, 1997, Reith et al., 1999). 
STAT-1 binds the GAS element within promoter IV of CllTA. Billding of the 
ubiquitously expressed transcription factor USF-1 (upstream stimulatory factor-1) to the E 
box enhances stability of STAT -1 binding to the GAS element (Muhlethaler-Mottet et al., 
1998). Following STAT-1 induced activation of.IRF-1 expression, IRF-1 interacts with the 
IRF-1 binding site within promoter IV (Piskurich et al., 1999). Interaction of STAT -1 , USF-
1 and IRF-1 with their respective regulatory elements induces CllT A expression. CIIT A is 
then able to activate class II expression (Reith et al., 1999). 
CliT A promoter ill is also induced by IFN -y in a number of cell types but its activity 
is weaker than that of promoter IV (Pish1rich et aL, 1999). 
1.6. HLA Class II Antigen Processing and Presentation 
HLA class II molecules are distinguished for their ability to present extracellular 
antigens to CD4+ T cells (Pieters, 1997). A description of the various components of the 
HLA class II presentation pathway (Figure 1.8) will ensue. 
1.6.1. The Invariant Chain 
Assembly of newly synthesized HLA class II n- and B-chains occurs in the 
endoplasmic reticulum (ER). Here, class II molecules associate with the invariant chain (Ii) 
or CD74 (Wubbolts & Neet]es, 1999). Specifically, three ap heterodimers interact with three 
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Figure L8. The HLA class II antigen processing and presentation pathway. i) In 
the ER, class II a and ~ chains associate with the Ii. The Ii has several important 
functions i.e. to prevent premature antigenic peptide loading, to stabilize class n 
molecules and to target class II to the endosomal compartments. Three Ii and 
three a~ complexes travel to the endocytic compartments. ii) Along the way, the 
Ii is degraded until only a portion of the Ii, CLIP, occupies the peptide binding 
site. iii) HLA-DM exchanges antigenic peptides for CLIP and also acts as a 
peptide editor. HLA-DO associates with HLA-DM and regulates DM activity in 
certain cell types. iv) The class II-peptide complex is transported to the cell 
surface. v) Class II molecules are recycled. This process allows cell surface class 
II to be internalized to endosomal compartments where antigenic peptide 
exchange occurs. Adapted from Pieters, .1997. 
26 
li subunits to form a nonamer (Cresswell, 1994). In the ER, correct class II protein folding 
and class II stabilization are mediated by the li. Additionally, the li, specifically a fragment 
termed CLIP (class TI-associated invaria.11t chain peptide), prevents peptide binding to the 
class II peptide binding groove in the ER (Wubbolts & Neefjes, 1999). Smting motifs within 
the li and the class ll molecule target the class 11-li complex to endocytic compartments 
(Bakke & Nordeng, 1999). As this complex traverses the endocytic pathway, the Ii is 
degraded by proteases until only CLIP remains. CLIP occupies the class II peptide binding 
site until exchange with antigenic peptide (Pieters, 1997). 
1.6.2. Extracellular Antigen Degradation 
Antigens can access cndocytic compartments by several means including receptor 
mediated endocytosis, phagocytosis, macropinocytosis and autophagy (Villadangos et al., 
1999). As antigens progress through the endocytic route, the environment within these 
vesicles becomes increasingly more acidic andrnore proteolytically active. Thus; antigens 
are gradually degraded (Villadengos et al., 1999). Antigenic peptides 12-24 residues in 
length (Germain, 1994) are bound by class II molecules in acidic endosomal/lysosomal 
compartments (Jensen et al., 1999). 
1.6.3. Antigenic Peptide Binding to HLA Class II Molecules: Role ofHLA-Dl\f and 
HLA-DO 
ID-A-DM associates with class II molecules in endosomal/lysosomal compartments 
and catalyzes the exchange of CLIP for antigenic peptides (Denzin & Cresswell, 1995, 
Shennan et al., 1995, Sloan et al., 1995). HLA-DM facilitated CLIP removal is class U allele 
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dependent. Those alleles which bind CLIP with high affinity require HLA-DM activity for 
efficient CLIP removal while those alleles with lOw affinity for CLIP do not (Kropshofer et 
al., 1999, Sette et al., 1995, Stebbins et al., 1996). Furthermore, CLIP may promote its own 
dissociation from class ll molecules in HLA-DM deficient cells (Kropshofer et al., 1995). 
HLA-DM is believed to function by transiently binding to the class rr..:cLJP complex. 
HLA~DM faciiitates CLIP removal and remains associated with empty class II molecules 
until binding of an antigenic peptide. Thus, DM acts to stabilize empty class Jl molecules 
(Kropshofer et al., 1999, Busch et al., 2000, van Ham et al., 2000). DM also functions as a 
peptide editor. It displaces peptides with low affinity from the class ·n peptide .binding 
groove in favor of high affinity peptides (Jensen et al., 1999, Krophshofer et al., 1999). 
Another. class nco-chaperone, HLA-DO, modifies the peptide binding repertoire of 
. . . 
. . . . . 
.class n molecules. l-ILA-DO is primarily expressed in B cells and thymic epithelial cells, 
although it has been detected in a subset of dendritic. cells (Alfonso et al., 1999). HLA-DO 
associates with HLA-DM and this association is required for its exit from the ER (Liljedahl · 
et al., 1996). DO may inhibit DM activity since its expression reduces DM facilitated CLIP 
release from class IT antigen binding sites (Denzin et al., 1997). This modulation of HLA-
DM activity may be pH dependent. For example, in lysosomes (pH 5.0) l-ILA-DO reduces 
HLA-DM activity while in early endosomes (pH 6.0) DO inhibits DM function altogether 
(van Ham et aL,2000). DO's function as a negative regulator of DM activity makes sense 
givenits involvement in B cell antigen presentation. In B cells, antigens are taken upby 
rec~ptor mediated endocytosis. Release of antigenfrom these receptors requires low pH. 
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Thus, DO inhibits premature DM mediated peptide exchange until release and processing 
of receptor bound antigens in lysosomal compartments (reviewed in Alfonso et al., 1999). 
Further, HLA-DO is a peptide editor (Kropshofer et al., 1998). The significance of DO 
expression in ceJls other than B cells is not known. 
In the absence ofHLA-DO, HLA-DM still retains allfunction (van Ham et al., 1997, 
Kropshofer et al., 1998). In fact, cla~s ll molecules in H2-0 deficient mice present an array 
of peptides similar to that of wild type mice (Liljedahl, et al., 1998). 
1.6.4. Cell Surface Transport of HLA Class II Molecules 
Following class U peptide loading, lysosomal/endosomal vesicles fuse with the 
plasma membrane depositing mature class ll molecules and other vesicle components 
including HLA-DM and HLA-DO on the cell surface. Most vesicle contents, with the 
exception of mature class II molecules, are rapidly retrieved via clathrin-mediated 
internalization (Wubbolts & Neefjes, 1999). 
1.6.5. Alternative HLA Class II Antigen Presentation Pathways 
Class II molecules expressed on the cell surface may recycle to ea.dy endosomes 
(Pinet et al., 1998). This recycling is mediated by endosome specific sorting signals in class 
II cytoplasmic tails (Pinet et al., 1995). Once internalized, HLA-DM may facilitate peptide 
exchange on these class II molecules (Arndt et al., 2000, Pathak et al., 2001). 
Fina1ly, it is important to note that even though class II molecules are primarily 
known for their ability to present exogenous antigens; these molecules frequently present 
endogenously derived antigen i.e. cytoplasmic, nuclear, mitochondrial and membrane 
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associated (Sant, 1994, Armstrong et al., 1997, Lich ct al., 2000, Qi et al., 2000). 
Endogenous antigens may gain access to antigenic peptide receptive class IT molecules in 
endosomal/lysosomal compartments by several means including chaperone-mediated 
trafficking from the cytosol, autophagy from the cytosol and direct trafficking from the Golgi 
(Loss et al., 1993). 
1. 7. HLA Class II and Cancer 
1.7.1 HLA Class II May Confer Susceptibility to or Protection from Cancer 
Given the critical role of HLA in the immune response, it is perhaps not surprising 
that an individual's HLA genotype influences whether a person develops particular types of 
cancer (Bateman & Howell, 1999, Little & Stern, 1999). For example, DRl may be 
associated with the development of multiple basal celi carcinomas (Bateman & Howell, 
1999). Iarygin et al. (1991) reported that HLA-DRB 1 *04 is conelated with a poor clinical 
prognosis in breast carcinoma. Not all HLA associations with neoplastic disease are 
negative. For example, Chaudhuri et al. (2000) reported that HLA-DRB1 *11 and 
DQB 1 *03032 are protective in early onset breast cancer. 
1. 7 .2. HLA Class II Expression by Breast Carcinomas 
To investigate class II expression in normal and neoplastic breast tissue, 
immunohistochemistry and monoclonal antibodies capable of recognizing class ll specific 
detenninants have been employed (Newman et al. , 1980, Whitwell et al. , 1984, Bartek et al., 
1987, Zuk & Walker, 1988, Koretz et al., 1989, Moller et al. , 1989, Garrido et al. , 1993, 
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Concha et al., 1995, Maiorana et al., 1995). 
Variable class IT expression was observed on normal breast tissue (Newman et al., 
1980, Bartek et al., 1987, Moller et al., 1989, Garrido et al., 1993). Class II was not 
expressed on normal non-lactating breast epithelium but was expressed during late pregnancy 
and lactation implying hormonal regulation of class ll expression (Newman et al., 1980, 
Bartek et al., 1987, Moller et al. , 1989). In fact, prolactin has been implicated in class IJ up-
regulation on normal mammary tissue (Klareskog et al., 1980, Newman et aL 1980). 
HLA class IT expression on breast neoplasms has been investigated (Whitwell et al., 
1984, Bartek et a1., 1987, Zuk & Walker, 1988, Koretz et al., 1989, Moller et al., 1989, 
Concha et al., 1995, Maiorana et al., 1995, Vitale et al., 1998). These studies revealed 
variable class II expression on breast cancers. For example, Concha et al. (1995) found that 
30% of breast carcinomas expressed class IT. Zuk & Walker ( 1988) showed that 39% of 
breast tumors were class ll positive. Moller et al. (1989) reported that 55% of breast tumors 
expressed class II. 
The biological significance of class II expression on breast tumors is controversial. 
While some studies have correlated class IT expression with good tumor differentiation and 
favorable clinical prognosis (Zuk & Walker, 1988, Bmnner et al., 1991, Concha et al., 
1991b, Concha et al., 1995) others have shown no such correlation (Moller et al., 1989, 
Wintzer et al., 1990, Maiorana et al., 1995). Since the biological function of class II 
molecules is to present antigenic peptidcs to CD4+ T cells, several studies have attempted 
to correlate clao;;s IT positive tumors with infiltrating immune cells. In many cases, there was 
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no correlation between the extent of infiltrating immune cells and class IT positive breast 
tumors (Whitwell et al., 1984, Bartek et al., 1987, Zuk & Walker, 1988, Concha et al., 1995). 
1n contrast, Gottlinger et al. ( 1985) and Zuk & Walker ( 1987) have shown a positive 
correlation between the extent of tumor infiltrates and class ll expression on breast tumors. 
1.7.3. The HLA Class II Restricted Anti-Tumor Immune Response 
The presentation of tumor antigen by class ll molecules is essential for generating a 
CD4+ T cell tumor antigen-specific immune response. A putative model of this immune 
response is depicted in Figure 1. 9. Class IT positive tumor cells may migrate to lympho]d 
· tissue where they encounter and activate T cells. Tumors that remain outside secondary 
lymphatic tissues are ignored by T cells (Ochsenbeinet al., 2001). As well, conventional 
. . 
APCs present tumor antigeninthe contextof class.ll after acquiring shed tumor debris. This 
process is termed cross-priming. These cells then traffic to lymphoid tissue and activate 
tumor specific CD4+ T cells (Armstrong et al., 1998b, Hung et al., 1998, PardoU & Topalian, 
1998). 
Assuming tumor antigen presentation by class II, activation of tumor specific T cells 
may not occur since many tumor antigens are recognized as self. Thus, tumors may be 
. . 
immunologically ignored (Costello et al., 1999, Marincola et al., 2000). 
Nevertheless, there is evidence suggesting that an HLA class II restricted immune 
response is elicited. For example, class ll restricted CD4+ tumor infiltrating lymphocytes 
have been isolated from multiple neoplasms including breast cancer (Schwartzentruber et al., 
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Figure 1.9. The role of CD4+ T cells in the anti-tumor immune response. Dendritic cells may capture shed tumor 
antigen and present antigenic tumor peptides to CD4+ and CD8+ T cells. This process is termed cross priming. 
Activated effector T cells may then destroy tumor cells. Tumor cells may also activate T cells (not shown). CD4+ T 
cells are essential in the tumor antigen-specific immune response. CD4+ T cells may i) help CD8+ T cel1s differentiate 
into potent tumor antigen-specific CTLs ii) eliminate cancer cells in a manner similar to CTL killing or generate 
cytokines which may iii) destroy tumor cells iv) recruit tumoricidal effector cells (i.e . macrophages, eosinophils). 
Adapted from Pardoll & Topalian, 1998. 
1992, Dadmarz et al., 1995, Robbins & Kawakarrii, 1996, Hiltbold et al., 1998, Tuttle et aJ. , 
1998). ··Whether tumor cells or conventional APCs mediated this CD4+ T cell activation is 
not known. Some studies have identified the class ll molecule involved with tumor antigen 
presentation (Fujita et al., 1998, Hiltbold et al., 1998, Tuttle et al., 1998, Manici et al., 1999, 
Kobayashi et al., 2000, Zarour et al., 2000). For example, Hiltbold et al. (1998) reported that 
MUCl was presented by HLA-DRBl *03 and that this complex activated CD4+ T cells. 
Despite induction of a tumor antigen-specific .immune response, tumor growth and 
disselilination may not be suppressed. This suggests that tumors evade immune recognition. 
Indeed, several immune evasion strategies have been recognized. Down-regulation of all 
classlmolecules or selective down-regulation of class I loci or class I alleles is frequently 
observed in tumors. Class I loss may be attributed to mutations in ~2-microglobulin, 
mutations in TAP proteins or chromosomal alterations or deletjons (Moller et al., 1992, 
.Cabrera et al., 1996, Vitale et al., 1998, Gilboa, 1999, Hicklin et al. , 1999, Seliger etal., 
2000). Secretion of cytokines such as IL~ 10 or TGF-~ may act to hinder an effective 
immune response by suppressing cell mediated immunity (CostelJoet al. , 1999, Geertsen et 
al., 1999). Additionally, malignant cells expressing FasL may interact with T cells 
expressing Fas, thus causing apoptotic cell death in T cells (Nagata, 1996, Costello et al., 
1999). Furthermore, lack of expressionof appropriate adhesion or co-stimulatory molecules 
on tumor cells may prevent T cell activation or induce T cell deletion or anergy (Costello et 
al., 1999). 
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1.9. Hypotheses 
Clfi'A has been charactetized as a master regulator of class II transcription (Steimle 
et al., 1993). While CIITA has also been implicated in regulating class II co-chaperone 
(invariant chain, HLA-DM and HLA-DOA) expression, several studies have demonstrated 
CIITA independent co-chaperone regulation (reviewed in Chang et al., 1999 and Harton & 
Ting, 2000). As such, we hypothesize that CIITA is expressed in correlation with class II but 
is not necessarily expressed in concert with class II co-chaperones. Thus, we expect that 
CllT A is not expressed constitutively by breast cancer cell lines but is up-regulated following 
IFN-r treatment. 
Studies indicate that class II positive tumor cells may present antigenic tumor peptide 
to CD4+ T cells thereby eliciting tumor specific immunity (Ostrand-Rosenberg, 1994, 
Armstrong et al., 1998b, Armstrong et al. , 1998c ). Given that constitutive HLA class II 
expression is normally restricted to conventional APCs, we predict that class li molecules 
(HLA-DR, -DP and -DQ) and class II co-chaperones (invariant chain and HLA-DM) will not 
be expressed constitutively by breast cancer cell lines but will be up-regulated in response 
to IFN-r. HLA-DO expression is not expected since this co-chaperone has only been 
identified in B cells, thymic epithelium and a subset of dendritic cells (Alfonso et al., 1999). 
We further predict that CD80 and CD86 are not expressed by breast cancer cell lines given 
that these co-stimulatory molecules are normally found on conventional APCs and cells of 
hematopoietic origin (Li et al. , 1996) but that CD40 is expressed since this co-stimulatory 
molecule is detected on many cell types (Alexandroff et aL, 2000). 
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As mentioned in section 1. 7 .2, discrepant findings were reported regarding HLA~DR 
expression on human breast carcinomas and clinical prognosis (Zuk & Walker, 1988, MoHer 
et al., 1989, Wintzer et al., 1990, Brunner et al., 1991, Concha et al., 1991, Concha et al., 
1995, Maiorana et al. , 1995). Despite years of research, this controversy has not been 
adequately resolved. Since these studies assessed HLA-DR expression using antibodies 
whichrecognized all HLA-DR types, it is unknown whether breast carcinomas up-regulated 
all HLA-DR types or select HLA-DR types. It is proposed that class II positive tumors not 
associated with a good clinical outcome did not express a particular HLA-DR allele that was 
particularly adept at presenting tumor antigen. This proposal is supported by the observation 
that selective loss of HLA class I alleles is frequently observed in human cancers (reviewed 
in Marincola et al., 2000). 
1.10. Objectives 
i) To examine CllTA expression in breast cancer cell lines and to correlate expression 
of this transactivator with class II and class IT co-chaperone transcription and protein 
expression. 
ii) To characterize breast cancer cell lines as potential HLAclass IT restricted antigen 
presenting cells by analyzing expression of HLA class II molecules, class II co-chaperones 
and co-stimulatory molecules. 
iii) To investigate selective HLA-DR up-regulation by breast cancer cell lines. 
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CHAPTER2.METHODOLOGY 
2.1. Culture and Mahitenance of Cell JAnes 
Eleven human breast cancer cell lines (Table 2.1 ), generous gifts from Dr. Shou-
Ching Tang and Dr. Alan Pater (Memorial University of Newfoundland, St. John's, NF) and 
Dr. Janice Blum (Indiana University, Indianapolis, IN) were acquired. These cells were 
grown as adherent cultures in 25 cm2 tissue culture flasks (Coming Incorporated, Corning, 
NY). MDA-MB-468 was cultured in Dulbecco's Modified Eagle Medium/F12 
(DMEMIF12) (GibcoBRL, Grand Island, NY) while all other cells were cultured in Iscove's 
Modified Dulbecco's Medium (IMDM) (GibcoBRL). B cell lines, used as positive controls 
throughout the project (Table 2.2), were cultured in IMDM. These cells were grown as 
suspension cultures in 25 cm2 tissue culture flasks. All media were supplemented with 10% 
inactivated fetal bovine serum (GibcoBRL), 2 mM L-glutamine (GibcoBRL) and Antibiotic-
Antimycotic (GibcoBRL) containing 100 U/rnl penicillin, 100 !Jg/ml streptomycin and 0.25 
!Jgl ml amphotericin B. Cell lines were maintained in a 3TC humidified atmosphere 
containing 6.5% C02• 
When breast cancer cell line growth was 80-100% confluent, as ascertained by phase 
contrast microscopy, cells were harvested and subcultured. This was done by removing 
medium from the tissue culture flask and by washing the adherent cells once with PBS 
(phosphate buffered saline-seeAppendix A). CeUs were detached from the flask by adding 
0.25% trypsin (GibcoBRL) diluted in PBS and by incubating at 3TC for 2.-5 minutes. When 
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Table 2.1. Description of human breast carcinoma cell lines used in this study. 
Breast Cancer ATCC" Morphology Description 
Cell Line Identification 
MDA-MB-435** HTB-129 Spindle-shaped Ductal carcinoma 
T-47D HTB-133 Epithelial Ductal carcinoma 
BT-20 HTB-19 Epithelial Adenocarcinoma 
MDA-MB-231 HTB-26 Epithelial Adenocarcinoma 
MCF7 HTB-22 Epithelial Adenocarcinoma 
SK-BR-3 HTB-30 Epithelial Adenocarcinoma 
Hs578T HTB-126 Epithelial Ductal carcinoma 
MDA-MB-436 HTB-130 Pleomorphic Adenocarcinoma 
MDA-MB-157 HTB-24 Epithelial Medulla carcinoma 
BT-474 HTB-20 Epithelial Ductal carcinoma 
MDA-MB-468 I HTB-132 Epithelial Adenocarcinoma 
* American Type Culture Collection (Manassas, VA) 
** Using DNA microanays, MDA-MB-435 was found to express genes associated with 
melanoma (Ross et al., 2000). Thus it is possible that this cell line is not a breast cancer cell 
line but instead a melanoma cell line. 
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Table 2.2. B cell lines used as controls in this study. 
B CellLine IHW* Identification HLA-DRType 
JESTHOM rnw 9004 DRB1*0101 
MGAR rnw 9014 DRB 1 * 1 501, DRB5*0 101 
cox IlfVV 9022 DRBJ *0301, DRB3*0101 
SAVC IHW 9034 DRBI *0401 , DRB4*0101 
MT14B IHW 9098 DRB I *0404, DRB4*0101 
HAS115 IHW 9298 DRB1*0405, DRB4*0101 
OMW IHW 9058 DRB1*1301, DRB3*0101 
CB6B rnw 9060 DRB1 *1301, DRB3*0202 
H0301 IHW 9055 DRB 1 * 1302, DRB3*0301 
PLH ·. · IHW 9047 DRB1 *0701, DRB4*0101 
• · .. 
* International Histocompaubllity Workshop 
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cells no longer adhered to the flask, the cell suspension was transferred to a 15 ml centrifuge 
tube and trypsin activity was terminated by adding an equivalent volume of complete media. 
Cells were centrifuged at 300 g for 7 minutes after which the supernatant was decanted and 
the cell pellet was re-suspended in 5 mlcomplete media. To maintain cell cultures, 3x105-
5xl05 cells were dispensed into 25 cm2 tissue culture flasks in a final volume of 7 ml 
complete media. 
B cell lines were maintained by removing approximately one third of mixed cell 
suspension and by adding the same volume of fresh media. This was done twice a week. 
2.2. IFN~y Treatment of Breast Cancer Cell Lines 
To up-regulate e](pression of HLA class II and class II co-chaperone genes, breast 
·. . 
cancer celllineswere treated with500 units/ml human recombinant interferon-gamma (IFN-
y)(Phamlingen, San Diego, CA). Twenty-four hours prior to IFN-ytreatment, cell lines were 
subcultured, as described above, into 25 cm2 tissue culture flasks such that each flask 
received 2x105-5x10S celJs in 7 ml complete media 
At the time oflFN-ytreatment, media was aspirated from cells and replaced with 
complete media containing 500 units/mllFN-y. To ascertain constitutive gene expression, 
a second flask containing the same cell line received complete media without IFN-y. Most 
experiments were incubated for 96 hours but to detennine the optimal time for induced 
expression some experiments were incubated for various times, from 6 hours to 168 hours. 
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2.3. HLA Class II Typing of Breast Cancer Cell Lines 
2.3.1. DNA Extraction 
Adherent breast cancer cells were harvested using 0.25% trypsin (see section.2.1) and 
washed once with PBS. The cell pellet was re-suspended in 1 ml of PBS and transferred to 
a 1.5 'ml Eppendorf tube. Cells were centrifuged at 12,000 g for 1 minute and the supernatant 
was drained .. Cells were lysed by re-suspending in 1 ml DNAZOL reagent (GibcoBRL) for 
3 minutes. DNA was precipitated by adding 0.5 ml 100% ethanol (Sigma, St. Louis, MO). 
Following centrifugation at 12,000 g for 30 seconds, the supernatant was decanted and the 
DNA pellet was washed twice using 1 rnl 95% ethanol. ·For each wash, the Eppendorf tube 
was inverted several times and centrifuged at 12,000 g for 30 seconds. Following the second 
ethanol wash, DNA was air dried for10 minutes and re-suspended in 50-100 w 8 mM NaOH, 
depending on the amount of DNA extracted. To facilitate DNA solubilization, DNA was 
heated at 65"C for 5 minutes. Finally, DNA was quantified using UV spectrophotometry. 
A A2«lA280 ratio ranging from 1.6-1.9 was used as an indication of DNA purity. Since A260 
= OD260 = 1 for a 50 jlg/rnl solution of double stranded DNA (Ryan et al. , 1997), the 
following calculation \vas used to determine the concentration of DNA: 
(OD260 - OD320) x 50 J.tg/ml x Dilution Factor = DNA Concentration (jlg/ml). 
The OD320 was subtracted as background. 
2.3.2. HLA Class II DNA Typing of Breast Cancer Cell Lines for HLA-DRB and HLA-
DQB Genes 
To identify the HLA-DRB and the I-ll..A-DQB1 genes in each breast cancer cell line, 
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the Micro SSP Generic HLA Class ll DNA Typing kit from One Lambda (Canoga Park, CA) 
was used. When this kit was unsuccessful in detennining I-ll..A-DQB 1 types, the FastypeDQ 
Low Resolution PCR-SSP Typing kit (Bio-Synthesis, Louisville, TX) was employed. Cell 
lines typing positive for HLA-DRBl*Ol, DRBl *04, DRB 1 * 13 and DRB3 were subtyped to 
identify I-ll..A-DRB alleles. The following commercially available kits were used: the Micro 
SSP HLA-DRB 1 *04 Allele Specific Class ll DNA Typing Tray (One Lambda), the Fastype 
DNA-SSP DRB1 *01 Subtyping kit (Bio-Synthesis), the Fastype DNA-SSP DRBl *13 
Subtyping kit (Bio-Synthesis) and the Fastype DNA-SSP DRB3 Subtyping kit (Bio-
Synthesis). The DRB 1 *01 and DRB 1 * 13 typing kits were generously provided by theHealth 
Sciences Centre Clinical hnmuriology Laboratory (St. John's, NF). Detailed instructions 
describing . usage of each typing kit were provided by the manufacturer. For this reason, 
methodologies wm not be repeated. However, a brief description of typing kits will ensue. 
Pre-aliquoted sequence speci fie primers . capable of amplifying class n alleles or 
groups of alleles by polymerase chain reaction (PCR) were supplied in DNA typing trays. 
As a control for successful PCRamplification, primers capable of amplifying housekeeping 
genes i.e. P-globin or glyceraldehyde 3-phosphate dehydrogenase (G3PDH) were included. 
Specially formulated mixes containing PCR buffer and dNTPS were provided. Taq DNA 
polymerase (5 unitsi!J.l) (GibcoBRL) was required but not provided. Class ll genes were 
amplified in the Lab-Line Programmable Them1al Blok ll (Melrose Park, IL) or the Biometra 
Temperature Gradient (Montreal Biotech Inc., Kirkland, QC) as per manufacturer's 
instructions. 
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2.3.3. Electrophoresis of PCR Products 
To visualize PCR products, each PCR reaction (10 I-Ll) was loaded into wells of a 
1.5% agarose gel. Electrophoresis dye wa<; not required since cresol red was included in 
reagents in the typing kits. To determine the size of amplified PCR products, -0.19 ~Lg of · 
a l OObp DNA ladder (GibcoBRL) was mixed with -1 ).llloading buffer (see Appendix A) 
and electrophoresed at the same time. The gel was made by dissolving 0.6 g agarose 
(GibcoBRL) in 40 ml 0.5x TBE buffer (Tris borate EDTA buffer-see Appenidx A ) 
containing 0.5 ~gfml ethidium bromide. PCR products were electrophoresed at 120V for 7-
15 minutes in the Mini Sub DNA Cell electrophoresis chamber (BioRad, Mississauga, ON) 
containing O~Sx TBE buffer. The gel was photographed under UV light and interpretation 
of HLA class II typing results was aided by the provided worksheets. 
2.4. Flow Cytometry . 
2.4.1 Primary Antibodies 
A description ofprimary antibodies used to detectexpression ofHLA class II (HLA-
DR, -DP, -DQ) and class II co-chaperones is presented in Table 2.3. NFLD.M67 was 
obtained locally. L243 (HB-55) and W6/32 (HB-95) were obtained from the American 
Type Culture Collection while the remaining antibodies were obtained commercially. 
Primary antibodies used to detennine expression of HLA-DR allelic products are described 
in Table 2.4. NFLD~DJ, NFLD.D7, NFLD.D2, NFLD;DlO and NFLD.Ml were obtained 
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Table 2.3. Primary antibodies used to detect HLA class II and class II co-chaperone protein 
expression by flow cytometry and immunocytochemistry. 
Antibody Isotype Specificity Concentration ·Reference/ 
Flow IC* Source 
L243 Mouse All HLA- 5pg/ml 2.4~g/rnl, Lampson & 
(Supernatant) IgG2a DR 19pg/ml 19pg/ml Levy, 1980 
SPV-L3 Mouse All HLA- 1/20 NT** Novocastra 
IgG2a DQ (Newcastle upon 
Tyne, UK) 
NFLD.M67 Mouse All HLA-' Neat NT Inoko et al., 
(Supernatant) IgG l DP 1992 
CD74 Mouse Invariant NT 1/5 Biotest 
Clone LN2 IgG1 chain Diagnostics 
(Denville, NJ) 
C074 Mouse Invariant 10pg/ml NT PharMingen 
Clone LN2 IgGl chain International 
(San Diego, CA) 
HLA-DM Mouse HLA-DM 5pg/ml 5~g/rn1 PharMingen 
·clone IgG1 International 
MaP.DMI I 
CD40 Mouse CD40 5pg/ml 5j..~g/ml PharMingen 
Clone 5C3 IgG1 International 
CD80 Mouse CD80 20pg/ml 20pg/ml Cedar lane 
CloneDAL-1 IgGl Laboratories 
(Hornby, ON) 
CD86 Mouse CD86 20j..~g/ml 20j..~g/ml Cedarlane 
CloneBU63 IgGl Laboratories 
*Immunocytochemistry** Not tested 
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Table 2.4. Primary antibodies used to detect expression of HLA-DR allelic products by flow cytometry and by 
i mmunocytochem:istry. 
Antibody Isotype Specificity Concentrati(;n Reference/ 
Flow IC* Source 
NFLD.Dl Mouse AIJDR4 39~g/ml lO~g/ml Drover et al., 1992a, 
(Purified) IgGl Drover et al., 1994 
NFLD.D7 Mouse DR4, DR15, DR16, DR52 Neat 1/100 Drover et al. , 1992a, 
. (Supernatant) lgGl Drover et al. , 1994 . 
NFLD.DlO Mouse DR1, DR4 except B 1*0402, DR9, 2.5pg/ml 2 .5~g/ml Drover et al. , 1992a, 
(Purified) IgGl DRlO, DR14, DR15, DRB5*0201 Drover et at. , 1994 
NFLD.D2 Mouse DR4 except B1 *0402, DR 1, DR 15, 5~tg/ml 5pg/ml Drover et al. , 1992a, 
(Purified) lgG1 DR14, DRB5*0201 Drover et al., 1994 
NFLD;Ml Mouse DR4, DRS, DR52 Neat 11100 Drover et al., 1985, 
(Supernatant) IgGl Fu et al. , 1995 
.TS-1 Mouse DRl except Bl *0103, DR3, DR4 1/100 111000 Sachs eta!., 1986 
(Supernatant) IgG2a except Bl*0402, DRBl *1402, DR52 ll1h IHW 
UK8. 1 Mouse DR3, DRll , DR 13, DR14 except 1/100 111000 Bodmer et al. , 1985, 
(Supernatant) IgG2b Bl*l404 111h IHW 
7.3 .19.1 Mouse DR3, DR52 · l/100 111000 Koning et al. , 1984, 
(Supernatant) IgG2b 11th IHW 
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Table 2.4. Continued. 
Antibody Isotype Specificity Concentration Reference/ 
Flow IC* Source 
NDS13 Mouse DR3, DR11, DR12, DR13, DR14, 1/100 1/1000 Fuggle et al., 1987, 
(Supernatant) IgGl DR8, DR52 lO'h IHW 
PL3 Mouse DR7, DR9, DR53 1/100 1/500 Horibe et al. , 1994, 
(Supernatant) JgG3 ll'h rnw 
SFR16.DR7M Rat DR7 11100 NT** Radka et al. , 1984, 
(Supernatant) IgG2b 11'11 IHW 
* hnmunocytochemistry **Not tested 
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locally while the remaining HLA-DR specific antibodies were obtained through the lOu' and 
the lith International Histocompatibility Workshops (lHW). Negative isotype control 
antibodies used for flow cytometry were generous gifts from Terra Nova Biotechnology (St. 
John's, NF). 
2.4.2. Secondary Antibody 
To detect primary antibody binding, a fluorescent labeled secondary antibody, R-
phycoerythrin conjugated AffiniPure F(ab')2 fragment goat anti-mouse IgG, Fe fragment 
specific (Jackson ImmunoResearch, West Grove, PA) was used. 
2.4.3. Extracellular Flow Cytometry 
To detect expression of cell surface antigens, extracellular flow cytometry ·was 
performed. Twenty-five microlitres of primary monoClonal antibody diluted to a pre-
determined concentration (Table 2.3 and Table 2.4) usingFACS buffer were added to each 
polystyrene12x75 mm tube (Fischer Scientific,Nepean, ON). FACS buffer contained 0.2% 
fetal bovine serum (GibcoBRL) and 0.02% sodium azide (BDH Chemicals, Poole, England) 
in PBS. IFN-y treated and untreated adherent breast cancer cell lines were removed from 
culture using 0.25% trypsin (see section 2.1). Non-adherent B cells, used as positive 
controls, were also removed from culture. Cells were washed once with PBS and re-
suspended in an appropriate volume of FACS buffer such that each tube received lxl05-
3x105 cells in a final volume of 100 j.il. The cell suspension and primary antibody were 
mixed and incubated for 30 minutes at 4°C in the dark. After the incubation, the cells were 
washed twice. For each wash, 2 ml FACS buffer were added to each tube and the cells were 
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centrifuged at 300 g at 4 OC for 7 minutes. Following the second wash, the supernatant was 
decanted and the lip of each tube blotted on gauze. Twenty-five tnicrolitres of secondary 
antibody, diluted 1120 in F ACS buffer, were placed in each tube. The cells and secondary 
antibody were incubated for 30 minutes at 4"C in the dark. Cells were washed twice using 
FACS buffer as described above. Finally, cells were re-suspended in 150-200 jll 1% 
parafom1aldehyde (see Appendix A). Tubes were stored a.t 4°C for approximately 24 hours 
until FACS analysis usingthe FACS Star Plus (Becton-Dickinson, San Jose, CA). 
2.4.4. Intracellular Flow Cytometry 
To assess expression of inlracellular antigens, intracellular flow cytometry was 
pedormed. This methodology is similar to flow cytometry for cell surface antigens with the 
notable exceptions that the cells were fixed and permeabilized. 
After breast cancer cell lines and B cell lines were removed from culture and washed 
once with PBS, cells were fixed in 5 ml2% paraformaldehyde for 15 minutes at 4 OC. To 
quench fixation, 8 ml complete media were added to the cells and the cells were centrifuged 
at 300 g for 7 minutes at 4 OC. Cells were washed once with 10 ml PBS and cells were 
centrifuged at 300 g for 7 minutes at 4°C. .To permeabilize cells, cells were re-suspended in 
5 ml PBS containing 0.2% saponin (Polysciences, Warrington, PA) for 15 minutes at 4°C. 
Cells were centrifuged at 300 g for 7 minutes at 4 OC and re-suspended in an appropriate 
volume of wash buffer. Wash buffer contained 0.5% bovine serum albumin (Sigma) and 
0.2% saponin (Polysciences). 
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The remainder of the assay proceeded as described for extracellular flow cytometry 
(section 2A.3) except that the primary antibodies and the secondary antibody were diluted 
in wash buffer and the cell washes were completed using wash buffer. This was done to 
ensure that the cells remained pe1meabilized throughout the assay. 
2.4.5. Interpretation of Flow Cytometry Data 
The degree of expression of a particular antigen was determined as follows: Test 
Mean Fluorescence Intensity/ Background Mean Fluorescence Intensity. Scoresof2.0 and 
below were considered negative. Scores of 2.1-5.0 were considered weakly positive. Scores 
of 5.1-10 were considered moderately positive while scores of 10 and above were considered 
strongly positive. This arbitrary analysis was adapted from Tibbo et al. (1998). 
When more than one experiment was performed, data was averaged and standard 
deviations between experiments were determined. 
2.5. Immunocytochemistry 
2.5.1. Primary Antibodies 
As described in section 2.4.1, primary antibodies used to assess HLA class IT and 
class ll co-chaperone expression are provided in Table 2.3. Similarly, expression of HLA-
DR allelic products was ascertained using antibodies described in Table 2.4. Negative 
control isotype antibodies used for immunocytochemistry were as follows: mouse lgG 1 
isotype control (Clone DAK-001) (DAKO), mouse IgGl isotype control (clone 15H6) 
(Southern Biotechnology, Birmingham, AL), mouse IgG2a isotype control (clone HOPC-1) 
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(Southern Biotechnology), mouse IgG2b isotype control (clone A-1) (Southem 
Biotechnology) and mouse IgG3 isotype control (clone B 10) (Southern Biotechnology). 
2.5.2. Secondary Antibodies 
DAKO EnVision peroxidase labeled polymer conjugated to goat anti-mouse 
immunoglobulins (Ig) (DAKO, Carpinteria, CA) or peroxidase conjugated AffiniPureF(ab')2 
fragment goat anti-mouse IgG + IgM (H+L) (Jackson ImmunoResearch) were used to detect 
primary antibody binding. 
2.5.3. Substrate 
To detect primary and secondary antibody complexes, Sigma Fast 3,3'-
diaminobenzidine (DAB) (Sigma) was used. This substrate was made by dissolving one 
DAB tablet and one urea hydrogen peroxide (H20 2) tablet in 1 ml distilled water. H20 2 
reacts with peroxidase conjugated to the secondary antibody liberating 0 2 and water. 0 2 
reacts with DAB and an insoluble, brown-black precipitate is formed. Thus cells positive 
for a particular protein were colored brown-black. 
2.5.4. Immunocytochemistry using Cytocentrifuge Preparations 
2.5.4.1. Cytocentrifuge Preparations 
Adherent IFN-y treated and untreated breast cancer cell lines were removed from 
culture using 0.25% trypsin (see section 2.1). Non-adherent B cell lines, used aspositive 
controls, were additionally collected. Cells were washed twice with PBS. For each wash, 
cells were re-suspended in approximately 6 ml 1 x PBS and centrifuged at 300 g for 7 
minutes. To permanently adhere cells to 3" x 1" microscope slides, cytocentrifuge 
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preparations were made. A filter card (Shandon Inc., Pittsburgh, PA) was assembled 
between the cytocentrifuge (Shandon, Inc.) sample chamber and the microscope slide. CeJls 
( 4x 104-5xl04), re-suspended in 0.5 ml PBS, were added to the cytocentrifuge sample 
chamber. Cells were cytocentrifuged at 200 g for 5 minutes. Prior to inmmnocytochemistry, 
cells were air dried for at least 24 hours. 
2.5.4.2. Immunoqtochemistry 
Cells were fixed with acetone for 15 minutes at -20°C and air dried for 1 hour. After 
washing cells \Vith PBS, cells were treated with 200 ~1 0.9% H20 2 diluted in PBS to release 
cellular endogenous peroxidase. Cells were washed once with PBS and once with wash 
buffer containing 0.5% bovine serum albumin (Sigma) and 0.05% Tween-20 (Fischer 
Scientific, Nepean, ON). The washes were performed by expeJJing a stream of PBS or wash 
buffer from a wash bottle. To prevent non-specific antibody binding, cells were treated with 
approximately 200 ~I blocking buffer, 15% goat serum diluted in PBS, for 1 hour. After 
removal of excess blocking buffer, 50 pJ primary antibody, diluted to a pre-determined 
concentration (Table 2.3 and Table 2.4) in wash buffer, were placed on cells for 1 hour. 
Ce~ls were then washed by a stream of wash buffer and also by immersing cells in wash 
buffer for 20 minutes. Fifty microliters of secondary antibody, DAKO En Vision peroxidase 
labeled polymer {DAKO), were added to cells for 30 minutes. Cells were then washed with 
wash buffer as described above except following immersion in wash buffer, slides were 
immersed in PBS for 15 minutes. The substrate, Sigma Fast 3,3'-DAB (Sigma), was added 
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to cel1s for 7-10 minutes. Cells were washed with distilled water and counterstained with 
Mayer's hematoxylin (see Appendix A) for 10 minutes. After washing cells in tap water to 
remove excess hematoxylin, cells were immersed in Scott' s tap water (see Appendix A) for 
1 minute. Cells were dehydrated by immersion in 70% ethanol, 95% ethanol, 2 changes of 
100% ethanol for 1 minute each and in 2 changes of xylene for 2 minutes each. Cells were 
permanently mounted in DPX (BDH Chemicals, Toronto, ON) or Micromount (SurgiPath, 
Winnipeg, MB) and examined by light microscopy. 
2.5.5. Immunocytochemistry using Chamber Slides 
2.5.5.1. Chamber Slide Set-Up 
Breast cancer cell lines were re-suspended in complete media containing IFN -y or in 
complete media without IFN -y. Complete media (200 Ill) containing 5x 104-1 x 10-1 cells were 
distributed into a 16-well Lab-Tek chamber slide (Nalge Nunc, Naperville, 1L) such that 8 
wells received IFN-ytreated cells and 8 wells received untreated cells. Chamber slides were 
incubated for 96 hours after which media was aspirated and cells were washed twice with 
PBS. For each wash, each well of the chamber slide was filled with PBS and then carefully 
aspirated using a Pasteur pipette. Prior to immunocytochemistry, cells were air dried for at 
least 24 hours. 
2~5.5.2. Immunocytochemistry 
Cells were fixed with acetone for 15 minutes at -20°C and air dried for 1 hour. Cells 
were washed twice using wash buffer containing 0.5% bovine serum albumin (Sigma) and 
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·. 0.05% Tween-20 (Fisher Scientific) in PBS. For each wash, each well of the chamber slide 
was filled with wash buffer and then carefully aspirated. Next, 100 Jll blocking buffer, 15% 
human AB serum in PBS, were added to cells for 1 hour. Blocking buffer was aspirated 
fTomcells and approximately 65 J..Ll primary antibody diluted to the appropriate concentration 
(Table 2.3 and Table 2.4) in wash buffer were added to cells for 1 hour. After washing cells 
3 times with wash buffer, 100 J..Ll secondary antibody diluted 11500 in wash buffer, were 
added to cellsfor 30 minutes. The secondary antibody was from Jackson ImmunoResearch 
(see section 2.5.2) . . Cells were washed twice with wash buffer and once with PBS. The 
substrate, Sigma Fast 3,3'-DAB (Sigma), was added to cells for 7-10 minutes. Cells were 
washed with distilled water and counterstained with Mayer' s hematoxylin and dehydrated 
as described in section 2.5.4.2. Finally, cells were pennanently mounted in DPX mount 
(BDH Chemicals) and examined by light microscopy. 
2.5.6. Interpretation of Immunocytochemistry Data 
Immunocytochemistry was analyzed independently by two different individuals. 
When possible, the percentage ofpositive cells was detem1ined and data was interpreted as 
follows: <20% positive cells was considered negative; 21-40% positive cells was considered 
weakly positive; 41-60% positive cells was considered moderately positive; 61-80% positive 
cells was considered strongly positive and 81-100% positive cells was considered very 
strongly positive. Staining intensity was also noted. This arbitrary analysis was adapted 
from Drover et al. (1994a) and Tibbo et al. (1998). 
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2.6. Reverse Transcriptase Polymerase Chain Reaction (RT -PCR) 
2.6.1. RNA Extraction 
IFN-1 treated and untreated adherent breast cancer cells, grown in 25 cm2 tissue 
culture flasks, were harvested using 0.25% trypsin (section 2.1) and washed once with PBS. 
B cells, used as controls, were removed fTOm suspension culture and washed once with PBS. 
After centrifugation at 300 g for 7 minutes, the cell pellet was re-suspended in lml PBS and 
transfen·ed to a 1.5 ml Eppendorf tube. Cells were centrifuged at 12,000 g for 1 minute and 
the supernatant was drained. Cells were lysed by re-suspending in 1 rnl TRIZOL reagent 
(GibcoBRL) for 3 minutes. Following centriguation at 12,000 g for 10 minutes, theTRIZOL 
mixture was transferred to a 1.5 ml Eppendorf tube. Chloroform (0.2 ml) (Sigma) was 
added to the tube and the tube was shaken vigorously for 20 seconds. After an incubation 
of 3 minutes, the mixture was centrifuged at 12,000 g for 15 minutes. The upper aqueous 
layer, containing the RNA, was transferred to a l.5 ml Eppendorf tube and then combined 
with 0.5 ml isopropanol (Sigma). RNA was precipitated overnight at -20CC. 
RNA was centrifuged at 12,000 g for 10 minutes after which the supernatant was 
drained from the tube. RNA was washed once with 1 ml 75% ethanol dissolved in DEPC 
(diethyl pyrocarbonate) water (see Appendix A). Following centrifugation at 12,000 g for 
5 minutes, the supernatant was removed and the RNA was air dried for I 0 minutes. RNA 
was re-suspended in 10~30 Jll DEPC water depending on the amount of RNA extracted. To 
facilitate RNA solubilization, RNA was heated at 65 CC for 5 minutes. Finally, RNA was 
quantified using UV spectrophotometry. A A26c/ A280 ratio ranging from 1.6-1.9 was used 
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as an indication of RNA purity. Since the A260 = OD260 = 1 for a 40 ~g/ml solution of RNA 
(Mullner & Garcia-Sanz, 1997), the following calculation was used to determine the RNA 
concentration: 
(OD260 - OD_120) x 40 f.lg/ml x Dilution Factor= RNA Concentration(~g/ml). 
The OD320 was subtracted as background. 
Alternatively, adherent breast cancer cells, grown in 25 cm2 tissue culture flasks, 
were washed once with PBS. After aspiration of PBS from cells, 1 ml TRJZOL reagent was 
added directly to cells in the tissue culture f1ask. The remainder of the RNA extraction 
followed the same protocol as described above. 
2.6.2 RNasin Treatment of RNA 
To protect RNA from ribonuclease activity, 30 Units RNasin (Promega, Madision, 
WI), a ribonuclease inhibitor, was added to each RNA sample. 
2.6.3. DNase Treatment of RNA 
In some instances, it was necessary to remove contaminating DNA from RNA using 
DNase. Critically, RNA extracted from cells exposed to trypsin was not suitable for DNase 
treatment. An explanation will be provided in section 3.2. Thus, RNA for treatment with 
DNase was extracted by adding TRIZOL directly to adherent cells in a tissue culture flask. 
DNA-freeDNase treatment and removal systemfromAmbion (Austin, TX) was used 
to remove contaminating DNA from RNA samples. Manufacturers instructions were 
followed in detail. Briefly, DNase l (2 units) and DNase I buffer containing 10 m.M Tris-
HC1, 2.5 mM MgC12 and 0.1 mM CaC12 were combined with RNA in a 0.2 ml thin walled 
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micro tube (Gordon Technologies, Mississauga, ON). This mixture was incubated at 3TC 
for 25 minutes. Following this incubation, DNase Inactivation Reagent was added to this 
RNA preparation and the tube was incubated at room temperature for 2 minutes. 
Centrifugation at 12,000 g for 1 minute was required to pellet the DNasc Inactivation 
Reagent. DNase treated RNA was stored at -70"C. 
2.6.4 eDNA Synthesis 
The synthesis ofcDNA from RNA samples was accomplished using the First Strand 
eDNA Synthesis kit form Pharmacia Biotech (Baie d'Urfe, QC). A 1.5 j..lg sample of RNA 
was placed in a 0.2 ml thin walled micro tube (Gordon Technologies} and DEPC water was 
added to the RNAsuch that the final volume was 8 j.tl. RNA was heated at 6YC for 10 
minutes and then quick chilled on ice. 
For each reaction, 5 j..tl bulk first-strand eDNA reaction mix, 1 j.tl DTT (dithiothreitol) 
solution and lj.tl Not I-d(T) 18 primer (diluted 1/25 inDEPC water) were combined and 
. . 
added to the denatured RNA. The sample was then incubated in the Lab-Line Programmable 
Thermal Block II (Melrose Park, IL) or the Biometra Temperature Gradient (Montreal 
Biotech Inc., Kirkland, QC) at 3TC for 1 hour and at 70'C for 10 minutes. eDNA was 
stored at -70"C until required. 
2.6.5. Primers for RT-PCR 
Bio-Synthesis (Louisville, TX) primer mixes, mainly intended for use in HLA-DR 
DNA typing, wereused to amplify DRBl, DRB3 and DRBS mRNA in PCR. Olerup and 
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Zetterquist ( 1992) provide a detailed description of these primers. Primers used to analyze 
gene transcription are listed in Table 2.5. For the most part, these primer sequences are 
published. However, sequences of ~-actin primers were kindly provided by Drs. Laura 
Gillespie and Gary Paterno (Memorial University of Newfoundland, St. John's, NF). HLA-
DQA and HLA-DQB primers were provided by Dr. David Haegart (Memorial University 
of Newfoundland, St. John's, NF). HLA-DMA, HLA-DMB, HLA-DOA and HLA-DOB 
· primers were designed using sequences acquired from Genbank. The accession numbers of 
the gene sequences used to construct these primers were: X76775 for DMA, X76776 for 
DMB, M26039 forDOAandL29472 forDOB. 
2~6.5.1. Primer Design 
Primer sequences, 20-22 bases in length, were devised using the Genbank sequences 
listed above (section 2.6.5). These sequences were entered in the Amplify program (Engels, 
1993). This software analyzes primers to ensure that primer pairs do not fmm dimers and 
to ensure that primer affinity to the gene of interest is suitable. As V\1ell, primer sequences 
were analyzed using OligoTech Analysis software (Wilsonville, OR) to determine the primer 
G+C content and melting temperature. Once primer sequences were selected, primers were 
synthesized by GibcoBRL. 
2.6.6. PCR Amplification of HLA-DRBI, DRB3, DRB4 and DRBS mRNA 
For each reaction, 15 f.!l primer mix (Bio-Synthesis) {see section 2.6.5) were added 
to each 0.2 ml thin walled polypropylene PCR tube (Gordon Technologies). Additionally, 
PCR buffer (GibcoBRL) containing 20 mM Tris-HCl (pH 8.4) and 50 mM KCI, 0.2 ruM 
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Table 2.5. Primers used to detect HLA class II and class II co-chaperone transcription hyRT-PCR. 
Primer· Primer Sequence (5' to 3') Reference/Source 
DRA Sense GTTCTGCTGCATTGCTTTTGCGCA Nandan & Reiner, 1997 
DRA Antisense CGAGTTCTATCTGAATCCTGACCA 
DRBSense CCCCACAGCACGTTTCTTG Kimura & Sasazuki, 1992 
DRB Antisense CCGCTGCACTGTGAAGCTCT 
DRB1*0404 Sense GTTTCTTGGAGCAGGTTAAACA Olerup & Zetterquist, 1992 
DRB I *0404 Antisense CTGCACTGTGAAGCTCTCAC 
DRB 1 *040 1/0405 Sense GTTTCTTGGAGCAGGTT AAACA Olerup & Zetterquist, 1992 
DRB 1 *0401/0405 Antisense CTGCACTGTGAAGCTCTCCA 
DRB 1 *07 Sense CCTGTGGCAGGGTAAGTATA Olerup & Zetterquist, 1992 
DRB l *07 Antisense CCCGTAGTTGTGTCTGCACAC 
DRB4 Sense GAGCGAGTGTGGAACCTGA Olerup & Zetterquist, 1992 
DRB4 Antisense CTGCACTGTGAAGCTCTCCA 
DQASense ATGGTGTAAACTTGTACCAGT Kimura & Sasazuki, 1992 
DQA Antisense TTGGTAGCAGCGGTAGAGTTG 
DQB.Sense CATGTGCTACTTCACCAACGG Kimura & Sasazuki, 1992 
DQB Antisense CTGGTAGTTGTGTCTGCACAC 
DPA Sense GCGGACCATGTGTCAACTTAT Kimura & Sasazuki, 1992 
DP A Antisense GCCTGAGTGTGGTTGGAACG 
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Table 2.5. Continued. 
Primer Primer Sequence (5' to 3') Reference/Source 
DPB Sense CCAGCTCCATGATGGTTC Peijnenburg et al. , 1995 
DPB Antisense CTGGACTCGGCGCTGCAGG 
CUT A Sense # 1 CCTGATGCACATGTACTGGGC Chin et al., 1994 
· ClJTA Antisense #1 GGTCTTCCACATCCTTCAGGG 
CUT A Sense #2 CAAGTCCCTGAAGGATGTGGA Tai et al., 1999 
CUT A Antisense #2 ACGTCCATCACCCGGAGGGAC 
Invariant chain Sense TCCCAAGCCTGTGAGCAAGATG Chang & Flavell, 1995 
Invariant chain Antisense CCAGTTCCAGTGACTCTTTCG 
. 
DMASense CCAATGTGGCCAGATGACCTGC See Section 2.6.5.1 
DMA Antisense GCGTGAACACTTCAGCGATAG 
DMB Sense GCAGAAGTGACTATCACGTGG See Section 2.6.5.1 
DMB Antisense CCGCCAGCTGATCACACCAAG 
DOA Sense CCACATGGGCTCCTACGGACC See Section 2.6.5.1 
DOA Antisense GGCAGGTAGTGGAACTTGCGG 
DOB Sense CTGCACTGCTCTGTGACAGGC See Section 2.6.5.1 
DOB Antisense GGACCTTAGCATGACTGAGG 
P~actin Sense ATCTGGCACCACACCTTCTACAATGAGCTGCG Patemo et aL, 1998 
B-actin Antisense CGTCATACTCCTGCTTGCTGATCCACATCTGC 
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dNTPs (GibcoBRL), 1.5 mM MgCI2 (GibcoBRL), 1 unit of Taq DNA polymerase 
(GibcoBRL) and 1 ~~eDNA or 1 J.Ll RNA were combined in a final volume of 25 Jll. An 
RNA sample was subjected to PCR to ensure that RNA was not inadvertently contaminated 
with DNA. Samples were placed in the Lab-Line Programmable ThermalBlok II or the 
PTC-lOOProgrammable Thermal Controller (MJ Research Inc., Watertown, MA). PCR was 
performed for 1 cycle at 94"C for 5 minutes and 34 cycles of 94°C for 30 seconds, 5TC for 
1 minute and 72°C for 1 minute. A final extension at 72"C for 5 minutes followed. 
HLA-DRBl *04, Bl*07 and DRB4 (DR53) primers were synthesized commercially 
by GibcoBRL from sequences obtained from Olerup & Zeitlerquist (1992) (see Table 2.5). 
The reaction mixes required for amplification of these HLA-DRB transcripts were the same 
. . 
as .that described above with some notable differences. The final volume of these reactions 
was 50 Jll. Primers were used at a concentration of 20 pmol and 1.25 m.M MgC12 was 
required in the DRBl *04 reaction mix. PCR amplification conditions are given in Table 2.6. 
2.6. 7. PCR Amplification of HLA Class II, Class II Co-chaperone and CIITA mRNA 
PCR was performed in a final volume of 50 Jll using: PCR Buffer (GibcoBRL) 
consisting of 20 mM Tris-HCl (pH 8.4) and 50 mM KCl, 0.2 mM dNTPs (GibcoBRL), 1 Unit 
of Taq DNA polymerase {GibcoBRL) and 1 ,:..,I ofcDNA or RNA. MgC12 (GibcoBRL) was 
required at a concentration 2 mM for DRB, DQB, DPA reactions and 1.5 mM for all other 
reactions. Concentrations of primers varied depending on the gene being amplified. 
Specifically, 10 pmol DMA and DMB primers were required, 25 pmol DRB, DQA, DQB 
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Table 2.6. PCR conditions used to amplify HLA class II and class ll co~chaperone mRNA. The expected size of the PCR product 
is also given. 
Primer Size ofPCR PCR Conditions 
Product (bp3 ) 
DRA 643 94 ·c for 1 minute, ss·c for 1 minute, 72·c for 3 minutes for 30 cycles. 
DRB 274 95"C for l minute, 63·c for 1 minute, 72"C for 1 minute for 3Qcycles. A final extension 
at 72"C for 5 minutes. 
DRB.1*04 260 94 ·c for l minute and 68"C for l minute for 2 cycles. 94 "Cfor 1 minute, 65"C for 
minute and 72"C for l minute for 30 cycles. 
DRB1 *07 ·. 232 94·c for 1 minute, 55"C for 1 minute, 72·c for lminute for 30 cycles. 
DRB4 213 94 ·c for I minute, 6o·c for l minute, 72·c for 1 minute for 30 cycles. 
DQA 229 9YC for 30 seconds, 55"C for 1 minute, 72"C for 1 minute for 30 cycles. Final 
extension at 12·c for 5 minutes 
DQB 214 95"C for 30 seconds, 5YC for 1 minute, 72"C for 1 minute for 30 cycles. Final 
extension at 72·c foi· 5 minutes. 
DPA 240 95"C for 30 seconds, 55"C for 1 minute, 72·c for I minute for 30 cycles. Final 
extension at 72"C for 5 minutes. 
DPB 376 . 94"Cfor l minute, 63 'C for 1 minute, 72"C for l minute for 30 cycles. 
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Table 2.6. Continued. 
Primer Size ~fPCR PCR Conditions 
Product (bpa) 
CHTASet#l 266 94 T for 1 minute, 60"C for 1 minute, 72"C for 3 minutes for 30 cycles. 
CllTA Set #2 470 94 OC for 1 minute, 60"C for 1 minute, 72"C for 3 minutes for 30 cycles. 
Invariant chain 340 94T for 1 minute; 55"C for 1 minute, 72°C for 3 minutes for 30 cycles. 
DMA 303 94·c for 1 ntinute, 6o·c for l minute, 72"C for 3 minutes for 30 cycles. 
DMB 296 94"C for 1 minute, 60"C for l minute, 72"C for 3 minutes for 30 cycles. 
DOA 446 94 ·c for 1 minute, 5YC for 1 minute, 72"C for 3 minutes for 30 cycles; 
DOB 406 94°C for 1 ininute, 55"C for 1 minute, 72"C for 3 minutes for 30 cycles. 
a base pairs 
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and DP A primers were required and 20 prnol of all remaining primers were required. PCR 
tubes were placed in the Lab-Line Programmable Thermal Block IT, the Biometra 
Temperature Gradient (Montreal Biotech lnc.) or the PTC-100 Programmable Thermal 
· Controller (MJ Research Inc.)~ Conditions employed to amplify eDNA are displayed in 
Table 2.6. 
2.6.8. Electrophoresis of PCR products 
To visualize PCR products, 5 ~of each PCR reaction were mixed with -1 ~I loading 
buffer (see Appendix A) and loaded into wells of a 1.5% agarose gel. At the same time, 
-0.19 ~g of a 1 OObp DNA ladder (GibcoBRL) was mixed with loading buffer and loaded 
into wells of the gel. The gel was made by dissolving 0.6 g agarose (GibcoBRL) in 40 rnl 
O.Sx TBE buffer containing 0.5 ~g/rnl ethidium bromide. PCR products were electrophoresed 
at 120V for 20-30 minutes inthe Mini Sub DNA Cell electrophoresis chamber (BioRad) 
containing 0.5x TBE buffer with 0.5 ~g/ml ethidium bromide. The gel was photographed 
under UV light and results were interpreted. 
2.6.9. Analysis of RT ·PCR Data 
Gene transcription was described as present or absent. No distinction between weak 
positives or strong positives was made. 
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CHAPTER 3. RESULTS 
3.1. Establishment of Optimal Conditions for Investigating Expression of HLA Genes 
in Breast Cancer Cell Lines 
3.1.1. Interferon-gamma (IFN-y) Culture Conditions 
JFN-y is the most potent inducer ofHLA expression (Jabrane-Ferret et al., 1990). For 
this reason, this agent is commonly used to up-regulate class II and class JI co-chaperone 
expression in a variety of cell types (Collins et al., 1984, Gastl et al., 1985, Boyer et al., 1989, 
Jabrane-Ferrat et al., 1990, Muczynski et aL, 1998, Kooy et al., 1999). JFN-y culture 
conditions reported in the literature vary from study to study. Previous research in our 
laboratory deterinined that a concentration of 500 units/mllFN-y was optimal for class II 
induction in synovial cells (Drover, unpublished data). Additionally, Tibbo (1998, Honor' s 
thesis) showed that the optimal lFN-y exposure time for breast cancer cell lines was 96 
hours. 
3.1.1.1. Concentration of IFN-y 
To confitm that 500 units/mllFN-')' was suitable for induction of HLA class II genes 
in breast cancer cell lines, T-47D was exposed to different 1FN-y concentrations, 100 
units/ml, 250 units/ml and 500 units/ml, for 96 hours. Cell surface HLA-DR expression was 
measured using the antibody L243 and flow cytometry. The results, reported in Figure 3.1 , 
show that HLA-DR up-regulation by T-47D cells was virtually the same for each 
concenu·ation of IFN-ytested. The concentration of 500 units/mllFN-y was chosen to up-
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Figure 3.1. Effect of different concentrations of IFN-y on the up-regulation 
of cell surface HLA-DR on the breast cancer cell line T-47D. Cells were 
cultured in the presence or absence of IFN-y for 96 hours and assayed for 
HLA-DR expression using the antibody L243 and flow cytometry. 
Expression is shown as test mean fluorescence intensity {MFI) minus 
negative control MFI. Standard deviations between two experiments are 
indicated. 
65 
regulate HLA class II and class ll co-chaperones in breast cancer cell lines since it was well 
above saturation. 
3.1.1.2. Exposure Time ofiFN-y 
Previous work in our laboratory showed that 96 hours was optimal for up-regulating 
cell surface HLA class ll expression on two breast carcinoma cell lines, BT -20 and MCF-7 
(Tibbo, 1998). To confirm these findings, two additional cell lines, MDA-MB-435 and 
MDA-MB-231, were treated with 500 units/rnl IFN~y for various times. For the cell line 
MDA-MB-435, cell surface HLA-DR expression was measured every 24 hours for 120 hours 
using the antibody L243 and flow cytometry (Figure 3.2A). HLA-DR expression was first 
observed at 24 hours, it increased 10 fold from 24 hours to 48 hours, remained steady from 
48to 72 hours, increased 3 fold from 72 to 96 hours and declined from 96 to 120 hours. This 
experiment confirmed Tibbo's (1998) findings that IFN-ytreatrnent for 96 hours was optimal 
for HLA-DR up-regulation on breast cancer cell lines. 
Contrasting these findings, another experiment showed that an IFN-y exposure time 
of96 hours was not always optimal. MDA-MB-231 was treated with 500 units/ml IFN-y and 
cell surface HLA-DR expression was measured every 24 hours for 168 hours except 120 
hours using L243 and flow cytometry. It wa.;; found that HLA-DR expression increased with 
increasing IFN-y exposure i.e. it did not plateau at 96 hours as previously observed (Figure 
3.2A). Optimally, each cell line should have been analyzed for their optimal IFN-y 
incubation time for induction of maximum HLA class II expression. However, for 
convenience, all breast cancer celUines were treated with IFN-y for 96 hours to induce or up-
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.Figure 3.2. Effects of IFN-y exposure time on HLA-DR expression in breast cancer 
cell lines. A) HLA-DR cell smiace expression on MDA-MB-435 and MDA-MB-231. 
Cells were cultured in the presence of 500 U/ml IFN-y and then assayed for HLA-DR 
expression using the antibody L243 and flow cytometry. Results are reported as mean 
fluorescence intensity (MFI) minus the background. B) HLA-DRA transcription in 
MDA-MB-435 as assessed by RT -PCR for 30 cycles. ~-actin was amplified as a 
control. eDNA was synthesized using non-DNase treated RNA from trypsinized cells. 
RNA was subjected to . PCR to ensure the absence of DNA contamination. IFN-y 
exposure time is listed along the top. The B cell line SA VC (S) was used as a positive 
control. 
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regulate gene expression .. It was reasoned that a longer period of time was not suitable Since 
most cell lines required harvesting after 96 hours in culture. 
Additionally, RNA was extracted from MDA-MB-435 prior to IFN~r treatment and 
every 24 hours during the 120 hour IFN-r time response. HLA-DRA and ~-actin mRNA 
were amplified using sequence specific primers and RT-PCR (see section 2.6). As seen in 
Figure 3.2B, HLA-DRA and ~-actin transcripts were detected at all intervals throughout the 
IFN-r time response. No DNA contamination was detected in this reaction (Figure 3.2B). 
Clearly, less HLA-DRA mRNA was detected in untreated cells i.e. at 0 hours. 
Quantitatively, there is little variation in the amount of DRA mRNA detected between 24 
hours and 120 hours of IFN~y treatment. The main reason for assessing class II transcription 
at various times of the IFN-y time response was to ensure that class II rnRNA \vas detectable 
following 96 hours of IFN-y treatment. This allowed the analysis of class II protein 
expression and class II transcription at the same time using the same passage of cells in 
certain experiments. 
3.1.2. Effects of Trypsin Treatment on Breast Cancer Cell Lines 
3.1.2.1. Cell Surface Expression 
To test whether trypsin treatment of cells reduced the level of HLA molecules, a B 
cell line, MT14B, which constitutively expresses HLA class II, was used. Cells (5 x 106) 
were re-suspended in 5ml PBS containing 0.25% trypsin for 2 minutes and for 5 minutes or 
in 5ml PBS for 5 minutes at 3TC. These times were chosen as they are the times typically 
required to detach adherent breast cancer cell lines. After adding 5ml complete media to 
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quench trypsin activity, cells were washed once with PBS and cell surface HLA-DR, -DP and 
-DQ expression were detemlined using monoclonal antibodies (mAbs) and flowcytometry 
(see section 2.4). The results, displayed in Figure 3.3, show that class II was only slightly 
modulated by trypsin treatment. Cells treated for 2 minutes and 5 minutes showed a5% and 
a 14% decrease in HLA-DR cell surface expression, respectively, while HLA-DQ expression 
increased by 18% and 8% with trypsin treatment for 2 and 5 minutes respectively. HLA-DP 
expression increased by 2% with 2 minutes of trypsin treatment and decreased by 7% with 
5 minutes of trypsin exposure. Since trypsin treatment insignificantly altered HLA class II · 
cell surface expression, all assays to determine cell surface expression of class ll molecules 
on breast cancer cell lines were carried out using trypsin to remove adherent cells. 
3.1.2.2. RNA Quality and RT -PCR 
. . . . 
While trypsin induced changes in cell surface antigenic determinants have been 
addressed· in the literature, no infom1ation was found regarding trypsin induced alterations 
ofmRNA. At the start of this project, experiments were set-up such that IFN-y induced and 
non-induced cell surface protein and mRNA were examined from the same cell culture. 
Thus, adherent breast cancer cell lines were treated with 0.25% trypsin to facilitate their 
removal from cell culture. A portion of these cells was used for flow cytometry while the 
remainder was stored at -70'C for RNA extraction at a later date. RT-PCR performed using 
eDNA synthesized from these RNA samples yielded satisfactory amplification of class II 
mRNA. 
Unfortunately, DNA contamination was detected in certain RNA samples. This was 
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Figure 3.3. Trypsin treatment minimally affected cell surface expression of 
HLA class II molecules on a B cell line, MT14B. The B cell line, MT14B 
was treated with 0.25% trypsin for 2 minutes and 5 minutes or not treated. 
Cell surface HLA class n expression was assessed using monoclonal 
antibodies (Table 2.3) and flow cytornetry. Results are depicted as test mean 
fluorescence intensity (MFI) minus the background MFI. 
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most noticeable when using primers that amplified genes with several copies in the genome 
i.e. DRB primers. For example, as seen in Figure 3.4, certain RNA samples subjected toRT-
PCR for DRB amplification were contaminated with DNA. Reagents were not contaminated 
since a water control was negative. 
To remove contaminating DNA from RNA, RNA was treated with DNase. When 
eDNA synthesized from DNase treated RNA extracted from trypsinized cells was subjected 
to RT-PCR, ~-actin mRNA amplification was drastically reduced or non-existent (data not 
. shown). Since B cell line RNA treated with DNase and subjected to RT-PCR showed good 
~-actin amplification, this suggested that the apparent RNA degradation was related to 
trypsin treatment of breast cancer cell lines. To test this theory, RNA was extracted from 
MDA-MB-435 cells that were removed from culture using 0.25% trypsin or by adding 
TRIZOL directly to the tissue culture flask i.e. cells were not trypsinized. Equal amounts of 
both MDA-MB-435 RNA samples were treated with DNasc. As a control, RNA was 
extracted from the B cell line, SA VC, which grows in suspension. A sample of SA VC RNA 
was treated with DNase as well. To detect RNA degradation, samples of all the above 
mentioned RNA were electrophoresed for 40 minutes on a 1.5% agarose gel containing 
etliidium bromide. Two prominent bands, one representing 28s rRNA ( -5kb in size) and one 
representing l8s rRNA (-2kb in size), were expected(product information sheet supplied 
with TRIZOL). As shown in Figure 3.5, RNA from trypsin treated MDA-MB-435 was 
degraded with further degradation occurring if this RNA was treated with DNase. In 
contrast, there was no degradation of RNA from untrypsinized MDA-MB-435 whether 
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Figure 3.4. DNA contamination in breast cancer cell line RNA. HLA-DRB 
transcription in non-induced cells ( -) and in IFN-y induced cells ( +) was assessed 
using sequence specific primers and RT-PCR. The B cell line SAVC(S) was the 
positive control. (A) eDNA synthesized from RNA extracted from trypsinzed cells 
(not treated with DNase) was subjected to RT-PCR. (B) RNA was subjected to 
PCR to detect DNA contamination. (C) ~-actin was a control for mRNA integrity. 
Lack of amplification in the water control (D) suggests that amplification in (B) 
was due to DNA contamination and not due to contamination of PCR reagents . 
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Figure 3.5. Trypsin causes degradation of breast cancer cell line RNA. A) RNA 
degradation was visualized on a 1.5% agarose gel. {1) RNA .from trypsin treated 
MDA-MB-435 (2) DNase treated RNA from trypsin t reated :MDA-MB-435, (3) 
RNA from untrypsinized MDA-MB-435, (4) DNase treated RNA from 
untrypsinized MDA-MB-435, (5) SAVC RNA and (6)SAVC RNA treated with 
DNase. A lOObpDNA ladder is displayed along the side. B) Invariant chain and 
~-actin mRNA were amplified using sequence specific primers and RT-PCR for 
30 cycles. Numbers along the top correspond to Rl~A samples in A. A H20 
control (7) was included to ensure that PCR reagents were not contaminated. 
... . 
RNA was subjected to PCR to detect DNA contamination. 
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treated with DNase or untreated. As expected, RNA from SA VC, regardless of DNase 
treatment, was undamaged. eDNA synthesized from the above mentioned RNA samples 
was subjected toRT :-:PCR to detect amplification of the invariant chain (Ti) and P-actin. li 
was used since previous experiments found that Ii mRNA was constitutively transcribed at 
high levels in MDA-MB~435. The results, displayed in Figure 3.5B, show that despite RNA 
degradation in trypsin treated MDA-MB-435 RNA, Ii and P-actin mRNA were detected. 
However, these transciipts were not detected after RNA treatment with DNase. In contrast, 
Ii and P-actin transcripts were observed in untrypsinized MDA-MB-435 and SAVC 
regardless of DNase treatment. Quantitatively, similar amounts of transcripts were seen in 
trypsinized MDA-MB-435 and untrypsinized MDA-MB-435 samples that were not treated 
with DNase. While Ii DNA was not amplified in the RNA control, P-actin DNA was 
detected in the non-DNase treated RNA. Treatment of RNA with DNase eliminated this 
amplification. 
Notably, the RNA degradation observed in trypsinized MDA-MB-435 and 
trypsinized MDA-MB-435 treated with DNase is not specific to this cell line. In fact, RNA 
degradation was observed in all cell lines when RNA was extracted from trypsinized cells 
(data not shown). Three additional trypsinized cell lines were analyzed for RNA degradation 
after DNase treatment. Again, RNA degradation was observed (data not shown). In 
summary, DNase treated RNA from trypsinized breast cancer cell lines was not suitable for 
R T-PCR but, as the data indicate, RNA from trypsinized breast cancer cell lines that was not 
DNase treated was stili suitable for use in RT-PCR. For the most part, RNA from 
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trypsinized breast cancer cells not treated with DNase was used for assessing class II and 
class II co-chaperone transcription in this study. Any deviations from this protocol will be 
described in the appropriate section. RNA controls, included in PCR to detect DNA 
contamination, were compared with eDNA reactions to ensure that amplified products were 
mRNA and not DNA. 
3.2. Transcription of the Class II Transactivator (CIITA) by Breast Cancer Cell Lines 
Since the class II transactivator (CIITA) has been deemed the master regulator of 
HLA class II and class II co-chaperone transcription in APCs (reviewed in Fontes et al., 
1999b ), breast cancer cell lines were analyzed for CIIT A transcripts to elucidate whether this 
factor regulates class II and class II co-chaperone expression in these cells. CIIT A 
transcription was analyzed using sequence specific primers and RT-PCR (see section 2.6). 
Two different sets of CIIT A primers capable of amplifying different regions of the CIIT A 
transcript were utilized. 
3.2.1. Constitutive CIITA Transcription 
CIIT A transcription in breast cancer cell lines is depicted in Figure 3.6 and 
summarized in Table 3 .1. Constitutive CIIT A transcription was detected in six cell lines. 
Cill'A mRNA was observed in MDA-MB-435 and .MCF7 using both CllT A primer sets. 
CIITA mRNA was detected in MDA-MB-231, BT-20, BT-474 and MDA-MB-468 with 
primer set #2 only. T-47D had an amplified product smaller than the expected 470bp using 
primer set #2 but none with primer set #1. The significance of the amplification of a smaller 
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Figure 3.6. Representative gels depicting constitutive (-) and IFN-y (+) induced 
CIIT A transcription in breast cancer cell lines. A) CIIT A transcripts were amplified 
using two sets of CIIT A primers and RT-PCR for 30 cycles. CIITA expression was 
analyzed at least three times using primer set #1 and once using primer set #2. eDNA 
was prepared from DNase treated RNA from non-trypsinized cells. The B cell line 
SAVC was the positive control. A H20 control was included to ensure that PCR 
reagents were not contaminated. A lOObp DNA ladder is displayed along the side of 
each gel with an arrow indicating 600bp. Primer set #1 amplified a transcript of 
266bp while set #2 amplified a transcript of470bp. B) RNA was subjected toRT-
PCR to ensure that it was not contaminated with DNA C) f3-actin mRNA 
amplification, performed at the same time as CIIT A amplification, was a control for 
mRNA integrity. 
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Table 3.1. CllT A transcription a in breast cancer cell lines . 
. . 
Breast Cancer Cell Constitutive mRNA IFN-y Induced mRNA 
Lines 
Primer set Primer set Primer set Primer set 
#1 #2 #1 #2 
MDA-1\-ffi-435 +b + + + 
T-470 c + + - -
MDA-MB-231 - + + + 
BT-20 - + + + 
MCF7 + + + + 
SK-BR-3 - - + + 
MDA-MB-436 - - + + 
.. 
Hs578T - - + + 
MDA-1\ffi-157 - - + + 
BT-474 - + + + 
MDA-MB-468 - + + + 
.. 
a CIITA mRNA was amplified usmg two sets of sequence spec1f1c pnmers and RT-PCR. 
eDNA was prepared from DNase treated RNA from non-trypsinized cells. 
b CIIT A was transcribed 
c CTIT A mRN A was not detected 
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CllT A product is not known but could suggest a mutation in the CllT A gene. CITT A mRN A 
was also not detected in SK-BR-3, MDA-MB-436, Hs578T andMDA-MB-157. Differences 
in CIIT A mRNA amplification by the two primer sets are most likely explained by 
differences in their affinities for the CllT A transcript i.e. primer set #2 has a higher melting 
temperature than primer set #1. In some instances, weak bands that are visible in gel 
photographs are not as apparent in Figure 3.6. All RNA samples were negative f~r CIITA 
amplification indicating that CliT A mRNA was amplified and not contaminating DNA 
3.2.2. IFN-y Induced CIITA Transcription 
Following IFN-"{ treatment, all breast cancer cell lines transctibed CITT A (Figure 3.6, 
Table 3.1). 
3.3. Selective Expression of HLA Class II lsotypes (HLA-DR~ -DQ and-DP) by Breast 
Cancer Cell Lines . 
To characterize breast cancer cell lines as potential HLA class II restricted APCs, it 
was obviously impmtant to determine whether class ll was constitutively expressed or could 
be induced by treatment with IFN-"(. Transcription of class IT genes was determined using 
sequence specific primers and RT-PCR (see section 2.5). Cell surface class II protein 
expression was measured using mAbs and flow cytometty (see section 2.4). All flow 
cytomeuy assays were done at least twice. The B cell line SA VC served as a positive control 
in flow cytometry and in RT-PCR. 
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3.3.1. HLA-DRExpression 
3.3.1.1 HLA-DRA and -DRB Transcription 
DRA and DRB transcription in breast cancer cell lines are summarized in Table 3.2 
and representative RT -PCR gels depicting DRA and DRB transcription are shown in Figure 
3.7. In some instances, weak bands that are visible in gel photographs are not as apparent 
inFigure 3.7. Constitutive HLA-DRA transcription was detected in all cell lines except 
Hs578T, MDA-MB-157, BT -474 and MDA-MB-468. HLA-DRB mRNA was detected in 
non-induced MDA-MB-435, T-47D, MDA-MB-231, BT-20, MCF7~ SK-BR-3 and BT -474. 
All breast cancer cell lines up-regulated DRA and DRB rnRNA following IFN-"{ 
treatment. 
3.3.1.2. HLA-DR Protein 
MDA-MB-435, T-47D, MDA-MB-231 and BT-20 constitutively expressed ce11 
smface HLA-DR as assessed by flow cytometry (Figure 3.8). Despite transcribing DRA and 
DRB mRNA, HLA-DR protein was not detected inMCF7. 
All breast cancer cell lines up-regulated cell surface HLA-DR (Figure 3.8). The four 
cell lines which constitutively expressed DR protein expressed the highest levels of HLA-DR 
protein following IFN-";' treatment. There was a broad range of HLA-DR expression with 
MDA-MB-435 expressing the most DR (degree of expression= 345) and MDA-MB-468 
(degree of expression = 6.0) expressing the least. Flow histograms depicting HLA-DR 
expression on select breast cancer cell lines are displayed in Figure 3.9. 
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Table 3.2. HLA-DRA and HLA-DRB transcriptiona in breast cancer cell lines as assessed 
using sequence specific primers and RT -PCR. 
Breast Cancer Cell Lines Constitutive mRNA IFN-y.lnduced mRNA . 
DRA DRB DRA DRB 
MDA-MB-435 +b + + + 
T-47D + + + + 
MDA-J.\iffi-231 + + + + 
BT-20 + + + + 
MCF7 + + + + 
SK-BR-3 + + + + 
MDA-MB-436 + - + + 
Hs578T -c ·- + + 
MDA-MB-157 - - + + 
.BT-474. - + + + 
MDA-MB-468 - - + + 
. 
a DRA transcnpt10n was assessed usmg eDNA synthesized from non-DNase treated RNA 
extracted from trypsinized cells. DRB transcription was assessed using eDNA synthesized 
from DNase treated RNA extracted from non-trypsinized cells. 
b mRNA was transcribed. 
c mRNA was not detected. 
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Figure 3.7. Representative gels depicting constitutive(-) and IFN-y induced(+) 
DRA and DRB expression in breast cancer cell lines. DRA transcription was 
analyzed once by RT -PCR for 30 cycles while DRB transcription was analyzed 
twice by RT -PCR for 30 cycles. P-actin was amplified as a control for mRNA 
integrity. The B cell line SA VC (S) was the positive control. R..NA was subjected 
to RT -PCR to ensure that it was not contaminated with DNA. 
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Figure 3.8. HLA-DR cell surface expression on breast cancer cell lines. HLA-DR 
expression was assessed using the antibody L243 and flow cytometry. Results are 
reported as degree of expression (see section 2.4.5) on non-induced (NI) cells (open 
bars) and on IFN-y induced cells (filled bars). Standard deviations between at least 
three independent experiments are indicated. Values of 2.1 and above (to the right 
of the black line) are considered positive. 
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Figure 3.9. Representative flow histograms depicting constitutive (pink) and IFN-y 
induced (blue) HLA-DR cell surface expression on breast cancer cell lines. Expression 
was assessed using the antibody L243 and flow cytometry. The negative control is 
shown in gray. 
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3.3.2. HLA-DP Expression 
3.3.2.1. HLA~DPA and -DPB Transcription 
Table 3.3 summarizes DPA and DPB transcription in breast cancer cell lines and 
representative gels depicting DPA and DPB transcription are shown in Figure 3.10. HLA-
DPA was constitutively transcribed by MDA-MB-435, T-47D, MDA~MB-231, BT-20, 
MCF7, SK-BR-3, Hs578T, MDA-MB-157 and MDA-MB-468. DPB mRNA was detected 
in non-induced MDA-MB-435, MDA-MB-231, BT-20, MCF7 andMDA-MB-157. There 
is a band, larger than the predicted 376bp, present on HLA-DPB gels, particularly noticeable 
in non-induced samples. While this non-specific band is clearly visible in non-induced 
MDA-MB-435, MCF7 and BT-474, the specific DPB band is only visible in MDA-MB-435 
and MCF7. Notably, more non-induced cells lines transcribed DPA mRNA than DPB 
mRNA. 
All breast cancer cell lines transcribed DPA and DPB genes in response to IFN-y. 
3.3.2.2. HLA-DP Protein 
WhileMDA-MB-435,MDA-MB-23l,BT-20,MCF7andMDA-MB-157transcribed 
HLA-DPA and HLA-DPB genes, HLA-DP cell surface expression was only observed on 
MDA-MB-435 and MDA-MB:.231 (Figure 3.11). 
After IFN-y treatment, cell surt'ace HLA-DP was up-regulated on 10/11 breast cancer 
cell lines (Figure 3.11). BT-474 did not up-regulate cell surface HLA-DP despite 
transcribing DP A and DPB genes. The two cell lines which constitutively expressed DP 
protein, MDA-MB-435 and MDA-MB-231, had the highest DP expression following IFN-y 
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Table 3.3. HLA-DPA and HLA-DPB transcriptiona in breast cancer cell lines as assessed 
using sequence specific primers and RT -PCR. 
Breast Cancer Cell Lines Constitutive mRNA IFN-y Induced mRNA 
DPAd DPB DPAd DPB 
MDA-MB-435 +b + + + 
T-47D + - + + 
MDA-MB-231 + + + + 
BT-20 
.. 
+ + + + 
MCF7 + + + + 
SK-BR-3 + - + + 
MDA-MB-436 -c + + -
Hs578T + - + + 
MDA-MB-157 + + + + 
BT-474 - - + + 
MDA-~IB-468 + - .· + + 
a DPA and DPB transcnpt10n were detennmed usmg eDNA synthcs1zed from non-DNase 
treated RNA extracted from trypsinized cells. 
b mRNA was transcribed. . 
c rnRN A was not detected. 
ct RT-PCR to determine HLA-DPA transcription was performed by h1grid Pardoe. 
87 
- + s + s + s 
eDNA 
RNA 
- + s - + s 
~-ACTIN 
Figure 3.10. Representative gels depicting constitutive (-) and lFN-y induced ( +) 
DP A and DPB expression in breast cancer cell lines. DPA and DPB transcription 
were assessed once by RT-PCR for 30 cycles. ~-actin was amplified as a control 
for mRNA integrity in DPB reactions but not in DPA reactions. The B cell lines 
COX (C) and SAVC (S} were positive controls. RNA was subjected to RT-PCR 
to ensure that it was not contaminated with DNA. 
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Figure 3.11. HLA-DP cell surface expression on breast cancer cell lines. HLA-DP 
expression was assessed using the antibody N'FLD.M67 and flow cytometry. 
Results are reported as degree of expression (see section 2.4.5) on non-induced (Nl) 
cells (open bars) and on IFN-y induced cells (filled bars). Standard deviations 
between at least two independent experiments are indicated. Values of 2.1 and 
above (to the right of the black line) are considered positive. 
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treatment. There was a broad range ofHLA-DP cell surface expression with MDA-MB-435 
expressing the most DP (degree of expression= 259) and BT-474 expressing no DP {degree 
of expression 1.6). Representative flow cytoinetry plots depicting cell surface HLA-DP 
expression on breast cancer cell lines are displayed in Figure 3.12. 
3.3.3. HLA-DQ Expression 
3.3.3.1. HLA-DQA and -DQB Transcription 
Breast cancer cell line DQA and DQB transcription is summarized in Table 3.4 and 
representative gels depicting DQA and DQB transcription are shown in Figure 3.13. In some 
instances, weak bands that are visible in gel photographs are not as apparent in Figure 3.13. 
HLA-DQA was constitutively transcribed by MDA-MB-435, T -47D, BT-20, MCF7 and SK-
BR-3 while HLA-DQB mRNA was found in MDA-MB-435, T -470, MDA-MB-231, BT-20, 
MCF7, Sl(-BR-3 and BT-474. 
Following IFN-y treatment, all breast cancer cell lines transcribed DQA and DQB 
mRNA. 
3.3.3.2. HLA-DQ Protein 
While five breast cancer cell lines, MDA-l\ffi-435, T-470, BT-20, MCF7 and SK-
BR-3, transcribed DQA and DQB genes, no cell line expressed constitutive cell surface 
HLA-DQ protein (Figure 3.14). 
MDA-MB-435, T-470, BT-20, MCF7 and SK-BR-3 up-regulated cell surface HLA-
DQ (Figure 3.14). Interestingly, these cell lines were the only ones to <:onstitutively 
transcribe DQA and DQB. Despite transcribing DQA and DQB genes, all other breast 
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Figure 3.12. Representative flow histograms depicting constitutive (pink) and IFN-y 
induced (blue) HLA-DP cell surface expression on breast cancer cell lines. Expression 
was assessed using the antibody NFLD.M67 and flow cytometry. The negative control 
is shown in gray. 
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Table 3.4. HLA-DQA and HLA-DQB transcriptiona in breast cancer cell lines as assessed 
using sequence specific primers and RT-PCR.. 
Breast Cancer Cell Lines Constitutive mRNA IFN~y Induced mRNA 
DQA DQB DQA DQB 
MDA-1\'ffi-435 +b + + + 
T-47D + + + + 
MDA-MB-231 -c + + + 
BT-20 + + + + 
MCF7 + + + + 
SK-BR~3 + + + + 
MDA~MB-436 - - + + 
Hs578T - - + + 
MDA-MB-157 - - + + 
BT-474 - + + + 
MDA-MB~468 - - + + 
" DQA and DQB transcnptton were determmed .uslrtg eDNA synthesized from DNase 
treated RNA extracted from non4rypsinized cells .. 
b mRNA was transcribed .. 
cmRNA was not detected .. 
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Figure 3.13. Representative gels depicting constitutive (-) and IFN-y induced ( +) 
DQA and DQB expression in breast cancer cell lines. DQA and DQB 
transcription were analyzed twice by RT..:PCR for 30 cycles. ~-actin was 
amplified as a control for mRNA integrity in both reactions. The B cell line 
SAVC (S) was the positive control. RNA was subjected to RT-PCR to ensure that 
it was not contaminated with DNA. 
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Figure 3.14. HLA-DQ cell surface expression on breast cancer cell lines. HLA-. 
DQ expression was assessed using the antibody SPVLJ and flow cytometry. 
Results are reported as degree of expression (see section 2.4.5) on non-induced 
(NI) cells (open bars) and on IFN-y induced cells (filJed bars). Standard deviations 
between at least two independent experiments are indicated. Values of 2.1 and 
above (to the right of the black line) are considered positive. 
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cancer cell lines did not express cell surface HLA-DQ. Representative flow histograms 
depicting HLA-DQ cell surface expression in breast cancer cell lines are displayed in Figure 
3J5. 
3.4. HLA Class II Co-chaperone Expression in Breast Cancer Cell Lines 
To further characterize breast cancer cell lines as potential HLA class II restricted 
APCs, constitutive and JFN.,y induced expression of class IT co-chaperones, the invariant 
chain (Ii), HLA-DM and HLA-DO, were analyzed. Transcription of these genes was 
assessed using sequence specific primers and RT-PCR (see section 2.6). The Bcellline 
SA VC or COX served as positive controls for all reactions. 
Ii and HLA-DM protein expression were detected using mAbs and flow cytometry 
(see section 2.4). SA VC was used as a positive control in all assays. All flow C)tometry 
assays were done at least twice with some exceptions. Ii expression in MCF7and MDA-
MBA68 and HLA-DM expression in T-47D and MDA-MB-468 were assessed only once. 
Co-chaperone protein expression was also examined using immunocytochemistry (IC) (see 
section 2.5). IC was perfom1ed on adherent breast cancer cells grown in chamber slides with 
the exception that ICon BT-474, MDA-.MB-231 and the positive control, SAVC, was done 
using cytocentrifuge preparations. IC followed protocols described in section 2.5.5.2 with 
the exception that ICon BT-474 and rviDA-MB-231 followed procedures in section 2.5.4.2. 
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Figure 3.15. Representative flow histograms depicting constitutive (pink) and IFN-y 
induced (blue) HLA-DQ cell surface expression on breast cancer cell lines. Expression 
was assessed using the antibody SPVL3 and flow cytometry. The negative control is 
shown in gray. 
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3.4.1. Invariant Chain Expression 
3.4.1.1. Invariant Chain Transcription 
Constitutive Ii transcription was detected in all breast cancer cell lines except 
Hs578T (Table 3.5). Following IFN-y treatment, all cell lines transcribed Ii mRNA. 
Representative gels depicting 1i transcription are shown in Figure 3.16. 
3.4.1.2. Invariant Chain Protein 
While constitutive Ii mRNA was observed in l0/11 cell lines, only four of these cells, 
MDA-MB-435, T-47D, MDA-MB-231 and MCF7, constitutively expressed Ii protein as 
detected using intracellular flow cytometry (Figure 3.17) and IC. Following IFN-y treatment, 
all cell lines up-regulated this co-chaperone. · Representative flow cytometry histograms and 
representative IC data depicting Ii protein expression in brea-;t cancer cell lines are displayed 
inFigure3.18. 
· 3.4.2. HLA-DM Expression 
3.4.2.1. HLA-DMA and -DMB Transcription 
HLA-DMA mRNA was transcribed constitutively by all breast cancer cell lines while 
HLA--DMB mRNA was detected in all cell lines except BT-474 (Table 3.6). In response to 
IFN-y, DMA and DMB genes were transcribed by all cell lines. Representative gels 
depicting DMA and DMB transcription are shown in Figure 3.19. In some instances, weak 
bands that are visible in gel photographs are not as apparent in Figure 3.19. 
3.4.2.2. HLA-DM Protein 
HLA-DM protein was not detected constitutively by any breast cancer cell line when 
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Table 3.5. Invariant chain (li) transcriptiona in breast cancer cell lines as assessed using 
sequence specific primers and RT -PCR. 
Breast Cancer Cell Lines Constitutive Ii mRNA IFN-y Induced Ii mRNA 
l\IDA-MB-435 +b + 
T-47D + + 
:MDA-1\fB-231 + + 
BT-20 + + 
MCF7 + + 
SK.;.BR-3 + + 
l\fDA-MB-436 + + 
Hs578T c + -
MDA-MB-157 + + 
BT-474 + + 
MDA-MB-468 + + 
a li transcription was determined using eDNA synthesized from non-DNase treated RNA 
extracted from trypsinized cells. RT-PCR to detect Ii transcrip6on was performed by Ingrid 
Pardoe. 
b mRNA was transcribed. 
c mRNA was not detected. 
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Figure 3.16. Representative gels depicting constitutive (-) and IFN-')' 
induced ( +) invariant chain (li) transcription in breast cancer cell lines as 
assessed by RT -PCR. Ii transcription was assessed once by RT -PCR for 30 
cycles. The B cell lines COX (C) and SA VC (S) were positive controls. 
RNA was subjected to RT-PCR to ensure that it was not contaminated with 
DNA. 
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Figure 3.17. Intracellular invariant chain (Ti) protein expression in breast cancer 
cell lines. Ii expression was assessed using the antibody LN2 and flow cytometry. 
Results are reported as degree of expression (see section 2A.5) on non-induced (Nl) 
cells (open bars) and on IFN-y induced cells (filled bars). Standard deviations 
between experiments are shown when more than one experiment was performed. 
Values of 2.1 and above (to the right of the black line) are considered positive. 
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Figure 3.18. Invariant chain (li) protein expression by breast cancer cell lines. A) Immunocytochemical analysis 
of Ii expression in untreated and IFN-y treated breast cancer cell lines. The negative control is shown alongside. 
B) Flow cytometry histograms depicting intracellular Ii expression in untreated (pink) and IFN-y treated (blue) 
breast cancer cell lines. The negative control is shown in gray. SA VC is the positive control for Ii expression in 
both assays. 
Table 3.6. HLA-DMA and HLA-DMB transcriptiona in breast cancer cell lines as assessed 
using sequence specific primers and RT-PCR. 
Breast Cancer Cell Lines Constitutive mRNA IFN-y lnduced mRNA 
DMA DMB DMA DMB 
MDA-:MB-435 +b + + + 
T-47D + + + + 
MDA-:MB-231 + + + + 
BT-20 + + + + 
MCF7 + · + + + 
.. 
SK-BR-3 + + + + 
MDA-MB-436 + + + + 
Hs578T + + + + 
MDA-MB-157 + + + + 
BT-474 . + -c + + 
MDA-:MB-468 + + + + 
a DMA and DMB transcnpt10n were deterrruned usmg eDNA synthesized from non-DNase 
treated RNA extractedfrom trypsinized treated cells. RT-PCR to assess HLA-DMA and 
HLA-DMB transcription was performed by Ingrid Pardoe. 
b mRNA was transcribed. 
c mRNA was not detected. 
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Figure 3.19. Representative gels depicting constitutive (-) and IFN-y induced 
( +) DMA and DMB expression in breast cancer cell lines. DMA and DMB 
transcription were assessed once by RT-PCR for 30 cycles. The B cell line 
COX (C) was the positive control. RNA was subjected to RT-PCR to ensure 
that it was not contaminated with DNA. 
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assessed using intracellular flow cytometry (Figure 3.20). However, using IC, DM protein 
was detected in non-induced MDA-MB-435, MDA-MB:-231 and BT-20 (Figure 3.21). IC 
was analyzed independently by two individuals to ensure accuracy of results. When cells 
were treated with IFN-y, DM expression was up-regulated by MDA-MB-435, T -47D, MDA-
MB-231 , BT-20, MCF7 and MDA-MB-468 as shown by flow cytometry (Figure 3.20) but 
using IC, DM was also detected in four additional cell lines, SK-BR-3, MDA-MB-436, 
Hs578T and MDA-MB-157 (Figure 3.22). 
It was serendipitously discovered that cell surface HLA-DM was expressed oh certain 
cell lines. This was determined using extracellular flow cytometry i.e. cells were not 
permeabilized by saponin. MDA-MB-231 and BT-20constitutively expressed surface DM 
whileMDA-MB-435, MDA-MB-231 , BT-20 and SK-BR-3 up-regulated surface DM in 
response to IFN-y. Extracellular DM was not expressed on MDA-MB-436, Hs578T, MDA-
MB-157 and BT-474. T-47D, MCF7 and MDA-MB-468 were notassayed for .extracellular 
DM. Thus, it is probable that immunocytochemical detection of DM innon-induced MDA-
MB-231 and BT-20 and IFN-y induced SK-BR-3 reflected cell surface expression of this co-
chaperone. It is not known why intracellular flow cytometry did not detect extracellular DM 
on breast cancer cell lines. However, it is possible that the fixation or the detergent required 
for intracellular flow cytometry destroyed the DM epitope. 
As stated above, discrepancies between IC and flow cytometry were observed. 
Specifically, IC revealed constitutive DM expression in MDA-MB-435 and IFN-y induced 
DM expression in MDA-MB-436, Hs578T and MDA-MB-157 but neither cell surface nor 
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Figure 3.20. Intracellular HLA-DM protein expression in breast cancer cell lines. 
HLA-DM expression was assessed using the antibody MaP.DMl and flow 
cytometry. Results are reported as degree of expression (see section 2.4.5) on non-
induced (NI) cells (open bars) and on IFN-y induced cells(filled bars). Standard 
deviations are shown when more than one experiment was performed. Values of 2. 1 
and above (to the right of the black line) are considered positive. 
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Figure 3.21. Constitutive HLA-DM expression in breast cancer cell lines. A) 
Immunocytochemical analysis of HLA-DM expression in breast cancer cell lines. 
The negative control is shown alongside. B) Flow cytometry histograms depicting 
cell surface (pink) and intracellular (blue) HLA-DM expression in breast cancer cell 
lines. The negative control is gray. SA VC is the positive control for HLA-DM 
expression in both assays. Note: Cell surface DM is not detected on SAVC. 
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Figure 3.22. IFN-y induced HLA-DM expression in breast cancer cell lines. A) 
Immunocytochemical analysis of HLA-DM expression in breast cancer cell lines. 
The negative control is shown alongside. B) Flow cytometry histograms depicting 
cell surface (pink) and intracellular (blue) HLA-DM expression in breast cancer 
cell lines. The negative control is gray. SA VC, the positive control in both assays, 
is shown in Figure 3.21. 
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intracellular DM were detected in these cells by flow cytometry (Figure 3.21, 3.22). 
Therefore, we decided to repeat flow cytometry on MDA-MB-435, MDA-MB-436 and 
Hs578T and, at the same time, prepare cytocentrifuge preparations. Thus, DM expression 
was assessed by flow cytometry and by IC simultaneously. Interestingly, DM was not 
observed in any of these cellsusing either methodology (data not shown). These discrepant 
findings may reflect differences in IC and flow cytometry protocols (see sections 2.4, 2.5) 
or differences in assay sensitivities. 
In summary, while ten breast cancer cell lines constitutively transcribed DMA and 
DMB genes, DM protein was only consistently detected in MDA-MB-231 and BT -20. 
Additionally, while all cell lines transcribed DMA and DMB genes in response to IFN-"{, 
7/11 cell lines consistently up-regulated DM protein. 
3.4.3. HLA-DO Expression 
3.4.3;1. HLA-DOA and -DOB Transcription 
HLA-DOA was not transcribed constitutively by any breast cancer cell line. 
However, HLA-DOB mRNA was detected in all non-induced cell lines (Table 3.7). HLA-
DO protein expression was not assessed but would not be expected given that DOA was not 
transcribed in any cell line. 
Following IFN-y treatment, HLA-DOAmRNA was detected in MDA-MB-435, T-
470, MDA-MB-231 , BT-20, MCF7 andHs578T (Table 3.7). HLA-DOB was transcribed 
by all cell lines. Representative RT-PCR results are displayed in Figure 3~23 . 
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Table 3.7. HLA-DOA and HLA-DOB transcriptiona in breast cancer cell lines as assessed 
using sequence specific primers and RT -PCR. 
Breast Cancer Cell Lines Constitutive mRNA · IFN-y Induced mRNA 
DOA DOB DOA DOB 
MDA-M:B-435 -b +c + + 
T-47D - + + + 
MDA-MB-231 - + + + 
BT-20 - + + + 
MCF7 - + + + 
SK-BR-3 - + - + 
MDA-MB-436 - + - + 
Hs578T - + + + 
MDA-MB-157 - + - + 
BT-474 - + - + 
MDA-MB-468 - + - + 
aDOA and DOB transcription were deterrtlined using eDNA synthesized from non-DNase 
treated RNA from trypsinized treated cells. RT -PCR to assess HLA-DOA and HLA-DOB 
transcription was performed by Ingrid Pardoe. 
b mRNA was transcribed. 
c mRN A was not detected. 
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Figure 3.23. Representative gels depicting constitutive (-) and IFN-y induced 
( +) DOA and DOB expression in breast cancer cell lines. DOA and DOB 
transcription were assessed once by RT-PCR for 30 cycles. The B cell line 
COX (C) was the positive control. RNA was subjected to RT-PCR to ensure 
that it was not contaminated with DNA. 
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Up-regulation of DO protein was not determined but IFN-y treated MDA-MB-435, 
T-47D, MDA-MB-231, BT-20, MCF7 and Hs578T had the potential to express DO protein 
since they transcribed DOA and DOB genes. 
3.5. Co-stimulatory Molecule Expression by Breast Cancer Cell Lines 
Activation ofT cell expansion and differentiation requires interactions between the 
T ceU and the APC i.e. breast cancer cell. HLA/peptide interaction with a specific T cell 
receptorconstitutes signal one. Signal two involves co-stimulatory molecule interaction with 
a cmTesponding ligand on T cells. CD80 and CD86 were believed to be the most important 
inducers ofT cell co-'-stimulation. However, other molecules including CD40 may also act 
in this capacity (Croft & Dubey, 1997). 
Cell surface expression of CD80, CD86 and CD40 on breast cancer cell lines was 
assessed using mAbs and flow cytomctry (see section 2.4). The B cell line SAVC was used 
as a positive control in each assay. Co,.stimulatory molecule expression was also examined 
using IC (see section 2.5). IC was performed on adherent breast cancer cells grown in 
chamber slides with the exception that ICon BT-474 and the positive control, SAVC, was 
done using cytocentrifuge preparations. IC followed protocols described in section 2.5.5.2 
with the exception that ICon BT-474 followed procedures in section 2.5.4.2. 
3.5.1. CD80 and CD86 
Constitutive and IFN-y induced CD80 and CD86 protein expression were not 
detected on any breast cancer cell line by flow cytometry. These results were confirmed by 
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IC. Representative data showing the lack of CD80 and CD86 expression on a breast cancer 
cell line as assessed by tlow cytometry and IC is depicted in Figure 3 .24. 
3.5.2. CD40 
CD40 was constitutively expressed on the cell surface of five breast cancer cell lines 
as assessed using t1ow cytometry (Figure 3.25). Strong CD40 expression was detected on 
MDA-MB-435, MDA-MB-231 and BT -20. Moderate CD40 expression was found on SK-
BR-3 while weak expression was detected on T-47D. Unexpectedly, constitutive CD40 
expression was not detected on any breast cancer cell line using IC. This was most 
surprising for MDA-MB-435, BT-20 and MDA-MB-231 which were found to express high 
levels of CD40 by flow cytometry. 
CD40 was up-regulated byMDA-MB-435, T-47D. MDA-MB-23l,BT-20, SK-BR-3, 
MDA-MB-436 and Hs578T butwas not expressed by MCF7, MDA-MB-157, BT-474 and 
MDA-MB-468. These findings were confim1ed by IC with one exception. WeakCD40 up-
regulation observed on Hs578T by flow cytometry was not detected immunocytochemically. 
Representative IC results and flow cytometry histograms are presented in Figure 3.26. 
3.6. Expression of HLA-DR Alleles in Breast Cancer Cell Lines 
HLA class I alleles may be selectively down-regulated in tumors (reviewed in 
Marcincola et al., 2000). It is not known whether class II alleles are also selectively 
expressed. This study examined HLA·DR allele expression in breast cancer cell lines. HLA-
DR was chosen, as opposed to HLA-DP or HLA-DQ, for several reasons. As described in 
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Figure 3.24. CD80 and CD86 expression in BT-20. A) Immunocytochemical 
analysis of CD80 and CD86 expression in IFN-y treated BT-20 and the positive 
control, SA VC. The negative control is shown alongside. B) Flow cytometry 
histograms depicting CD80 (pink) and CD86 (blue) cell surface expression on 
IFN-y treated BT -20 and on SA VC. The negative control is shown in gray. 
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Figure 3.25. CD40 cell surface expression on breast cancer cell lines. CD40 
expression was assessed using the antibody 5C3 and flow cytometry. Results are 
reported as degree of expression {see section 2.4.5) on non-induced (ND cells 
(open bars) and IFN-yinduced cells (filled bars). Standard deviations are reported 
when more than one experiment was performed. Values of 2.1 and above (to the 
right of the black line) are considered positive. 
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Figure 3.26. CD40 protein expression in breast cancer cell lines. A) Immunocytochemical analysis of CD40 
expression in untreated and IFN-y treated breast cancer cell lines. The negative control is shown alongside. 
B) Flow cytometry histograms depicting cell surface CD40 expression in untreated (pink) and IFN-y treated 
(blue) breast cancer cell lines. The negative control is shown in gray. SA VC is the positive control for CD40 
expression in both assays. 
section 3.3, cell surface HLA-DR was up-regulated by all cell lines. ln most cells (10/11), 
. . 
HLA-DR was expressed at higher levels than otherdass II isotypes. Importantly, monoclonal 
antibodies capable of recognizing one HLA-DR type or a combination of HLA-DR types 
were available. Even though HLA-DP was up-regulated on 10/11 cell lines, HLA-DP typing 
is not routinely performed so HLA-DP typing kits are not readily available. HLA-DQ was 
not studied given its comparatively low cell surface expression and its up-regulation on only 
5/11 cell lines. 
3.6.1. HLA Class ll DNA Typing of Breast Cancer Cell Lines 
To investigate selective up-regulation of HLA-DR allelic products, it \Vas first 
necessary to identifY the HLA-D RB alleles in each breast cancer cell line. This was done by 
DNA typing using commercially available HLA class II DNA typing and subtyping kits (see 
section 2.3.2). The HLA-DRB and HLA-DQBl alleles in each breast cancer cell line are 
listed in: Table 3.8. The HLA-DRB3 subtyping was performed by Dianne Codner. 
3.6.2. Specificity ofHLA-DR Specific Monoclonal Antibodies 
To determine expressionofHLA-DR allelic products in breast cancer cell lines, HLA-
DR specific mAbs were utilized. The specificity of these a.11tibodies has been extensively 
· studied and published (see Table 2.4). However, to ensure that the antibodies bound a 
particular HLA-DR molecule, their binding to B cell lines expressing the appropriate HLA-
DR type was assayed using flow cytometry (Table 3.9). Since all HLA-DR specific mAbs 
bound HLA-DR protein, it is reasonably certain that whenHLA-DR allelic products were not 
detected in breast carcinoma cell lines, it was because tb..ese HLA-DR types were not up-
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Table 3.8. HLA-DRB and HLA-DQBl genes in breast cancer cell lines. DR and DQ 
types were determined by DNA typing usir)g commercially available kits. 
Breast Cancer Cell HLA-DR Type HLA-DQType 
Line 
MDA-l\ffi-435 DRB 1 *04051, DRB4, DQBl *08, DQB1*06 
DRBl * 1320, DRB3*0202 
T-470 DRB1*0102 DQB1*05 
MDA-MB-231 DRB1 *07, DRB4, DQB 1 *02, DQB 1 *03 
DRB 1 * 13, DRB3*0202 
BT-20 DRB 1 *0404, DRB4, DQBl *03, DQB1*06 
DRB1*1301, DRB3*01 
.MCF7 . :j:DRB1*03, DRB3*0202, =l:DQB 1 *02, DQB 1 *06 
DRB1*15, DRB5 
SK-BR-3 DRB1*07, DRB4, DQB 1 *02, DQB 1 *06 
DRB 1 * 1302; DRB3*0302 
MDA-l\ffi-436 DRB 1 *03, DRB3*01 DQB1*02 
Hs578T :j:DRB1*0101, :j:DQB 1 *05, DQB 1 *06 
DRB1 *15, DRB5 
MDA-MB-157 :j:DRB 1 *040 1, DRB4, :j:DQB 1 *03, DQBl *06 
DRB1*15, DRB5 
BT-474 DRB1*0401 , DRB4, DQB1*03, DQB1 *06 
DRB1*15, DRB5 
MDA-MB-468 DRB1*0102, DQB 1 *05, DQB 1 *02 
DRB 1 *07, DRB4 
:j:HLA-DRB and HLA-DQB 1 types, excluding subtypings, reported previously by Tibbo, 
1998. 
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T bJ 39 n· d. " fHLADR 111 'fi 1 t'b d' t ll f HLA DR B 11 r a e . . m mg- o - a e e spec1 IC monoc ona an 1 o 1es o ce · sur ace - on ce mes. 
Antibodies BCELLLINES 
JEST- MGAR . COX SAVC MT14B HAS15 OMW CB6B H0301 PLH 
HOM Bl * l501 Bl*0301 131*0401 131 *0404 B1 *0405 B 1 *1301 B1 *1301 B I * 1302 B 1*0701 · 
hBI *OJOI B5~'010J B3*0101 B4'1'0101 B4*0101 B4*0JOJ · B3*010I B3*0202 B3*0301 B4*0101 . 
L243 2806.3d 1563.6 3102.2 2271.0 f2627.0 5453.5 1232.3 f590.0 fl495.0 3082.0 
'All DR (304.4)e (170.2) (343:8) (264.6) (238.9) (444.9) (174.2) (74.8) (250.2) (233.3) 
JS-1 3544.5 . - - - - - - - - -
DRl ( 421. 9) 
NFLD.DlO 2374.8 1207.5 - 2209.3 fl665.0 - - - - -
DRl, DR4, (259.3) (131.5) (243.0) (152.4) 
DR15 
NFLD.D2 1733.0 - - f1368.0 ~'1609.0 - - - - -
DRl , DR4 (204.8) (153.0) (147.3) 
NFLD.Dl - - - 486.0 1800.0 2847.5 . - - - -
DR4 (55.2) (73.7) (243.2) 
NFLD.J.\tll - - 456.5 544.5 rsso.o - 255.5 - - -
DR4,DR52 (54.4) (73.0) (81.0) (31.2) 
NI~'LD.D7 - 3140.0 3262.6 - - - 1717.5 f524.0 fl4 1.0 -
DR4,DR15, (332.8) (366.4) (212.5) (66.5) (24.5) 
DR52 
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Table 3 9 Continued . . .· 
Antibodies 
JEST- . MGAR cox SAVC .· 
HOM 81 *1501 BJ *0301 B 1 *0401 
B I*OIOI 85*0101 B3*0101 84*0101 
NDS13 - - 4476.8 . -
DR52 (502.9) 
7.3.19.1 - - 7307.5 -
DR3, DR52 (852.8) 
UKS.l - - 4307.7 -
DR3, DR13 (481.9) 
SFR16 - - - -
DR7 
PL3 - - - 987.3 
DR7, DR53 (108.6) 
''Antibody bmdtng was detenmned usmg tlow cytometry. 
b B cell Jine HLA-DR types. 
. 
B CELl:, LINES 
MT14B HAS15 OMW CB6B H0301 PLH 
B 1*0404 B 1*0405 BJ*I301 Bl * l30 l B l* 1302 B 1 *0701 
B4*0101 B4*0l01 83*0101 B3*0202 B3*030J B4*0!01 
- - 1881.5 ~'979.0 f1964.0 -
(210.6) ( t23.4) (328.3) 
- - 4478.3 f1811.0 f5083.0 -
(615.1) (227.4) (848.2) 
-
- 1687.5 - - -
(254.3) 
- - - - - 1336.5 
(94.5) 
- 1833.0 - - - 4073.0 
(157.3) (503.6) 
c HLA-DR types recognized by the antibodies. Note: Antibodies may recognize more HLA-DR types than listed (see Table 2.4). 
Presented hei·e are the antibody specificities important for detection of HLA-DR on breast cancer cell lines. 
d Mean fluorescence intensity with the background subtracted. 
" Degree of HLA-DR expression (see section 2.4.5). 
~'Antibody binding was detected only once. All other data are an average of at least two separate assays. 
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regulated and not because rnAbs were non-reactive. 
3.6.3. Expression of lll.A-DR Allelic Products by Breast Cancer Cell Lines 
HLA-DRB gene transcription was analyzed using sequence specific primers and RT-
PCR (see section 2.6). Cell surface expression of HLA-DR allelic products was assessed 
using HLA-DR specific mAbs and flow cytometry (see section 2.4). When HLA-DR 
allotypes were not up-regulated on the cell surface, IC was performed to determine whether 
HLA-DR protein was made but retained intracellularly. 
3.6.3.1. Transcription ofHLA-DR Alleles 
Constitutive and IFN-y induced HLA-DRB allele transcription in breast cancer cell 
lines is depicted in Figure 3.27 and summarized in Table 3.10. In some instances, weak bands · 
that are visible in gel photographs are not as apparent in Figure 3.27. HLA-DRB allele 
mRNA was constitutively transcribed by 9/11 breast cancer cell lines (Table 3.10). These 
findings correlated with those found using generic HLA-DRB primers with two notable 
exceptions. Non-induced MDA-MB-157 did not transcribe DRB as assessed using generic 
DRBprimersbutdidweaklytranscribeDRB4mRNA. Similarly,non-inducedMDA-MB-468 
did not transcribe DRB as assessed using generic DRB primers but did weakly transcribe 
DRBl *01 mRNA. 
We were unable to differentiate between all HLA-DR allelic products in breast cancer 
cell lines. For example, DR53 protein expression could not be detennined in DR7 expressing 
cell lines, MDA-MB-231 and SK-BR-3, since the antibody PL3 recognizes both DR7 and 
DR53. Similarly, a DR51 antibody was not available for this study. However, transcription 
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Figure 3.27. HLA-DRB transcription in breast cancer cell lines. Expression in non-
induced cells ( -) and IFN-y induced cells ( +) was assessed using sequence specific 
primers and RT -PCR (see section 2.6). P-actin amplification was a control for 
DRB 1 *04, DRB 1 *07 and DRB4 reactions. An internal control, a non allelic sequence 
in exon 3 of the DRB gene, was included in all other reactions and is shown at 
-600bp. The arrow indicates 600bp on the DNA ladder. 
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Table 3.10. HLA-DRB transcriptiona in breast cancer cell lines. 
HLA-DRGene 
Cell 
Line DRBl DRBl DRBl DRBl DRBl DRBl DRB3 
*01 *15 *03 *04 *13 *07 
l.VIDA- - - - cb c - c 
MB-435 
' 
T-47D c - - - - - -
MDA- - - - - c c c 
MB-231 
BT-20 - - - c c - c 
MCF7 - c JC - - - I 
SK- - - . - - I I I 
BR-3 
MDA- - - I - - - I 
MB-436 
Hs578T I I - - - - -
MDA- ·- I - I - - -
MB-157 
BT-474 - c - I - - -
MDA- c - - - - 1 -
MB-468 
. . 
a Expression was assessed usiri.g sequence spec1f1c prnners and RT-PCR. 
11 Constitutive transcription. 
c IFN -y induced transcription. 
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DRB4 DRBS 
c -
- -
c -
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ofthese genes was assessed. MDA-MB-231 and SK-BR-3 were found to constitutively 
express DRB4 and up-regulate DRB4 (Table 3.1 0). DRB5 was constitutively transcribed by 
MCF7 and was up-regulated by MCF7, Hs578T, MDA-MB-157 and BT-474. In certain 
instances, for unknown reasons, amplification of ~-actin, used as a control for mRNA 
integrity, was poor. This was particularly noticeable for DRB 1 *07 reactions and for DRB4 
amplification in MDA-MB-157. However, these eDNA were suitable for use in RT-PCR 
since amplification of P-actin was achieved readily in other PCR reactions. 
3.6.3.2. Expression of HLA-DR Allelic Products 
Since 9/11 cell lines constitutively transcribed HLA-DRB alleles and all cell lines 
transcribed HLA-D RB alleles in response to IFN -y, cell surface expression ofHLA-DR allelic 
products was assessed. A description ofHLA-DR allele expression in each breast cancer cell 
line will follow. 
3.6.3.2A. MDA-MB435 
MDA-MB-435 constitutively expressed cell surface HLA-DR and strongly up-
regulated this antigen as assessed by the antibody L243 and flow cytometry (Figure 3.28). 
HLA-DRBl * 13, detected using UK8.1, was constitutively expressed and was further up-
regulated by IFN•y. Similarly, HLA-DRB3 (DR52), determined using 7.3.19.1 and NDS13, 
was constitutively expressed and was strongly up-regulated. Using NFLD.Dl and 
NFLD.D10, HLA-DRB1 *04 was found to be strongly up-regulated and using PL3, HLA-
DRB4 (DR53) expression was found to be strongly induced. 
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Figure 3.28. Cell smf ace expression of HLA-DR allelic products on MDA-MB-
435. Non-induced (open bars) and IFN-y induced (filled bars) expression were 
assessed using monoclonal antibodies that distinguished DR allotypes (shown in 
parenthesis) and flow cytometry. Results, reported as degree of HLA-DR 
expression (see section 2.4.5), are averages of at least two experiments. Standard 
deviations are indicated. Values of 2. 1 and above (to the right of the black line) 
are considered positive. 
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3.6.3.2B. T-47D 
T -47D constitutively expressed and strongly up-regulated cell surface HLA-DR as 
detected using the antibody L243 (Figure 3.29). This cell line had only one HLA-DR type, 
HLA-DRB1 *0102. Interestingly, although constitutive HLA-DR expression was observed 
using L243, constitutive HLA-DRl expression was not detected using NFLD.D10, JS-1 or 
NFLD.D2. Following IFN-y treatment, HLA-DR1 was strongly up-regulated on the cell 
surface ofT-470 (Figure 3.29). 
3.6.3.2C. MDA-MB-231 
Even though constitutive HLA-DR cell surface expression was observed on MDA-
MB-231 using the pan anti-HLA-DR antibody L243, constitutive expression of HLA-DR 
allelic products was not detected using HLA-DR specific mAbs (Figure 3.30). Following 
IFN-ytreatment, cell surface HLA-DR was strongly up-regulated as assessed using L243. 
Similarly, HLA-DRB1*13 expression, detected using UK8.1, and HLA-DRB3 (DR52) 
expression, detected using NFLD.D7 and 7.3.19.1 , were strongly induced. Using SFR16, 
it was determined that HLA-DR7 was moderately up-regulated. Unfortunately, HLA-DR7 
expression was measured only once since we could not acquire more DR7-specific antibody. 
PL3, the antibody used to detect HLA-DRB4 (DR53) expression also measured HLA-DR7 
expression. For this reason, it was not possible to determine whether DR53 protein was up-
regulated by this cell line. 
3.6.3.2D. BT -20 
As described for T-47Dand MDA-MB-231, constitutive HLA-DR expression was 
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Figure 3.29. Cell surface expression of HLA-DR allelic products on T-47D. 
Non-induced (open bars) and IFN-y induced (filled bars) expression were 
assessed using monoclonal antibodies that distinguished DR allotypes (shown in 
parenthesis) and flow cytometry. Results are reported as degree of HLA-DR 
expression (see section 2.4.5) and are averages of more than one experiment 
unless indicated by an asteiisk. Standard deviations are indicated where 
appropriate. Values of 2.1 and above (to the right of the black line) are 
considered positive. 
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Figure 3.30. Cell surface expression of HLA-DR allelic products on MDA-MB-
231. Non-induced (open bars) and IFN-y induced (filledbars) expression were 
assessed using monoclonal antibodies that distinguished DR allotypes (shown in 
parenthesis) and flmv cytometry. Results are reported as degree of HLA-DR 
expression (see section 2.4.5) and are averages of more than one experiment 
unless indicated by an asterisk. Standard deviations are shown where appropriate. 
Values of 2.1 and above (to the 1ight of the black line) are considered positive. · 
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detected on BT-20 using the antibody L243 but was not detected using HLA-DR specific 
mAbs (Figure 3.31). HLA-DR was strongly up-regulated in response to IFN-')' as assessed 
using L243 (Figure 3.31). Accordingly, cel1 surface HLA-DRBl *13 expression, ascertained 
using UK8.1 and HLA-DRB3 (DR52) expression, ascertained using 7.3.19.1, were strongly 
up-regulated. IFN-')' induced cell surface expression ofHLA-DRB 1 *04 differed considerably 
depending on the antibody used to detect it (Figure 3.31 ). For example, when NFLD .D 1 and 
NFLD.Ml were used, HLA-DR4 was found to be weakly up-regulated. However, when 
NFLD.D10 and NFLD.D2 were used, strong DR4 up-regulation was observed. This 
phenomenon was described previously by Tibbo (1998). HLA-DRB4 (DR53) expression, 
detected using PL3, was strongly induced. 
SinceNFLD.M1 also binds HLA-DR52(Table 2.4), it would suggest thatDR52 was 
weakly up-regulated by BT -20. However, using 7.3 .19 .1, DR52 was found to be strongly 
up-regulated. 
Immunocytochemistry (IC), shown in Figure 3.32, was used to further characterize 
HLA-DR4 expression in BT-20. Moderate to strong HLA-DR expression was observed in 
~75% ofBT-20 using the antibody L243 . Immunocytochemical detection ofHLA-DR4 
revealed that ~60% of cells were moderately to strongly positive as assessed using NFLD .D 1; . 
~50% of cells were weakly to moderately positive as detected using NFLD.M1; ~ 70% of cells 
were moderately to strongly positive as determined using NFLD. D 1 0 and ~ 3 5% of cells were 
weakly to moderately positive as assessed using NFLD.D2. These observations suggest that 
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Figure 3.31. Cell surface expression of HLA-DR allelic products on BT-20. Non-
induced (open bars) and IFN-y induced (fj!led bars) expression were assessed using 
monoclonal antibodies that distinguished DR allotypes (shown in parenthesis) and 
flow cytometry. Results; reported as degree of HLA-DR expression (see section 
2.4.5), are averages · of at least two experiments. Standard deviations ate indicated. 
Values of 2.1 and above (to the r ight of the black line)· are considered positive. 
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NEGATIVE NFLD.Ml (DR4,DR52) 
L243 (All DR) NFLD.D2 (DR4) 
NFLD.Dl (DR4) NFLD.DlO (DR4) 
Figure 3.32. Immunocytochemical analysis of HLA-DR4 up-regulation in 
IFN-y treated BT-20. HLA-DR4 expression was assessed using NFLD.Dl, 
NFLD.Ml, NFLD.D2 and NFLD.D10. Expression of all DR types was 
analyzed using L243. The negative control is shown alongside. 
131 
NFLD.Dl and NFLD.Ml binding to cell surface HLA-DR4 was impeded in BT-20. 
3.6.3.2E. MCF7 
Cell surface HLA-DR was strongly up-regulated by MCF7 following IFN-y treatment 
(Figure 3.33). HLA-DRB1*03 expression, determined by UK8.1, was strongly induced. 
Using NDS13, HLA-DRB3 (DR52) was found to be moderately up-regulated. Oddly, 
constitutive HLA-DR52 cell surface expression was also observed using NDS 13 even though 
this gene was not constitutively tra.rlscribed (Figure 3.27) (see section 4.4.2 for further 
discussion). Constitutive HLA-DR expression, as assessed using L243, was also not 
detected. HLA-DRB 1 * 15 expression, assessed using NFLD .D 1 0, was strongly up-regulated 
by MCF7. HLA-DR15 expression was analyzed previously with similar findings (Tibbo, 
1998). Unfortunately, HLA-DRB5 (DR51) protein expression was not assessed since a 
DR51 specific antibody was not available. 
3.6.3.2F. SK-BR-3 
HLA-DR was strongly up-regulated by SK-BR-3 in response to IFN-y as assessed 
usingtheantibodyL243 (Figure 3.34). HLA-DRBl *13 expression, determined using UK8.1 , 
was moderately induced. HLA-DRB3 (DR52) was strongly up-regulated as assessed using 
7.3 .19.1. HLA-DRB1*07, detected using SFR16, was moderately up-regulated but was only 
measured once since the DR 7 specific antibody was depleted. As previously stated, PL3, the 
antibody used to determine DRB4 (DR53) expression, also bound HLA-DR7. Thus, it was 
not possible to ascertain DR53 protein expression in this cell line. 
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Figure 3.33. Cell surface expression of HLA-DR allelic products on MCF7. Non-
induced (open bars) and IFN-y induced (filled bars) expression were assessed using 
monoclonal antibodies that distinguished DR allotypes (shown in parenthesis) and 
flow cytometry. Results, reported as degree of .HLA-DR expression (see section 
2.4.5), are averages of at least two experiments. · Standard deviations are indicated. 
Values of 2.1 and above (to the right of the black line) are considered positive. 
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Figure 3.34. Cell surface expression of HLA-DR allelic products on SK-BR-3. 
Non-induced (open bars) and IFN-y induced (filled bars) expression were 
assessed using monoclonal antibodies that distinguished DR allotypes (shown in 
parenthesis) and flow · cytometry. Results are reported as degree of HLA-DR 
expression (see section 2.4.5) and are averages of more than one experiment 
unless indicated by an asterisk. Standard deviations are shown where appropriate. 
Values of 2.1 and above (to the right of the black line) are considered positive. 
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3.6.3.2G. MDA-:MB-436 
MDA-MB-436 strongly up-regulated cell surface HLA-DR as assessed using L243 
(Figure 3.35). HLA-DRBl *03 expression, determined by UK8.1 , was strongly induced. In 
comparison, HLA-DRB3 (DR52) expression, detected using NFLD.D7 and NDS 13, was 
weakly up-regulated. 
Immunocytochemically, weak to moderate HLA-DR52 expression was observed in 
'--14% ofMDA-MB-436 using NFLD.D7 (Figure 3.36). This confirmed flow cytometry 
results which revealed weak DR52 up-regulation in this cell line. In contrast, no DR52 
protein was detected using the antibody NDS13. NFLD.D7 was effective for use in IC as 
observed by its moderate to strong binding to ~90% of the B cell line control COX. 
However, the epitope recognized by NDS13 may have been altered by acetone fixation or by 
detergent since NDS13 weakly to moderately bound ~77% of COX. (Figure 3.36). 
3.6.3.2H. Hs578T 
Cell surface HLA-DR was strongly up-regulated by Hs578T as determined using the 
antibody L243 (Figure 3.37). HLA-DRBl*Ol, assessed by JS-1, was not up-regulated. 
HLA-DRB 1 * 15 expression, determined by NFLD.D7, was strongly induced following IFN-y 
treatment. HLA-DRB5 (DR51) expression was not analyzed since we didnot have aDR51 
specific antibody. 
Immunocytochemically, no DRl protein was detected in Hs578T (Figure 3.38). This 
confirmed flow cytometry data. JS-1 was suitable for use in I C since weak to moderate 
staining of ~80% of cells was observed in the positive control JESTHOM. 
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Figure 3.35. Cell surface expression of HLA-DR allelic products on MDA-MB-
436. Non-induced (open bars) and IFN-y induced (filled bars) expression were 
assessed using monoclonal antibodies that distinguished DR allotypes (shown in 
parenthesis) and flow cytometry. Results, reported as degree of HLA-DR 
expression (see section 2.4.5), are averages of at least two experiments. Standard 
deviations are indicated. Values of 2.1 and above (to the right of the black line) are 
considered positive. 
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MDA-MB-436 + IFN-y cox 
NEGATIVE NEGATIVE 
L243 (ALL DR) L243 (ALL DR) 
NFLD.D7 (DR52) NFLD.D7 (DR52) 
NDS13 (DR52) NDS13 (DR52) 
Figure 3.36. Immunocytochemical analysis of HLA-DR52 up-regulation in IFN-y 
treated MDA-MB-436. HLA-DR52 expression was assessed using NFLD.D7 and 
NDS 13. Expression of all DR types was analyzed using L243. The negative 
control is shown alongside. COX is the positive control for DR52 antibody 
binding. 
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Figure 3.37. Cell surface expression of HLA-DR allelic products on Hs578T. Non-
induced (open bars) and IFN-y induced (filled bars) expression were assessed using 
monoclonal antibodies that distinguished DR allotypes (shown in parer\thesis) and 
flow cytometry. Results, reported as degree of HLA-DR expression (see section 
2.4.5), are averages of at least two experiments. Standard deviations are indicated. 
Values of2.1 and above (to the right of the black line) are considered positive. 
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Hs 578T + IFN -y JESTHOM 
NEGATIVE NEGATIVE 
L243 (ALL DR) L243 (ALL DR) 
JS-1 (DRl) JS-1 (DR1) 
Figure 3.38. Immunocytochemical analysis of HLA-DR1 up-regulation in 
IFN-y treated Hs578T. HLA-DR1 expression was assessed using JS-1. 
Expression of all DR types was analyzed using L243. The negative control 
is shown alongside. JESTHOM is the positive control for JS-1 binding. 
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3.6.3.21. MDA-MB-157 
Following IFN-y treatment, MDA-MB-157 strongly up-regulated cell surface HLA-
DR as assessed using L243 (Figure 3.39). However, HLA-DRB1 *04 expression, analyzed 
using NFLD.Dl and NFLD.Ml, andHLA-DRB4 (DR53) expression, assessed using PL3, 
were not induced. HLA-DRB1 *15 cell surface expression, detected using NFLD.D10 and 
NFLD.D7, was moderately up-regulated. NFLD.D1 0 and NFLD.D7 recognize DR4 and 
DR15 but since DR4 was not up-regulated by MDA-MB-157, these antibodies were useful 
. for DR15 detection. HLA-DRB5 (DR51) protein expression could not be assessed since a 
DR51 specific mAb was not available. These data confirmed findings by Tibbo (1998) 
regarding HLA-DR4 and DR15 protein expression in MDA-MB-157. 
Immunocytochemically, weak to moderate HLA-DR4 expression, assessed by 
NFLD.Dl and NFLD.Ml , was observed in -15% of cells (Figure 3.40). NFLD.D1 and 
NFLD.Ml were suitable for use in IC as observed by their binding to positive control cell 
lines (Figure 3 .38). Specifically, NFLD.D 1 strongly bound -95% of SA VC while NFLD.Ml 
moderately bound ~85% ofMDA-MB-435. Additionally, IC analysis, using the antibody 
PL3, revealed that ~20% of cells were weakly positive for DR53 expression. Thus, DR53 
protein was weakly up-regulated intracellularly in MDA-MB-157. PL3 was suitable for lC 
since this antibody strongly bound - 87% ofMDA-MB-435 (Figure 3.40). 
3.6.3.2J. BT-474 
BT -474 moderately up-regulated cell surface HLA-DR following exposure to IFN-y 
as assessed using L243 (Figure 3.41 ). HLA-DRB 1 *04 expression, assessed by NFLD.D 1 and 
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Figure 3.39. Cell surface expression of HLA-DR allelic products on MDA-MB-
157. Non-induced (open bars) and IFN-y induced (filled bars) expression were 
assessed using monoclonal antibodies that distinguished DR allotypes (shown in 
parenthesis) and . flow cytometry. Results, reported as degree of HLA-DR 
expression (see section 2.4.5), are averages of at least two experiments. Standard 
deviations are indicated. Values of 2.1 and above (to the right of the black line) are 
considered positive. 
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MDA-MB-157 + IFN-y SAVC MDA-MB-435 + IFN-y 
• 
NEGATIVE NEGATIVE NEGATIVE 
L243 (ALL DR) L243 (ALL DR) L243 (ALL DR) 
NFLD.Dl (DR4) NFLD.Dl (DR4) 
NFLD.Ml (DR4) NFLD.Ml (DR4) 
PL3 (DR53) PL3 (DR53) 
Figure 3.40. Immunocytochemical analysis of HLA-DR4 and HLA-DR53 
expression in IFN-y treated MDA-MB-157. DR4 expression was assessed using 
NFLD.D1 and NFLD.M1 while DR53 expression was assessed using PL3. 
Expression of all DR types was analyzed using . L243. The negative control is 
shown alongside. SA VC and MDA-MB-435 are positive controls for DR4 and 
DR53 antibody binding. MDA-MB-435 IC was done by Sharon Oldford. 
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Figure 3.41. Cell surface expression of HLA-DR allelic products on BT-474. 
Non-induced (open bars) and IFN-y induced (filled bars) expression were 
assessed using monoclonal antibodies that distinguished DRallotypes (shown in 
· parenthesis) and t1ow cytometry. Results are reported as degree of HLA-DR 
expression (see section 2.4.5) and are averages of more than one experiment 
unless indicated by an asterisk. Standard deviations are indicated where 
appropriate. Values of 2.1 and above (to the right of the black line) are 
considered positive. 
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NFLD.Ml , and HLA-DRB4 (DR53) expression, analyzed by PL3, were not observed. 
NFLD.Ml detection ofDR4 expression was done only once. HLA-DRBl *15 expression, 
determined by NFLD.DlO and NFLD.D7, was moderately induced. Again, HLA-DRBS 
(DR51) expression could not be analyzed. 
Immunocytochemically,~ 14% of cells were weakly or strongly positive for HLA-DR 4 
as assessed using NFLD.Dl and ~6% of cells were strongly positive for DR4 expression as 
determined using NFLD.Ml (Figure 3.42). Additionally, <5% of cells were weakly to 
moderately positive for HLA-DR53 expression as detected using PL3. These observations 
confirmed flow cytometry results. NFLD.Dl, NFLD.Ml and PL3 were effective for use in 
IC given that they strongly bound positive control cell lines (see section 3.7.3.21.). 
3.6.3.2K. MDA-MB-468 
Following IFN-y treatment, MDA-MB-468 moderately up-regulated cell surface 
HLA-DR as assessed using L243. This cell line had the lowest HLA-DR up-regulation of all 
breast cancer cell lines (Figure 3.8). HLA-DRBl *01 expressio~ assessed by NFLD.DlO, 
was not detected (Figure 3.43). Similarly, HLA-DRB l *07 expression, analyzed using 
SFR16, was not up-regulated. Since DR7 expression was not induced by MDA-MB-468, 
PL3 was suitable for assessing DR53 expression. However, using PL3, cell surface DR53 up-
regulation was not observed. 
IC con£rmed flow cytometry data (Figure 3.44). Using NFLD.DlO, ~9% of cells 
were weakly to moderately positive for DRl. IC using SFR16 was not done because this 
antibody was depleted. Immunocytochemically, <5% of cells were weakly to moderately 
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BT-474 + IFN-y SAVC MDA-MB-435 + IFN-y 
• 
NEGATIVE NEGATIVE NEGATIVE 
L243 (ALL DR) L243 (ALL DR) L243 (ALL DR) 
NFLD.Dl (DR4) NFLD.Dl (DR4) 
NFLD.Ml (DR4) NFLD.Ml (DR4) 
PL3 (DR53) PL3 (DR53) 
Figure 3.42. Immunocytochemical analysis of HLA-DR4 and HLA-DR53 
expression in IFN-y treated BT -474. DR4 expression was assessed using 
NFLD.Dl and NFLD.Ml while DR53 expression was assessed using PL3. 
Expression of all DR types was analyzed using L243. The negative control is 
shown alongside. SA VC and MDA-MB-435 are positive controls for DR4 and 
DR53 antibody binding. MDA-MB-435 IC was done by Sharon Oldford. 
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Figure 3.43. Cell surface expression of HLA-DR allelic products on MDA-MB-
468. Non-induced (open bars) and IFN-y induced (filled bars) expression were 
assessed using monoclonal antibodies that distinguished DR allotypes (shown in 
parenthesis) and flow cytometry. Results, reported as degree of HLA-DR 
expression (see section 2.4.5), are . averages of at least two experiments. Standard 
deviations are indicated. Values of 2.1 and above (to the right of the black line) are 
considered positive. 
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MDA -l\ffi-468 + IFN -y JESTHOM 
NEGATIVE NEGATIVE NEGATIVE 
L243 (ALL DR) L243 (ALL DR) L243 (ALL DR) 
NFLD.DlO (DRl) NFLD.DlO (DRl) 
PL3 (DR7, DR53) PL3 (DR7, DR53) 
Figure 3.44. Immunocytochemical analysis of HLA-DR allele expression in 
IFN-y treated MDA-MB-468. DRl expression was assessed using NFLD.Dl. 
DR7 and DR53 expression were assessed using PL3. Expression of all DR types 
was analyzed using L243. The negative control is shown alongside. JESTHOM 
and SK-BR-3 are positive controls for NFLD.DlO and PL3 binding. 
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positive when analyzed using PL3. NFLD .D 10 and PL3 were suitable for use in IC since they 
moderately to strongly bound positive control cell lines (Figure 3.44). For example, 
NFLD.DlO bound ~90% of JESTHOM while PL3 bound ~65% ofSK-BR-3. 
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CHAPTER 4. DISCUSSION 
The CD4+ T cell tumor antigen-specific immune response may have a critical role 
in the eradication of breast tumors (Ostrand-Rosenberg, 1994, Baskar, 1996, Armstrong et 
aL, 1998c). Since this immune response may be significantly altered by HLA class 1I 
expressing carcinomas, an important goal of our research was to characterize breast cancer 
cells as potential APC. 
4.1. Study Concerns 
4.1.1. Cell Lines 
Breast carcinoma cell lines utilized in our investigation were kindly provided by 
several laboratories (sec section 2.1). When working with cultured cell lines, there is always 
the possibility of cell line mix-up or contamination (Kaplan et al., 1998, MacLeod et al., 
1999, Masters et al., 2001). However, the identity of each breast cancer cell line. used in our 
study has been confirmed via comparison with short .tandem: repeat (STR) sequences 
published by the ATCC (data not shown). 
One cell line, MDA-MB-435, classified as a breast carcinoma by the ATCC, has 
been found to express several genes associated with melanoma (Ross etal., 2000). While 
this · gene expression may have been indicative of neuroendocrine features of some breast 
tumors, more likely these results indicate that MDA-MB~435 originated ti·om a melanoma 
(Ross et al., 2000). Thus, even though this thesis reports MDA-MB-435 findings, it is 
cautioned that this cell line may not be a breast carcinoma. 
Of course, itis not known whether data obtained using our in vitro model of breast 
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cancer parallel the situation in vivo. Current work in our laboratory is addressing this issue 
by examining the selective expression of HLA-DR allelic products in situ. 
4.1.2. Trypsin 
The idea that weak class II expression on cettain breast carcinoma cells was due to 
trypsin induced class ll shedding was addressed. Trypsin degrades the extracellular matrix 
of proteins involved in cell adhesion thereby facilitating the removal of adherent cells 
(Vogel, 1978, Carver et al., 1995). This enzyme may also strip glycopeptides, 
glycosaminoglycans and proteins from the cell surface (Anghileri & Dermietzel, 1976, 
Vogel, 1978). Despite these trypsin induced cell alterations, Co rver et a1. ( 1995) observed 
limited loss of cell surface antigens on ovarian cancer cell lines following trypsin treatment. 
In agreement, our study found that class IT cell surface expression on the B cell line MT14B 
was not significantly altered by trypsin (Figure 3.3). Furthermore, trypsin was not 
responsible for low levels of class IT cell surface antigens on IFN-'Y treated BT -474 and 
MDA-MB-468 since these cells had correspondingly weak up-regulation of intracellular 
class li (data not shown). 
4.2. CIIT A Independent HLA Class II and Class II Co-chaperone Regulation in Breast 
Cancer Cell Lines 
4.2.1. Primer Concerns 
CIITA transcription in breast carcinoma cells was analyzed by RT-PCR using two 
primer sets which amplified different regions of the CUT A transcript. Notably, constitutive 
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CTITA expression was detected in more breast cancer cell lines using primer set #2 than 
primer set #1 (Table 3.1). While both primer sets amplified CIITA mRNA in all IFN-y 
treated breast cancer cell lines, primer set #2 consistently amplified more product (Figure 
3.6). These data suggest that primer pair #2 had a higher affinity for the CIIT A transcript 
than primer pair# 1 and indeed primer pair #2 has a higher melting temperature than primer 
pair# 1. Thus, all conclusions are based on data obtained using primer set #2. Future work 
could obtain additional primers to confirm these results. 
4.2.2. Findings 
To our knowledge, this was the first investigation of CIIT A expression in breast 
carcinoma cells. CIITA expression was assessed in terms of gene transcription, but since 
transcription does not always parallel translation it is important that future work analyze 
CUTA protein expression in these cells. 
As expected, all cell lines transcribed CIIT A following IFN-y stimulation. These data 
suppmt the dogma that CUT A mediates IFN -y induction of class IT and class ll co-chaperone 
genes (Steimle et al., 1994). 
Constitutive CIIT A transcription was observed in MDA-MB-435, MDA-MB-231, 
BT-20, MCF7, BT-474 and MDA-MB-468 but was not detected in T-47D, SK-BR~3, 
Hs578T, MDA-MB-436 and MDA-MB-157. Interestingly, all CIITA negative cell lines 
constitutively transcribed one or more class II and class ll co-chaperone genes suggesting 
CIITA independent regulation of these genes. One cell Jin:e, T-47D, even constitutively 
expressed HLA-DR and li protein. Notably, a CllTA transcript was amplified in T-47D but 
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its size was smaller than the predicted size. Whether this indicates a mutation or deletion in 
CIITA is not known ru1drequires further investigation. 
This is not the first study to provide evidence for CTIT A independent class IT and 
class ll co-chaperone regulation. Chang et al. ( 1996) described class II protein expression 
in the thymus of CllTA knockout mice. Furthermore, Williams et al. ( 199g), using ditl erent 
CTIT A deficient mice, demonstrated class II protein in thymic cortex cells, germinal center 
B cells and lymph node dendritic cells. Chang et al. (1996) emphasized that low levels of 
class II transcripts detected in APCs from CIIT A deficient mice may not be sufficient for 
translation (Chang et al., 1996). Future research could quantify class II transcripts in cell 
lines not expressing CIIT A to assess whether levels are suitable for translation. This would 
also be informative for CllTA positive cell lines constitutively transcribing class IT or class 
II co-chaperones, but not expressing protein. 
Douhan et al. (1997) described a CIIT A negative B cell line, clone 13, which 
expressed HLA-DQ protein but no HLA-DR nor HLA-DP protein. This suggests differential 
regulation of class II isotypes by CIIT A. This phenomenon was not observed in our study 
as no cell line expressed HLA-DQ protein without concomitant HLA-DR and HLA-DP 
expression. However, our results do suggest that CIIT A may preferentially regulate class II 
~-chains. For example, HLA-DQB mRNA was detected in only 2/5 CllTA negative cell 
lines but was detected in 5/6 CIIT A positive cell lines. HLA-DQA mRNA was found in 2/5 
CIIT A negative cell lines and similarly in 3/6 CIIT A positive cell lines. A similar 
phenomenon was observed for transcription of HLA-DR and HLA-DP o.- and ~-chains. 
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CIIT A independent regulation of class II co-chaperones is also supported by our 
findings. Specifically, DMA and DMB were constitutively transcribed by all CllTA negative 
breast cancer cell lines and Jj was transcribed in 4/5 ofthese cell lines. Similarly, Chang e t 
al. (1996) showed that HLA-2M and Ii genes were transcribed in splenocytes from CIITA 
deficient mice, but at reduced levels. Williams et al. (1998) described Ii protein in the 
thymus, spleen and lymph nodes of CITrA deficient mice. Sartoris et al. ( 1998) also repmted 
constitutive Ii, DMA and DMB transcription in the absence of constitutive CIIT A 
transcription in a pancreatic carcinoma cell line, CFP AC-1. Tai et al. ( 1999) have even 
described the molecular basis for CllT A independent Ii transcription. It is not surprising that 
factors other than CIIT A may activate Ii and DM transcription since their promoters contain 
extra regulatory regions in addition to the characteristicW/S, Xl , X2 andY box class II 
promoter elements (Westerheide et al., 1997, Moore et al., 1998, Tai ct al. , 1999). 
Intriguingly, constitutive HLA-DOAtranscription was not detected in any cell line, 
regardless of CIITA expression. Following IFN-y treatment, DOA mRNA was detected in 
6/11 cell lines. This suggests that another factor, not present constitutively in breast 
carcinoma cells but inducible by IFN-y in some cells, may act independently or in concert 
with CIITA to regulate HLA-DOA expression. HLA-DOB transcription is not regulated by 
CITrA (Taxman et al., 2000). 
Our investigation and the others described above support the notion that CIITA is not 
a master regulator of class II and class II co-chaperone expression in all cells. However, 
CUT A may be required for optimal class II and class II co-chaperone transcription and 
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translation. There is evidence to suggest that other factors may activate class D transcription 
in the absence of Clff A For example, CITfA deficient RJ2.2.5 cells expressed cell surface 
HLA-DR and HLA-DQ following transfection with activated ras genes (Burne et al., 1987). 
4.3. Breast Carcinoma Cell Lines as Potential HLA Class II Restricted APCs 
There is evidence suggesting that cancer cells may act as APCs (Ostrand-Rosenberg, 
1994, Armstrong et al. , 1998b, Annstrong et al., 1998c). Thus, our study examined whether 
breast cancer cells express components of the class II antigen presentation pathway and co-
stimulatory molecules. 
4.3.1. IFN-y as an Inducer of Class II and Class II Co-chaperone Expression 
IFN-y was used since this agent is the most potent inducer of HLA class II and class 
II co~chaperones (Jabrane-Ferrat et al., 1990). As well, this factor may be released into the 
tumor microenvironment by tumor infiltrating lymphocytes such as CD4+ and CD8+ T cells 
and natural killer cells; thus it has a physiological role (Blanck, 1999). Based on previous 
work in our laboratory and preliminary research, we decided that cells would be stimulated 
with 500 units/ml IFN-y for 96 hours. In fact, successful class D induction has been achieved 
using a broad range of IFN-y concentrations from 10 units/rnl to 1000 units/ml {Schwartz et 
al., 1985, Jabrane-Ferrat et al., 1990, Lu et al., 1994, Muczynski et al., 1998, Kooy et al. , 
1999, Walter et al., 2000). The 96 hour incubation period is longer than that utilized in most 
studies in which 48-72 hours are standard (Jabrane-Ferrat etal. , 1990, Sedlak et al., 1992, 
Lu et al., 1994) but as shown in our study (section 3.1.1.2), the optimal time is also cell line 
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dependent. 
4.3.2. HLA Class II and Class II Co-chaperone Expression in Breast Cancer Cell Lines 
Our findings, summarized in Table 4.1, show that after treatment with JFN-y, most 
breast cancer cell lines up-regulate the molecules involved in class II antigen presentation. 
These data both confirm and contradict the limited published data describing class II and 
class II co-chaperone expression in breast carcinoma cell lines (Table 4.2). Contradictory 
findings are not surprising considering that culture conditions and/or methodologies used in 
other studies often differed from those in our study (Table 4.2). As well, cultured cell lines 
may simply mutate over time. Thus, cell line passage number may intluence the cell's 
ability to express different molecules. 
4.3.2.1. HLA-DR 
Our study found constitutive HLADR protein in MDA-MB-435, T-47D, MDA-MB-
231 and BT-20 (Figure 3.8). Even though constitutive DRA and DRB transcription were 
detected in MCF7 and SK-BR-3, constitutive DR protein expression was not. Gene 
transcription in the absence of protein expression was frequently observed in our study. 
There are several potential explanations for this phenomenon including mRNA instability 
which could hinder accumulation of protein product or low levels of mRNA which could 
prevent efficient gene translation or gene mutations which could prevent successful gene 
translation or proper protein folding. Also, the assays used to assess gene transcription and 
protein expression had differences intheir detection sensitivity i. e. PCR is very sensitive 
while flow cytometry is not as sensitive. 
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Table 4.1. Summary of HLA class II, class II co-chaperone and co-stimulatory molecule 
protein expressiona on breast cancer cell lines. 
Protein 
Cell Une 
HLA- HLA- HLA- Ii 
DR DP DQ 
MDA-MB-435 cb c f c 
T-47D c I I c 
MDA-MB-231 c c - c 
BT-20 c I I I 
MCF7 I I I c . 
SK-BR-3 I I I I 
MDA-MB-436 1 1 - I 
Hs578T I I - I 
MDA-MB-157 I I - I 
BT-474 I - - I 
MDA-MB-468 I I - I 
a Data is based on flow cytometry findings 
b Constitutive and IFN-y induced expression observed. 
c lFN-y induced expression observed. 
d No expression detected. 
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HLA· CDSO/ CD40 
DM CD86 
I -d c 
I - c 
c - c 
c - c 
I - -
I - c 
- - I 
- - I 
- - -
- - -' 
I - -
Table 4.2. Comparison of othei· studies analyzing HLA class Tland class TT co-chaperone expression in breast cancer cell lines. 
Study ·cell Lines Culture Methodologies Results 
Analyzed Conditions 
Armstrong MDA-MB-435 • lMDM medium • Immunofluorescence and flow • MDA-435 48% DR positive; MDA-23 1 
et al., MDA-MB-231 • Culture time not cytometry using L243 (anti-HLA- 40% DR positive; MCF7 38% DR 
1998a MCF7 reported DR), PIN. I (anti-Ii) and polyclonal positive; SK-BR-3 17% positive 
SK-BR-3 rabbit anti-DM • MDA-435 55% Ii positive; MDA-231 
25% Ii positive; MCF7 33% positive; 
SK-BR-3 39% positive 
• MDA-435 49% DM positive; MDA-
231 9% DM positive, MCF7 28% DM 
posi tive; SK~BR-3 22% DM positive 
Sedlak et BT-20 • 500 U/ml IFN-y • Immunofluorescence and flow • All cell lines up-regulated I-ILA-DR 
al., 1992 MDA-MB-468 • 72 hours cytometry using Bra30 (anti-HLA-
MCF7 • MErv'l medium DR) 
Nouri et T-470 • 100 U/ml IFN-y • Radioinununoassay using L243 • No constitutive HLA-DR protein 
at., 1992 MCF7 • 48 hours (anti- HLA-DR) • All cell lines up"regulated HLA-DR 
Jabrane- T-47D • 1000 U/ml IFN-y • Immunofluorescence and • No constitutive mRNA or protein 
Ferrat et MDA-MB-231 • 48 hours fluorescence microscopy using D l- • All cells up-regulated DR & DP 
al.. 1990 MCF7 • DMEM medium 12 (anti-HLA-DR), L2 and TU22 • T-470 up-regulated DQ; MDA-MB-
(anti- HLA-DQ) & B7-2J (anti- 231 & MCF7 did not · 
HLA-DP) • DQA & DQB not transcribed in MDA-
• Northern blotting for mRNA MB-23 1 and MCF7 
• 2-D gel electrophoresis using • Ii up-regulated but not constitutive 
VIC.·Y 1 (ariti-li) 
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Table 4.2. Continued. 
Study Cell Culture Conditions Methodologies Results 
Lines 
Analyzed 
Boyer et al., BT-20 • 1000 U/ml IFN-y • Radioimmunoassay using L243 • No constitutive HLA-DR 
1989 MCF7 • 48-72 hours (anti-HLA-DR) • All cell lines up-regulated HLA-DR 
SK-BR-3 • RPMI 1640 (BT-20, 
SKBR3) ; DMEM (MCF7) 
Gastl et al ., BT-20 • 500 units/ml IFN-y • Immunofluorescence and • No constituti ve HLA-DR 
1985 MCF7 • 72 hours tluorescence microscopy using • BT-20 90-100% HLA-DR positive; 
Hs578T •MEMmedium VID-1 (anti-HLA-DR) and anti- MCF7 & Hs578T <5% HLA-DR 
DR from Becton Dickinson positive 
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Armstrong et al. (1998a) also detected constitutive HLA-DR on MDA-MB-435 and 
MDA-MB-23lbut in contrast to our findings, they found constitutive expression on MCF7 
and SK-BR-3 as well. However, other investigations have not reported constitutive DR 
expression by breast cancer cell lines (Table 4.2). Specifically, Gastl etal. (1985) and Boyer 
et al. (1989) did not detect constitutive DR protein in BT-20. HLA-DR protein nor mRNA 
were detected in T-47D, MDA-MB-231 and MCF7 (Jabrane-Ferrat et al. , 1990). 
Constitutive DR protein was also not detected in T-47D by Nouri et al. (1992). In agreement 
with other studies (Jabrane-Ferrat et al., 1990, Sedlak et aL, 1992, Nouri et al., 1992), we 
found strong HLA-:DR up-regulation on T-47D, MDA-MB-231, BT-20, MCF7 and SK-BR-
3. However, our findings disagreed with those of Gastl et al. (1985) who described minimal 
HLA-DR up-regulation in MCF7 and Hs578T. While MDA-MB-468up-regulated HLA-DR 
the least in our study, Sedlak et al. (1992) reported higher levels of HLA-DR in MDA-MB-
468 than MCF7. We also showed that MDA-MB-435, MDA~MB-436, MDA-MB-157 and 
BT -474 up-regulated HLA-DR (Figure 3.8) but no other studies reported such data. 
4.3.2.2. HLA~DP 
We observed constitutive HLA-DP cell surface expression only on MDA-MB-435 
and MDA-MB-231 even though constitutive DPA and DPBtranscription were also detected 
inBT -20, MCF7 and MDA-MB-157 (Figure 3.11, Table 3.3). Jabrane-Ferrat et al. ( 1990) 
is the only other group to describe HLA-DP expression in several of the cell lines examined 
in our study. Specifically, Jabrane-Fenat et al. ( 1990) also reported constitutive HLA-DPB 
transcription in T -47D but unlike our study, this group did not detect constitutive HLA-DPB 
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mRNA in MDA-MB-231 or MCF7 nor HLA-DP protein in MDA-MB-231. 
Following IFN-y stimulation, we found that 10/11 breast cancer cell lines expressed 
cell surface HLA-DP (Figure 3.11); BT-474 did not express this class ll antigen but 
transcribed DPA and DPB genes (fable 3.3). Coinciding with our data, Jabrane-Ferrat et al. 
(1990) also found that T-470, MDA-MB-231 and MCF7 up-regulated HLA-DP protein: 
4.3.2.3. HLA-DQ 
Constitutive HLA-DQ cell surface expression was not detected on any breast cancer 
cell line even though MDA-MB-435, T-47D, BT-20, MCF7 and SK-BR-3 constitutively 
transcribed DQA and DQB genes (Figure 3.14, Table 3.4). Again, the study by .Tabrane-
Ferrat et al. (1990) was the only other describing HLA-DQ expression in cell lines used in 
our study . . This group also reported the absence of constitutive HLA-DQ expression in T-
. . . 
47D, MDA-MB-231 and MCF7, but contrasting with om findings, they did not detect 
constitutive DQA and DQB transcription in T-47D and MCF7. 
Following IFN-y treatment, all cell lines transcribed DQA and DQB genes but only 
MDA-:MB-435, T-47D, BT-20, MCF7 and SK-BR-3 expressed cell surface HLA-DQ (Table 
3.4, Figure 3.14). Our data, therefore, confirm those of Jabrane-Ferrat et al. (1990) in that 
HLA-DQ protein was detected in T-47D and not in MDA-MB-231 but contradicting our 
findings, Jabrane-Fenat et al. (1990) reported that MCF7 did not up-regulate HLA-DQ and 
that DQA and DQB were not transcribed by MDA-MB-231 and MCF7 . . 
4.3.2.4. Invariant Chain 
Even though we detected constitutive li transcription in all breast cancer cell lines 
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except Hs578T, intracellular protein expression was observed in only four cell lines, MDA-
MB-435, T-470, MDA-MB-231 and MCF7 using flow cytometry or IC (Table 3.5 and 
Figure 3.17). These data confirm those of Armstrong et al. (1998a) in that MDA-MB-435, 
MDA-MB-231 and MCF7 constitutively expressed Ii but unlike our study, Armstrong et al. 
( 1998a) also detected constitutive Ii expression in SK-BR-3. In contrast to these findings, 
Jabrane-Ferratet al. {1990) did not detect constitutive Ii protein in TA7D, MDA-MB-231 
and MCF7 . 
Our data confirmed those of Jabrane-Ferrat et al. (1990} in that Ii was up-regulated 
by T-47D, MDA-MB-231 andMCF7. Our study also found that nine other breast carcinoma 
cell lines up-regulated Ii (Figure 3.17); findings that had not been previously published .. 
4.3.2.5. HLA-DM 
While no cell line constitutively expressed intracellular HLA-DM, as assessed by 
flow cytometry, DM was detected in MDA-MBA35, MDA-MB-231 and BT-20 by IC 
(Figures 3.20, 3.21). Armstrong et al. (l998a) also detected constitutive DM in MDA-MB-
435 but in contrast to our findings, they found constitutive DM in MCF7 and SK-BR-3 but 
not in MDA-MB-231. 
Since Armstrong et al. (1998a) only reported constitutive DM expression in breast 
cancer cell lines, our study was the first to examine lFN-y induced DM expression. While 
all breast cancer cell lines transcribed HLA-DMAand HLA-DMB genes in response to IFN-y 
(Table 3.6), intracellular DM protein, as assessed by flow cytometry, was up~rcgulatcd by 
MDA-MB-435, T-47D, MDA-MB-231, BT-20, MCF7 and MDA-MB-468 (Figure 3.20). 
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However, using IC, DMwas detected in all cell lines except BT-474 (Figure 3.22). 
Notably, our study is the first to describe cell surface HLA-DM expression by breast 
carcinoma cells (see section 3.4.2.2). These novel findings may partially resolve 
discrepancies between intracellular flow cytometry and IC data (described above). Since 
smfaceDM was constitutively expressed by MDA-MB-231 andBT-20 and was up-regulated 
by SK-BR-3, it is speculated that IC revealed surface DM that was not detected by 
intracellular flow cytomctry. Theoretically, intracellular flow should have detected surface 
DM but it is possible that the fixative or the detergent used in IC altered the DM epitope. 
Other discrepancies between intracellular flow cytometry and IC are more difficult 
to interpret. For example, constitutive DM detected in MDA-MB-435 using IC was not 
detected by intracellular nor extracellular t1ow cytometry. When IC and intracellular flow 
cytornetry were repeated simultaneously, HLA-DM expression was not detected by either 
method (data not shown). Similar observations were made for MDA-MB-436, Hs578T and 
MDA-MB-157 (see section 3.4.2.2). Notably, when DM expression was detected in these 
cells immunocy1ochemically, cells were grown in chamber slides. In other experiments 
analyzing DM expression (i.e. t1ow cytometry and IC using cytocentrifuge preparations), 
cells were trypsinized prior to the assay. This suggests that trypsin may have destroyed the 
DM epitope in certain cell lines. Future work necessitates repeating IC using chamber slides. 
Alternatively, discrepant findings may be clarified by an experiment assessing constitutive 
intracellular HLA-DM expression in MDA-MB-435 at 24-hour intervals for 120 hours. 
HLA-DM was detected at 24, 48, 72 and 120 hours but not at 96 hours (David Spurrell, 
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unpublished observations). This suggests that DM expression may be cyclic but further 
experiments are required to confirm this observation. 
4.3.2.6. HLA-DO 
HLA-DO expression in breast carcinoma cells had never been assessed prior to this 
study. While no cell line constitutively transcribed HLA-DOA, all cells except MCF7 
transc1ibed HLA-DOB suggesting differential regulation of these genes. Indeed, it is known 
that DOA is regulated by CIIT A while DOB is not (Taxman et al., 2000). Following IFN-y 
stimulation, DOAtranscription was detected in six cell lines whileDOB was transcribed in 
all cell lines (Table 3.7). Notably, of all class IT and class IT co-chaperone genes, DOA was 
up-regulated the least suggesting differential regulation of DOA in breast carcinoma cells. 
HLA-DO protein expression was not determined but could be assessedusing a commercially 
available anti-DO antibody and IC. 
4.3.3. Factors Potentially Mediating Differential HLA Class II Expression by Breast 
Carcinoma Cell Lines 
Interestingly, each breast cancer cell line expressed different levels of HLA class II 
and class II co-chaperones. Some cell lines constitutively expressed and strongly up-
regulated class II i. e. MDA-MB-435, T-47D, MDA-MB-231 and BT-20 while others 
displayed comparatively weak class Il up-regulation i.e. BT -474 and MDA-MB-468. 
The above mentioned low expressors were susceptible to IFN-y induction i. e. 
possessed IFN-y receptors and components ofthe JFN-y signaling pathway since they up-
regulated class I (data not shown), clas's ll and class ll co-chaperone genes. However, IFN-y 
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receptor expression could have drastically differed between cell lines thereby promoting 
variations in class Il cell smface expression. This theory is supported by a study by Ucer et 
al. ( 1985) that demonstrated a relationship between the number of IFN-y receptors on cancer 
cell lines and the concentration ofJFN-y required to up-regulate HLA-DR. Thus, cells with 
more fr"N-y receptors should up-regulate higher levels of HLA class Il than cell lines with 
fewer receptors when cultured in 500 units/ml IFN-y. Future studies could attempt to 
correlate class II up-:-regulation on breast cancer cell lines with the expression of IFN-y 
receptors. 
Prolactin has been implicated in inducing class ll on non-neoplastic breast epithelium 
and on a breast cancer cell line, MCF7 (Klareskog et al., 1980, Bernard et al., 1986, Bartek 
et al., 1987). Ginsburg & Vonderhaar (1995) have reported that MCF7 andT -4 7Dco (clone 
ofT -4 7D) secrete prolactin and possess prolactin receptors suggesting autocrine regulation 
of class II expression in these cells. Indeed, as discussed above, these cell lines constitutively 
transcribed DRA and DRB genes and T -47b constitutively expressed HLA-DR protein. 
Another potential autocrine mediator of constitutive class n expression, epidermal 
growth factor (EGF); was shown to up-regulate de novo class Il expression in breast cancer 
cell lines (Bernard et al.,1992). Martinez-Carpio et al. (1999) demonstrated that MDA..:MB-
231 secretes EGF and possesses EGF receptors and as stated above, this cell line 
constitutively expressed HLA-DR and HLA-DP. It is possible that autocrine mediated class 
II induction was more noticeable in our study given that our 96 hour incubation is longer than 
thatused in most other studies (see section 4.3.1). 
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Oncogenes may also induce de novo class II expression. For example, when Albino 
et al. (1986) transferred viruses containing mutated (i.e. activated) ras genes into class 11 
negative melanocytes, HLA-DR was up-regulated. Similarly, Hume et al. (1987) partially 
restored class II expression in a mutant Burkitt's lymphoma cell line, RJ2.2.5, upon infection 
of these cells with retroviruses containing activated ras genes. MDA-MB-231 has an 
activated ras gene (Kozma et al., 1987) but whether this cell line or others poss~ss mutant 
ras genes capable of activating class ll expression is not known. 
Other factors secreted by breast cancer cell lines may have impeded efficient class 
II up-regulation. For example, TGF-B impairs class II expression by impairing CIIT A 
mRNA accumulation (Lee et al. , 1997, Dong et al., 2001). Several breast cancer cell lines 
including MDA-MB-468, MCF7, T-47D, MDA-MB-231, BT-20, SK-BR-3 and Hs578T 
secrete this factor (Zugmaier & Lippman, 1990, Arteaga et al. , 1988). However, not all are 
TGF-B sensitive. Unfortunately, contradictory findings regarding TGF-B sensitivity have 
been reported (Arteaga et al., 1988, Reiss & Barcellos-Hoff, 1997, Pouliot & Labrie, 1999, 
Lynch et al, 2001) and suggest that TGF-B resistant clones are selected during routine cell 
culture (Lynch et al., 2001 ). Thus, while TGF-B is a candidate for class II down-regulation 
in breast cancer cell lines, future experiments would be required to elucidate whether these 
cells are TGF-P sensitive. Future studies could also characterize growth factors and 
cytokines secreted by breast cancer cell lines and deduce their involvement in class TI 
regulation. 
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4.3.4. Differential Expression of HLA Class II Isotypes by Breast Cancer Cell Lines 
In agreement with published data, HLA class II isotypes were differentially expressed 
on breast cancer cell lines. Most cell lines expressed higher levels of HLA-DR than HLA-
DP. HLA-DQ was expressed at much lowerlevels or not at all. This pattern of differential 
class II expression has been described on breast carcinomas (Koretz et al., 1989, Moller et 
al., 1989, Jabrane-Ferrat et al., 1990) and otbernon-conventional APCs (Natali et al., 1986. 
Alcaide-Loridan et al., 1999, Redondo et al., 1999). 
The above mentioned cases indicate that HLA class II isotype specific regulation 
exists and indeed several have been previouslydescribed. For example, Otten et al. (1998) 
demonstrated that low levels of CIIT A induced class II cell surface expression in a non-
coordinate manner in HeLa-derived HtTa cells i.e. HLA-DR and HLA-DP protein were 
strongly up-regulated while HLA-DQ was weakly expressed. This disparity disappeared 
when high levels of CIITA were present. Since HtTa cells with low levels of CIIT A 
transcribed all class II genes, it was speculated that other factors regulated by CIIT A were 
critical for inducing DQ cell surface expression (Otten et al., 1998, Alcaide-Loridan et al., 
1999). Our study did not quantify mRNA but future research could attempt to associate 
levels of CIIT A transcripts with DQ cell surface expression. 
De Lerma Barbaro et al. (1994) suggested that a specific post-transcriptional 
mechanism controlled HLA-DQ expression but not HLA-DR or HLA-DP expression in 
interspecies somatic cell hybrids. These cells had stable DQA and DQB mRNA which were 
not translated or were not properly assembled given the lack of mature a~ heterodimers. Our 
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study did not examine post-transcriptional mechanisms regulatingHLA-DQ in breast cancer 
. cell lines but Juture studies could ascertain the pi·esence of mature a~ heterodimers. 
Several investigat~ons have described distinct cell surface transport of HLA-DQ 
molecules (Alcaide-Loridan et a!., 1999). For example, Maurer et al. ( 1987) examined the 
intracellular expression of class 1I isotypes in IFN-y treated dermal fibroblasts. DR and DP 
were localized in discrete . vesicles while DQ was dispersed throughout the cytoplasm 
suggesting differential intracellular transport of class IT antigens (Maurer et al., 1987). 
Muczynski et al . (1998) reported delayed cell surface expression of HLA-DP and 
HLA-DQ in an IFN-y treated melanoma cell line, ThM: Cell surface HLA-DR was apparent . 
after 48 hours of IFN-y treatment while cell surface HLA-DP and HLA-DQ appeared after 
1 to 2 weeks of culture~ This delay was not due to impaired class 1I transcription since class 
. . . . . 
· n rn:RNA was detected following IFN-y exposure for 48 hours. Similar observations were 
made in primary culture of kidney proximaltubular cells and a transformed kidney cell line 
(Muczynski et al., 1998). Similarly, Beaty et al. (1992) found that HLA~DQ requires a 
longer IFN-y induction than HLA-DR for cell surface expression on primary skin fibroblasts. 
Breast cancer cell lines may also exhibit delayed cell surface expression of HLA-DQ. 
For example, in one experiment, MDA-MB~231 was assayed for IFN-y induced class IT cell 
surface expression over time. While cell smface expression of HLA-DR appeared instantly 
(at time 0) and HLA-DP appeared at 24 hours, HLA-DQ expression was not apparent until 
144 hours (data not shown). Future investigations could assess cell sudace and intracellular 
HLA-DQ expression over time in other breast cancer cell lines to address whether these cells 
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exhibit delayed HLA-DQ intracellular transport. 
One cell line, MDA-MB-468, expressed higher levels ofHLA-DP than HLA-DR and 
no HLA-DQ. A similar pattern of class II expression was observed in a malignant B cell 
line, BALM-4 (Pesando et al., 1986). Although Pesando et al. (1986) did not elucidate the 
mechanism(s) responsible for this differential class II expression, different regulatory factors 
or processes were suggested. 
4.3.5. Co-stimulatory Molecule Expression by Breast Carcinoma Cell Lines 
4.3.5.1. CD80 and CD86 
No brea<>t cancer cell line constitutively expressed or up-regulated CD80 or CD86. 
This is not surprising given that most tumors of non-hematopoietic origin do not express 
these co-stimulatory molecules (Nieland et al., 1998). However, it was logical to assess 
CD80 and CD86 expression on breast carcinoma cells given their expression on 
gastrointestinal and hepatocellular carcinomas where they help induce anti-tumor irrununity 
(Li et al., 1996, Tatsumi et al., 1997, Koyama et al., 1998). 
4.3.5.2. CD40 
As seen in Figure 3.25, CD40 expression was detected on MDA-MB-435, T-47D, 
MDA-MB-231, BT-20 and SK-BR-3 constitutively and was up-regulated on these cells plus 
two additional ones, MDA-MB-436 and Hs578T. These findings confirm those reported in 
other studies in that CD40 was constitutively expressed and up-regulated by T-47D, MDA-
MB-231 and BT -20 and that no CD40 was detected on MCF7 (Wingett et al., 1998, Hirano 
et al. , 1999, Alexandroff et al., 2000, Tong et al., 2001). 
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Oddly, some breast cancer cell lines were found to express CD40by flow cytometry 
but not by IC (see section 3.52) suggesting that the CD40 antibody (clone 5C3) may not be 
suitable for IC. It is possible that acetone fixation or detergent used in IC altered the CD40 
epitope. This speculation is supported by the observation that the positive control SAVC 
strongly expressed CD40 when assessed by now cytometry but weakly expressed CD40 
when assessed inununocytochemically (Figure 3.26). Especially disconcerting was that the 
CD40 antibody did not detect constitutive CD40 on breast carcinoma cells 
immunocytochemically. Perhaps trypsin treatment, required prior to now cytometry, 
unmasked the CD40 epitope on non-induced breast cancer cells allowing its easy detection 
by flow cytometry. 
4.3.6. Significance of Breast Carcinoma Cells as Potential HLA Class II Restricted 
APCs 
Our findings show that breast carcinoma cells possess the antigen presentation 
molecules and the co-stimulatory molecule CD40 required to engage T cells and thus may 
potentially act as HLA class H restricted APCs. The next step is to determine whetherthese 
cells activate CD4+ T cells by measuring T cell proliferation in a mixed lymphocyte reaction. 
Since we found that all breast carcinoma cell lines up-regulated Ii following IFN-y · 
treatment, their ability to present endogenous tumor antigens may be impaired. For example, 
mice injected with class II transfected Sal sarcoma successfully rejected this tumor. 
However, class H positive Sal transfected with Ii or CUT A were highly malignant (Clements 
et aL, 1992, Annslrong et al., 1997). As well, Jiang et al. ( 1999) correlated high levels of Ii 
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with poorly differentiated colon carcmomas which suggested that Ii reduces tumor 
immunogenicity. Since one pivotal function of Ii is to inhibit peptide loading of the class ll 
peptide binding site until class lllocalization to endosomes (Cresswell, 1996, Wubbolts & 
Neefjes, 1999), Ii may prevent loading and presentation of endogenous tumor antigens by 
tumor cells (Ostrand-Rosenberg, 1994, Armstrong et al., 1997, Xu et al. , 2000}. Howevel', 
Loss et al. (1993) reported that saturating levels of Ii did not impair presentation of a class 
II restricted endogenously derived class I peptide in murine fibroblasts. Thus, whether Ii 
hinders class ll mediated presentation of endogenous tumor antigens in breast tumors is not 
known but could be investigated further. 
While this was the first study to identify cell surface DM on breast carcinoma cells, 
surface DM has been detected on B cells and immature dendritic cells. Here, it associates 
with empty class IT molecules and facilitates loading of extracellular peptides (Santarnbrogio 
et al., 1999, Arndt etal., 2000). Extracellular DM may also facilitate peptide exchange on 
recycled class ll molecules in early endosomal compartments (Arndt et al. , 2000, Parhak et 
al., 2001). It is possible that cell surface DM on breast cancer cells has a role in extracellular 
antigen presentation or altering the peptide repertoire on recycling class II molecules. 
Further research could investigate these intriguing possibilities. 
HLA-DO expression in breast carcinoma cells is a novel finding. The primary 
function of this co-chaperone in B cells, as described in section 1.6.3, is to modulate HLA-
DM activity (Alfonso et al., 1999). Its role in cells other than B cells has not been elucidated. 
Interestingly, transfection .of HLA-DO af:3 dirners into a melanoma cell line, Mel JuSo, 
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drastically impaired HLA-DM mediated antigen presentation toT cell clones(van Ham et 
al., 1997). This suggests that DO may negatively regulate class II restricted antigen 
presentation in non-conventional APCs such as breast carcinoma cells. This intriguing 
possibility infers that tumor cells may be poor presenters of tumor antigen if they express 
HLA-DO. 
Co-stimulatory molecules on APCs are required for Tcell activation. In fact, antigen 
presentation in the absence of co-stimulation is thought to induce T cell anergy (Croft & 
Dubey, 1997). Our study found that CD40 was expressed on several breast carcinoma cell 
lines but that CD80 and CD86 were not. However, breast carcinoma cells not expressing 
CD80, CD86 and CD40 may still.co.,stimulate T cells given the existence of several other 
co-stimulatory molecules including CD70, OX40L, ICAM, 41BB-ligand and B7-h (Baskar, 
1996, Watts & DeBenedette, 1999, Mueller, 2000). The requirement of co-stimulation for 
T cell activation has recently been challenged by Ochsenbein et al. (2001) and Zinkernagel 
(2001), whoproposed that negative signals i.e. antigen presentation alone, do not regulate 
T cell activation. Instead, the dose of antigen, the time it is available and its localization 
within or outside lymphoid tissue are critical. 
Class II restricted tumor antigen presentation by carcinoma cells may not necessarily 
activate CD4+ T cells. In fact, T cells may be anergized if class II presentation proceeds in 
the absence of co-stimulation (Croft & Dubey, 1997, Martinet al., 1999). The observation 
that class II expressing breast tumors tend to be associated with a favorable clinical outcome 
(Zuk & Walker, 1988, Brunner et al., 1991 , Concha et al., 1991, Concha et al., 1995) 
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supports the idea that these tumors activate CD4+ T cells. Even when CD4+ T cells are not 
directly activated by tumor cells, they may be activated by conventional APCs (cross-
presentation). These T cells may then engage class ll expressing tumor cells and orchestrate 
their destruction (Armstrong ct al., 1998a, Armsu·ong et al., 1998b, Hung et al., 1998, Pardoll 
& Topalian, 1998). 
4.4. Selective Expression of Hl..A~DR by Breast Carcinoma Cell Lines 
To our knowledge, this is the first study to report selective up-regulation of HLA-DR . 
alleles by human cancer cell lines. These findings are summarized in Table 4.3. Even 
though selective down-regulation of HLA class I alleles is frequently observed in carcinomas 
(reviewed in Marincola et al., 2000), several factors have impeded the study of class ll allele 
expression in cancers. The availability of class 11 allele specific antibodies was one factor. 
More importantly, the significance of CD4+ T cells in the anti-tumor immune response has 
only recently been acknowledged (Armstrong et al. 1998b, Hung et al. , 1998, Topalian & 
Pardoll 1998). 
4.4.1. Assay Limitations 
Cell surface expression of HLA-DR allelic products was assessed using HLA-DR 
specific antibodies and tlow cytometry. An HLA-DR type was deemed expressed when the 
test antibody mean fluorescence was more than two t imes that of the negative control. When 
assessing protein expression in this manner, several limitations must be considered. For 
example, primary antibodies bind antigens with different affinities. Thus, low expression 
of a particular HLA-DR type could have been due to poor antibody binding ~atherthan poor 
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Table 4.3. Selective expressiona of HLA-DR by breast cancer cell lines. 
DR Cells. on which allotypes up- Cells on which allotypes weakly 
Type regulated up-regulated or not up-regulated 
DRl T-47D · Hs578T, MDA-MB-468 
DR15 MCF7, Hs578T, MDA-MB-157, -
BT-474 
DR3 MCF7, MDA-MB-436 -
DR4 MDA-MB-435, BT-20 MDA-MB-157, BT-474 
DR13 MDA-MB:-436, MDA-MB-231, · -
BT -20, SK-BR-3 
DR7 MDA-MB-231, SK-BR-3 MDA-MB-468 
DR51 NDb ND 
DR52 MDA-MB-435, MDA-MB-231, MDA-MB-436 
BT-20, MCF7, SK-BR-3 
DR53b MDA-MB-435, BT -:20 MDA-MB-157, BT-474, 
MDA-MB:-468 
acell surface expression was detemlined using HLA-DR allele specific antibodies and flow 
cytometry. 
~>Not deternlined since we did not have a DR51 specific antibody. 
· cDR53 expression could not be assessed in DR7 expressing cell lines since PL3, the antibody 
used to detect DR53, also recognized DR7. . 
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expression of a HLA-DR type. However, binding of mAbs to positive control B cell lines 
was a control for this possibility and mAbs were used at saturating concentrations. Similarly, 
the secondary antibody may bind primary antibodies with differing affinities depending on 
the primary antibody isotype. One way to control for this problem is to directly label primary 
antibodies with fluorescent tags. Unfortunately, this procedure often destroys antigen 
recognition by primary antibodies (Drover, personal communication). 
Further, even though HLA-DR specific antibodies bound positive control B cell lines, 
this does not absolutely mean that they will bind DR molecules expressed by breast cancer 
cells. HLA-DR molecules in different cell types may have differentpatterns ofglycosylation 
or may bind different peptides so antibodies may bind certain HLA-DR conformations better 
than others (Drover et al., 1994a). It is important to note, however, that the mAbs used in 
this study were .selected because they bound to HLA-DR molecules on many cell types. 
Additionally, each mAh bound to one or more breast cancer cell line indicating their 
suitability for binding HLADR on breast carcinoma cells. 
Thus, despite possible limitations, our method of analyzing expression of HLA-DR 
allelic products on breast cancer cells is effective. Future research could use quantum beads 
to quantitatively detemrine the actual number ofHLA-DR molecules on a cell' s surface. The 
expression of a particular HLA-DR allele could then be assessed based on the number of 
HLA-DR molecules required for successful T cell engagement. 
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4.4.2. Findings 
HLA class II typing revealed a total of nine different HLA-DR genes in the eleven 
breast carcinoma cell lines. HLA-DR specific antibodies, used to assess DR protein 
expression, were shown to strongly bind HLA-DR allelic products using the appropriate DR 
expressing B cell line controls (Table 3.9). Thus, failure to detect a particular HLA-DR type 
was most probably due to its lack of expression rather than weakly reactive antibodies. 
However, DR specific mAbs may not have detected expression of a particular DR type if · 
expression levels were markedly reduced. 
Constitutive ceJJ surface expression of HLA-DR allelic products using HLA-DR 
specific mAbs was observed in only one cell line, MDA-MB-435. However, constitutive 
HLA-DR expression was detected in three additional cell lines, T-47D, MDA-MB-231 and 
BT-20, using the pan anti-OR antibody L243. T-47D typed positive for only one HLA-DR 
allele, DRB 1 *0102, suggesting that L243 has a higher affinity for !ll.A-DRl than the HLA-
DRl specitic mAbs, NFLD.DlO, JS-1 and NFLD.D2. 
Altematjvely, this cell line could have constitutively expressed another HLA-DR type 
· not detected by the HLA class ll DNA typing kit. Since MDA-MB-231 and BT-20 had four 
HLA-DR alleles it is possible that low levels of HLA-DR allelic products were undetectable 
using HLA-DR allele specific antibodies but were detectable using L243 since this antibody 
recognizes all DR types collectively. Another possibility, although unlikely, is that L243 was 
recognizing something other than HLA-DR on these cells. 
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Several intriguing findings were made regarding up:...regulation of HLA-DR allelic · 
products by breast carcinoma cell lines. Some HLA-DR alleles were consistently up-
regulated regardless of the cell line on which they were expressed. For example, MCF7 and 
MDA-MB-436 (2/2 cell lines) which typed positiveforHLA-DRBl *03, up-regulated DR3. 
MDA~MB-435, BT-20, MDA-MB-231 and SK-BR-3 (4/4 cell lines) which typedpositive 
for HLA-DRB J * 13, up-regulated cell surface DR13. Similarly, MCF7, Hs578T, MDA-MB-
. 157 and BT-474 (4/4 cell lines), which typed positive for HLA-DRB 1 * 15, up-regulated this 
HLA-DR type. In contrast, other HLA-DR types were not up-regulated or were weakly up-
regulated by certain breast cancer cell lines (discussed below). Biologically, failure to up~ 
regulate a particular HLA or even its weak up-regulation may inhibit a tumor specific T cell 
response (Costello et al., 1999). 
HLA-DRB 1 *01 protein was not up-regulated by Hs578T nor by MDA-MB-468 (2/3 
cell lines). Notably, MDA-MB-468 failed to up-regulate any HLA-DR allelic product (i.e. 
DRB 1 *01, DRB 1 *07 or DRB4) as assessed using HLA-DR specific mAbs even though DR 
up-regulation was observed using L243. This suggests that levels of individual DR allotypes 
were too low for detection by DR specific mAbs but that L243 bound all three DR types 
collectively. 
T-47D strongly up-regulated DRB 1 *01. The antibodies used to assess DRI 
expression on T-47D seemed to bind DRl with differing affinities with NFLD.DlO showing 
the highest binding and NFLD.D2 showing the lowest (Figure 3.29). The relatively low DRl 
176 
binding by NFLD.D2 may be explained by the fact that this antibody is peptide dependent 
(Drover et al., 1994b). 
Of the four cell lines that typed positive for HLA-DRBl *04, only one cell line, 
MDA-MB-435, strongly up-regulated cell surface HLA-DR4. Interestingly, DR4 expression 
on BT-20 varied considerably depending on the antibody used to assess it. Weak DR4 up-
regulation was detected using NFLD.Dl and NFLD.Ml while strong DR4 up-regulation was 
assessed using NFLD.D2 and "NRD.DlO (Figure 3.31). Since NFLD.DlO may weakly bind 
DR53 (Drover, personal communication), its assessment of DR4 expression may have been 
an overestimate. On the other hand, NFLD.D2 assessment of DR4 expression may have 
been an underestimate since the NFLD.D2 epitope is peptide dependent (Drover et al., 
1994b). Notably, NFLD;Dl and NFLD.Ml binding to DR4 on the B cell line control 
MTl4B was two-fold less than NFLD.D2 and NFLD.DlO binding suggesting that NFLD.D 1 
and NFLD.Ml affinity for DR4 was less than that of NFLD.D2 and NFLD.DlO. However, 
since NFLD.Dl and NFLD.Ml binding to DR4 on BT-20 was three times less than 
NFLD.D2 binding and eleventimes less than NFLD.DlO binding, antibody affinity cannot 
be the sole explanation for differences in mAb binding to DR4 on BT-20. 
A closer look at the epitopes recognized by the DR4 specific antibodies is 
inf01mative. NFLD.Dl and NH,D.Ml bind epitopes in the DR~2domain i. e. the membrane 
proximal domain (Drover ct al. 1994a, Fu et al. 1995). In contrast, NFLD.DlO and 
NFLD.D2 recognize overlapping epitopes in the DR~l domain (Drover et al.1994b). Thus, 
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it is possible that weak NFLD.Dl and NFLD.Ml binding to cell surface DR4 was caused by 
a ~2 domain mutation that conformationally altered epitopes recognized by these mAbs. 
Alternatively, it is possible that cell surface HLA-DM on BT-20 (see section 3.4.2.2) 
hindered formation of the epitope recognized by NFLD.Dl (Drover, personal 
communication). 
Another more probable explanation is that ~2 domain epitopes were partially masked 
from antibody recognition on BT-20's cell surface. Antigen masking may be the 
consequence of an overabundant glycocalyx. In fact, thick glycocalyx have been described 
on normal human mammary tissue and on primary tumors (Kim et al. 1975, Ghosh et al. 
1981 ). Similarly, the epithelial mucin MUC-1 is known to inhibit cell adhesion by masking 
cell surface antigens. Since BT-20 expresses an abundance of this polysaccharide (Walsh 
et al. 1999), it is possible that recognition of membrane proximal HLA-DR epitopes was 
hindered on these cells due to MUC-1 over-expression. 
This theory is supported by several observations. Firstly, NFLD.Ml also recognizes 
HLA-DR52 and thus should have bound both DR4 and DR52 on BT-20 (Table 2.4). 
However, as stated above, only weak binding of this antibody was observed. This weak 
binding in view of strong binding by another DR52 mAb (7.3.19.1) supports the idea that 
~2 domain epitopes were masked. 
Additionally, analysis of intracellular DR4 expression by IC detem1ined that -60% 
of BT-20 were DR4 positive using NFLD.Dl; -50% of BT-20 were DR4/DR52 positive 
usingNFLD.Ml; -35% ofBT-20 were DR4 positive using NFLD.D2 and .:....70% of BT-20 
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were DR4 positive using NFLD.DlO. Low NFLD.D2 binding could be att1ibuted to 
NFLD.D2 epitope alteration by the fixative acetone (Drover, personal communication). 
Taken together, these data suggest that recognition of f32 domain epitopes on BT -20's 
cell surface were hindered. Since the T cell co-receptor CD4 interacts with residues in the 
~2 domain (Cammarota et al. 1992, Brogden et al. 1998), inhibition of this binding could 
deleteriously alter CD4 binding and impair T cell engagement mediated by al1 class II 
molecules on BT-20. Future research could strip polysaccharides and/or mucins from BT-20 
and re-assess cell surface HLA class II allele expression: For example, 0-gylcosidase 
removes 0-'linked glycans (Garner et al., 2001) such as those attached to the mucin backbone 
(Bergeron et al., 1997). Additionally, a DR4 specific antibody recognizing a p1 dom:ain 
epitope could be used to re-examine DR4 up-regulation on this cell line. 
Two additional breast cancer cell lines, MD A -MB-157 and BT -4 7 4, did not up-
regulate intracellular nor cell smface HLA-DR4 following IFN -y treatment. This finding was 
confirmed by two different mAbs, NFLD.D 1 and NFLD.Ml and by three different assays, 
extracellular and intracellular flow cytometry and IC. 
Three cell lines typed positivefor HLA-DRB1*07; MDA-MB-231 , SK-BR-3 and 
MDA-MB-468. As discussed above, MDA-MB-468 did not up-regulate this HLA-DR type 
but moderate DR7 up-regulation was detected on MDA-MB-231 and SK-BR-3. 
Of the six cell lines which typed positive for HLA-DRB3, MDA-MB-435, BT-20, 
MDA-MB-231 and SK-BR-3 strongly up-regulated cell surface DR52 and MCF7 moderately 
up-regulated this DR antigen. As described above, NDS 13, the antibody used to characte1ize 
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DR52 expression by MCF7, bound DR52 constitutively on this cell line. This is improbable, 
however; since DRB3 mRNA was not constitutively transcribed in MCF7. The exact epitope 
recognized by NDS13 has not been mapped. Its specificity as determined by binding to B 
cell lines is HLA-DRB3, DRB1*03, DRB1*08, DRBl *ll, DRB 1*12, DRB1*13 and 
DRB 1 * 14 (Fuggle et al., 1987). Since B cell lines expressing DR3, DRll, DR12, DR13 and 
DR 14 also express DR52, it is probable that NDS13 recognizes DR52 exclusively or together 
with another DRB 1 type (Fuggle et al ., 1987) or together with another unidentified molecule . . 
These observations challenge whether DR52 is truly up-regulated by MCF7. Unfortunately, 
another antibody capable of assessing DR52 expression by MCF7 was not available for our 
study but could be obtained for future work. 
HLA-DR52 was weakly up-tegulated byMDA-MB-436 as assessed using NFLD.D7 
. . 
and NDS 13. Immunocytochemical analysis of DR52 expression using NFLD.D7 confrrmed 
this weak DR52 up"'regulation. Ho\vever, using NDS 13, no DR52 protein was detected. As 
described in section 3.3, the epitbpe i;ecognized by NDS 13 may have been altered by acetone 
fixation or by detergent used in IC. 
Seven breast carcinoma cell lines typed positive for HLA-DRB4 (DR53). Cell 
surface HLA-DR53 was strongly up-regulated by MDA-MB-435 and BT -20. In contrast, 
MDA-MB-468 (see above), MDA-MB-157 and BT-474 did notup-regulate ceil surface 
DR53. While no intracellular DR53 was observed in BT-474 and MDA-MB-468, weak 
intracellular DR53 expression was detected in MDA-MB-157. This may simply reflect 
differences in the sensitivity of these two assays. Alternatively, this could suggest that cell 
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surface transport of DR53 was impeded in MDA-MB-157. Perhaps, misfolded DR53 protein 
was retained in the ER or Golgi (Dusseljee et al. , 1998). 
It was not possible to detect protein expression of all HLA-DR types in breast 
carcinoma cell lines (see section 3.7.3.1) since DR53 protein expression could not be 
assessed in DR7 expressing cell lines and DR51 protein expression could not be determined 
in any cell line. Thus, it is possible that additional HLA-DR types were not up-regulated or 
were weakly up-regulated by these cells. 
4.4.3. Mechanisms Potentially Implicated in Selective HLA-DR Expression 
To accurately assess HLA-DR expression on breast cancer cells, it is important to 
consider whether cells not expressing or weakly expressing HLA-DR alleles do so as a result 
of naturally occmTing HLA-DRB promoter polymorphism or as a result of tumorigenesis. 
·The class ll promoter is characterized by a conserved set of cis-acting regulatory elements· 
which include the W/S box, the X1 box, the X2 box and theY box (van den Elsen et al. 
1998). Sequencing of numerous HLA-DRB allele promoters has revealed sequence 
variations within X and Y boxes and spacing differences between regulatory elements 
(Emery et al. 1993, Perfetto et al. 1993, Singal et al. 1993, Louis et al . 1994, Singal & Qiu 
1995). These variations alter binding oftransctiption factors and thus alter gene transcription 
(Louis et al. 1994, Singal & Qiu 1995). 
Using CAT reporter assays, it has been found that DRB promoters have different 
transcriptional activities (Emery et al. 1993, Louis et al. 1994, Singal & Qiu 1995). For the 
most part, these transcriptional activities correlate with levels of steady state DRB mRNA 
181 
(Vincent et al ., 1994}. Since DRB3 and DRB 1 *0 1 promoters have high transcriptional 
activity (Louis et al., 1994), the weak up-regttlation of DR52 protein detected in MDA-MB-
436 and the lack of DR 1 protein in Hs578T were most likely not attributable to naturally 
occurring promoter polymorphisms. Despite observations that DRB 1 *04 promoters have 
low transcriptional activity (Louis et al. 1994), Vincent et al. (1996) observed a relatively 
high steady state level of DRB 1 *04 mRNA. Thus, whether poor promoter activity 
contributed to the lack of DR4 up-regulation in 2/4 breast cancer cell lines is not known. 
Louis et al. (1994) have also shown that DRB4 promoters have low transcriptional activity. 
Thus, it is possible that cell lines not expressing or weakly DR53 did so as a result of 
naturally occurring promoter polymorphism. 
Mechanisms responsible for the lack of HLA-DR up-regulation by breast cancer cell 
lines were not elucidated. However, when DR protein was not up-regulated, DRA and DRB 
genes were transcribed in response to IFN-y. Interestingly, HLA-DRB transcription, assessed 
using HLA-DRB generic primers coincided with DRB transcription assessed using allele 
specific primers with two notable exceptions. Non-induced MDA-MB-157 did not transcribe 
DRB as assessed using generic DRB primers but did transcribe DRB4 mRNA. Similarly, 
non~iriduced MDA-MB-468 did not transcribe DRB as assessed using generic DRB primers 
but did transcribe DRB 1 *01 mRNA. Perhaps, the allele specific primers were better at 
amplifying DRB genes than the generic DRB primer. 
There are several possible explanations as to why cettain DR allelic products were 
not up-regulated. For example, since primers used to assess DR allele transcription were 
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specific for sequences within exon 2, it is possible that mutations resulting in premature stop 
codons in other exons or that gene deletions prevented successful transcription of the entire 
DR gene. These phenomena has been implicated in class I allele down-regulation in cervical 
cancers (Koopman et al., 1999, Brady et al. 2000, Koopman eta!., 2000). For example, the 
lack of HLA-A2 expression in the cervical cancer cell line 808 was caused by a point 
mutation in exon 3 which encoded a premature stop codon (Brady et al., 2000). 
Alternatively, mutations in splice sites within introns may prevent proper mRNA processing. 
Aberrant mRNA splicing was determined to be the mechanism responsible for selective loss 
of HLA-A2 in 624MEL28 melanoma cells (Wang et al., 1999). Future research could 
sequence DR genes not up-regulated by breast cancer cells to identify putative gene . 
mutations; 
Inhetited mutations in some HLA-DRB4 alleles may prevent their translation. One 
such null allele, HLA-DRB4*0103102N, has been found in association with DRBl *0401, 
DQBl *0301 positive individuals (Voorter et al. 2000). Since BT-474 typed positive for 
DRB 1 *040 1 and DQB 1 *03, the presence of this B4 null allele could explain the lack of 
DR53 expression in this cell line. Using sequence specific primers, a future study could 
determine whether BT-474 has a DRB4 null allele. 
Cancer induced mutagenesis of regulatory elements in the HLA-DRB promoter could 
have hindered DRB transcription such that mRNA levels were too low for efficient gene 
translation. This is plausible since sequence variations in class ll regulatory regions 
influence binding of TFs and thus influence gene transcription (Louis et al. 1994, Singal & 
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Qiu 1995). Other possible mechanisms impeding up-regulation of HLA-DR allelic products 
could include instability of HLA-DRB rnRNA or rapid degradation of HLA-DR protein. · 
Finally, while shedding of HLA class ll molecules by cancer cells has been described, 
selective shedding of class II antigen has not (Ziai et al., 1985, Maio et al., 1989). However, 
selective secretion of class ll antigens has been demonstrated. Briata et al. (1986) described 
B cell lines that secreted HLA-DQB. Of four cell lines analyzed for DQB secretion: 2/4 
. secreted DQB, suggesting allele specific secretion. These cell lines displayed alternative 
splicing of DQB which deleted DQB 's transmembrane portion and resulted in its secretion. 
All of these cells produced nonnal DQB transcripts as well. Thus, it is possible that HLA-DR 
allelic products were selectively shed or selectively secreted. To investigate these 
possibilities, future experiments could assess cell line supernatant for DR allelic products . 
. 4.4.4. Significance of Selective HLA-DR Expression in Brea~t Carcinoma Cells 
As stated above, selective expression of HLA alleles is not without precedence, since 
selective loss of HLA class I alleles occurs frequently in human cancers including breast 
carcinomas (Perez et al. 1986, MoHer et al. 1989, Concha et al. 199la, Moller & Hamrnerling 
1 992, Cabrera et al. 1996, Hicklin et al. 1999, Algarra et al. 2000, Marincola et al. 2000). 
The biological relevance of class I allele down-regulation is inferred by the observation that 
. metastases have a higher frequency of class I allele loss than primary tumors (Tait, 2000). 
Furthermore, several investigations have linked loss of class I allele expression with an 
unfavorable clinical oulcome. For example, vart Driel et al. ( 1996) reported that the loss of 
HLA-A2 expression in cervical carcinomas was associated with accelerated disease 
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progression. The characterization of HPV peptides capable of binding HLA-A2 (Y oon et al., 
1998, Rudolf et al., 2001) and HLA-A2-:-restricted HPV peptide-specific CTLs (Evans et al., 
1997, Yoon et al., 1998) support the involvement of HLA-A2 in the immune response 
towards HPV-induced cervical carcinoma. Additionally, the loss ofHLA-A2 expression in 
melanomacells was shown to prevent HLA-A2-restricted cytotoxic T cell (CTL) recognition 
of these cells. Intriguingly, re-expression of HLA-A2 in these melanoma cells partially 
restored immunological recognition by CTLs (Pandolfi et al., 1991). 
The physiological importance of selective HLA-DR allele expression m breast 
carcinomas is not known. In fact, the significance of HLA-DR expression by breast 
carcinomas remains controversial. While several investigations have corrclatcdHLA-DR 
expression with well differentiated breast tumors and favorable prognosis (Zuk & Walker, 
1988, Brunner et al., 1991, Concha et al., 1991b, Concha et·al., 1995) others have found no 
· such correlation (Moller et al., 1989, Wintzer et al., 1990, Lucin et al., 1994, Maiorana ct al., 
1995). Since these studies assessed DR expression using pan anti-DR antibodies, it is not 
known whether breast carcinomas up-regulated all HLA-DRtypes or select DR types. We 
propose that class II positive tumors not associated with a favorable clinical outcome did not 
up-:regulate the HLA-DR allele that was particularly adept at presenting tumor antigen. This 
theory is now supported since selective HLA-DR up-regulation was documented in our 
study. 
The implication that HLA-DR positive carcinomas are associated with a favorable 
clinical outcome suggests that these tumors are recognized and eradicated by CD4+ T cells. 
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Indeed, evidence of HLA class II restricted tumor antigen presentation exists (see section 
1.7 .3 ). Therefore; if like class I allele loss, lack of class II allele expression impairs T cell 
recognition, then it may represent another mechanism by which tumors evade immune 
surveillance. It is intriguing to speculate that failure to up-regulate a particular HLA-DR type 
by breast cancer cell lines was the result of selective immunological pressure encountered 
in vivo. For example, one of the cell lines in our study, BT -4 74, that did not up-regulate 
DR4, has been shown to over-express Her-2/neu (Brodowicz et al.,l997). Since DRB 1*04 
is known to present Her-2/neu peptides (Kobayashi et al., 2000), its lack of expression may 
have allowed this tumor to evade a Her-2/neu specific CD4+ T cell immune response. 
This study revealed that certain breast carcinoma cell lines did not up-regulate several 
different HLA-DR types (see Table 4.3). More subtle changes in DR expression on tumor 
cells may also impede their recognition by CD4+ T cells. For example, DR52 was weakly 
·· up-regulated by MDA-MB-436. As stated previously, failure to up-regulate HLA or even 
its weak up-regulation may impair the tumor antigen-specific T cell response (Costello et 
al.,1999). Further, CD4+ T cell recognition of class II molecules on BT -20 may be hindered 
by polysaccharides or mucins. Since one DR allotype was not consistently absent in breast 
cancer cells, it suggests that different tumors require different class IT molecules for tumor 
antigen presentation. This is not surprising given that multiple tumor antigens exist 
(Renkvist et al., 200l ,Scanlan & Jager, 2001). 
To ensure that selective HLA-DR up-regulation is not a phenomenon restrictedto 
cultured breast carcinoma cell lines, ongoing work in our laboratory is assessing DR allele 
186 
expression in situ. Since in situ tumor cells are under more selective immunological pressure 
than in vitro established cell lines (Ferrone & Marincola, 1995), it is _predicted that a higher 
frequency ofse]ective DR allele up-regulation wil1 be observed. 
4.5. Summary and Potential Implications of J1'indiugs . 
Some breast carcinoma cell lines constitutively expressed HLA class IT, class ll co-
chaperones and the co-stimulatory molecule CD40. Whether the expression level of these 
molecules would be sufficient to engage CD4+ Tcells is not known. CIITA independent 
regulation of constitutive HLA class II and co-chaperone expression was described in our 
study ahd may provide insight into different mechanisms of class ll regulation in non-
conventional APCs. 
Following stimulation with IFN-y, most cell lines up-regulated class ll, co-chaperones 
and the co-stimulatory molecule CD40. This has physiological significance since IFN-y, 
along with other immunomodulators, may act in situ. Again, it is not known whether these 
tumor cells would engage CD4+ T cells. However, since several studies have shown that 
class ll positive tumors are associated with a favorable clinical prognosis (Zuk & Walker, 
1988, Bmnner et al. , 1991 , Concha et al. , l99lb, Concha et al., 1995), it suggests that breast 
tumors can engage T cells. However, there are several mechanisms by which tumors escape 
immune recognition. For example, interaction of HLA class II expressing tumors with CD4+ 
T cells in the absence of concomitant co-stimulation may anergize tumor specific T cells 
(Croft & Dubey, 1997, Martinet al., 1999). Also, li expression may hinder an effective HLA 
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class II restricted anti-tumor immune response. Presumably, Ii blocks the class Il peptide 
binding groove thus preventing binding of endogenous tumor peptides (Ostrand-Rosenberg, 
1994, Armstrong et al., 1997, Xu et al., 2000). Notably, in our study, all class II positive 
breast carcinoma cell lines also expressed Ti. 
For the first time, our study has shown that breast carcinoma cells may differentially 
express HLA-DR allotypes. Thus, it may be that tumors evade immune recognition by not 
expressing a particular HLA class ll allele adept at tumor antigen presentation. Class I allele 
down-regulation is common in brcasttumors and it has been associated with a poor clinical 
outcome (Concha et al. 1991a, Cabrera et al. 1996, Algarra et al. 2000, Marincola et al. 
2000). Increased understanding of the immune response towards tumors and the mechanisms 
by which tumors escape this response may be critical for effective immunotherapies. 
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APPENDIX A: SOLUTIONS 
1 Ox PBS (Phosphate Buffered Saline) 
80 g sodium chloride (BDH Inc., Toronto, ON), 2 g potassium chloride (Fisher Scientific, 
Fair Lawn, NJ), 14.4 g di-sodium hydrogen orthophosphate anhydrous (BDH Inc., Toronto, 
ON), 2.4 g potassium dihyrdogen phosphate (Fisher Scientific) were dissolved in distilled 
water (800 ml) and the final volume was corrected to 1000 ml using distilled water. The pH 
was adjusted to 7.4 using l NNaOH. lx PBS was made by diluting lOx PBS 1/ lOin distilled 
water. 
4% Paraformaldehyde 
8 g paraformaldehyde (Sigma, St. Louis, MO) was added to 100 ml distilled water. The 
mixture was heated until dissolved and three drops ofl N NaOH was added to clear the 
solution. After cooling to room temperature, 4% paraformaldehyde was made by adding 
100 ml2x PBS. The pH was adjusted to approximately 7.4 using IN NaOH. To make I% 
paraformaldehyde, 4% parafonnaldehyde was diluted 1/4 in lx PBS. 
lOx TBE 
. 53.9 g Tris base (Life Technologies, Gaithersburg, MD) and 3.72 g EDTA (Sigma) were 
combined in 400 ml distilled water. Slowly, 27.5 g boric acid were added. The final volume 
was adjusted to 500 rn1 using distilled water. The pH was adjusted to 8.3 using INNaOH. 
To make 0.5x TBE, lOx TBE was dissolved 1/20 in distilled water. 
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Loading Buffer 
10 ml50% glycerol in water, 0.01 g bromophenol blue (J.T. Baker Chemical, Phillipsburg, 
NJ) and 0.01 g xylene cyanol were combined. Loading buffer was stored at ~20°C until 
required. 
Mayer's ·Hematoxylin 
1 g haematoxyin (BDH Inc.), 0.2 g sodium iodate (Sigma) and 50 g potassium alum (Sigma) 
were · dissolved overnight in 1000 ml distilled water. 1.09 g citric acid (BDH Chemicals, 
Toronto, ON) and 50 g chloral hydrate (BDH Laboratory Supplies, Poole, England) were 
added to the above mixture. The solution was boiled for 5 minutes and cooled to room 
temperature. 
Scott's Tap Water · 
7 g sodium bicarbonate (Mallinckrodt, Paris, KY) were added to 1 L tap water and 7 g 
magnesium sulfate 7~hydrate (J.T. Baker Chemical) were added to 1 L tap water. These 
solutions were combined 1: 1 to make Scott's Tap Water. 
DEPC Water 
0.1% diethyl pyrocarbonate (DEPC) (Sigma) was dissolved in distilled water and incubated 
for 6 hours at room temperature. The solution was then autoclaved for 20 minutes. 
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